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An ongoing objective of the chemical industry is to reduce the use of eco-destructive 
chemicals in cost effective and sustainable synthesis routes for high value chemicals. 
Biocatalysis is an established strategy for green chemistry. In this approach, artificial 
metalloenzymes have emerged as advanced biocatalysts, able to support a wide 
range of non-naturally occurring reactions in a biological environment. They are built 
by combining the selectivity of enzymes with the appropriate non-natural reactivity 
of transition metal catalysts. Current examples of these hybrids often lack control 
over the structure and function. They are also based on proteins with no naturally 
evolved binding pockets, thus lacking the advantage of proximity between a wide 
range of substrates and the metal catalysts.  
The research presented here investigates the design and development of artificial 
metalloenzymes for the transfer hydrogenation of imines, using the cofactor binding 
pocket of alcohol dehydrogenases to supramolecularly bind catalytic complexes.  
A computational methodology was first created to conceptualise artificial 
metalloenzymes, starting with two NAD(P)H-dependent enzymes: the horse liver 
alcohol dehydrogenase (HLADH) and the Thermoanaerobacter brockii alcohol 
dehydrogenase (TbADH). The in silico study was used to understand the cofactor 
binding site and to identify the strongest non-covalent interactions. Computationally 
designed library of NADH analogues were then screened as anchors for the metal 
catalyst, resulting in the selection of a set of lead structures.  
In the next step, a divergent total synthesis was proposed to create a small library of 
catalysts complexes via one key intermediate compound. Three iridium(III) catalysts 
were synthesised, based on the lead structures selected for their predicted high 
affinity in alcohol dehydrogenases.  
The complexes were then tested for their capacity to form artificial metalloenzymes. 
The binding affinity was investigated via competition and ITC experiments, while the 
catalytic activity was assessed for the transfer hydrogenation of aromatic imines. This 
resulted in mutual inhibition of the metal complexes and the two wild type alcohol 
dehydrogenases, while the TbADH mutant without catalytic zinc ion formed a 
working artificial metalloenzyme.   
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Challenges in the production of high-value compounds for the chemical and 
pharmaceutical industry includes the development of green processes. The 
increasing production of toxic and hazardous wastes needs actions for the protection 
of humans and the ecosphere. More sustainable and environmentally friendly 
techniques are now required, alongside a low cost and efficient synthesis.  
Biocatalysis stands as an appealing technology and a key solution for the coming 
years. The use of biological entities, such as enzymes, reduces the application of 
chemical products (e.g. derived from fossil fuels), while bringing selectivity and 
decreasing the amount of waste (e.g., biodegradable catalyst, no chemical reagents, 
no side reactions).  
Biocatalysis is an attractive and expanding field also due to the necessity to produce 
enantiopure products. Based on improvements in protein engineering technologies 
(e.g. bioinformatics, genome sequencing, directed evolution, chemical optimisation 
etc.), biocatalysis is in constant innovation, with an evolution in the portfolio of 
available biocatalysts.  
Nowadays, the increasing use of computational aided approaches has improved the 
protein engineering capacities further.1,2 Numerous studies aimed to construct 
advanced biocatalysts by re-designing protein active sites, or by de novo construction 
of catalytic sites.3 The focus of these studies is the creation of biocatalysts with novel, 
non-natural activities.  
A particularly promising strategy is the introduction of a non-native metal ion inside 
a protein scaffold through various anchoring methods. The resulting product is called 
an artificial metalloenzymes (AMs). These biocatalysts combine the non-natural 
catalytic activity of a given transition metal catalyst with the controlled environment 
of natural enzymes.4 These entities are able to address challenges of green chemistry: 
reaction control, renewable catalyst, enantioselectivity and environmentally friendly 
conditions. Studies already proved the construction of efficient AMs.5 However, only 
a few attempted the design of AMs by computational methods. On the other hand, 
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the drug design literature offers many examples where non-natural chemical 
structures are docked within proteins using supramolecular interaction for inhibition 
purposes.6 This strategy could be investigated to build AMs accommodating metal 
catalysts in the binding site.7  
In the industrial biocatalysis field, a better design of AMs would help the 
development of a truly adaptable catalyst, addressing some of the green chemistry 
challenge and enhancing the selective synthesis of compounds.  
Hence, this project proposes the development of an AMs catalysing the transfer 
hydrogenation of imines for the synthesis of chiral amines. This functional group is 
commonly found in natural and synthetic products, where it can be responsible for 
biological activity. Chiral amines are of importance in the pharmaceutical industry, 
where they are used as building blocks in the synthesis of many drugs. The production 
of chiral amines is generally achieved through asymmetric synthesis. Therefore, the 
use of AMs for the creation of chiral amines is a good opportunity to develop a safer 
process that fulfils the requirements of green chemistry.  
 
 
In biocatalysis domain, one attractive strategy to achieve non-natural activities in 
biological environment is the use of AMs. These advanced hybrids are created by the 
incorporation of a metal ion in a protein or enzyme scaffold. AMs make use of the 
enzyme scaffold selectivity and the reactivity of a non-native metal catalyst. By 
variation of the metal complex nature, chemists can adapt the AMs to their targeted 
reaction. Thus, AMs support a larger range of biological and non-natural reactions in 
aqueous media, while providing a better stereoselectivity recognition of substrate 
and products.4 Several studies have already proven this concept and a variety of 
enantioselective catalysis reactions have emerged.8 One prominent example of 
efficient AMs is the biotin-streptavidin technology developed by the Ward group, 
which led to the development of artificial asymmetric transfer hydrogenases with 
high stereoselectivity.9 
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Three important parameters describe the unique nature of AMs: the host (enzyme 
structure), the transition metal complex and the interaction between these two 
entities. The transition metal represents the first coordination sphere, responsible 
for the catalytic activity. The metal must be inserted orthogonally inside the enzyme 
structure to avoid interferences with the selective functionalities of the protein 
scaffold. The combination of interactions between hosts and the first coordination 
sphere is known as the second coordination sphere. This is a key parameter in the 
stability of the complex and the efficiency of the AMs.10 Careful design and strong 
interactions form a stable enzyme-metal catalyst complex, and thus a robust AM in 
its reactivity and selectivity. The evaluation of space inside the enzyme scaffold and 
the mode of anchoring of the metal catalyst are therefore part of prerequisites 
parameters necessary to engineer an efficient AM.8,11 
The engineering of AMs is challenging in the design of the two coordination spheres. 
For the 1st coordination sphere, evaluation of space inside the enzyme is a 
prerequisite at the introduction of a reactive transition metal catalyst able to fit. In 
the 2nd sphere, the mode of anchoring, the various interactions for a stable binding 
or the proximity with the substrate are important choices. 
 
The introduction of a metal or a metal complex inside the protein scaffold adopts 
different anchoring approaches (Figure 1): dative, covalent or supramolecular 
anchoring.4  
 
Figure 1: Representation of metal anchoring methods, to build AMs. The following codes were applied: 
the amino acid (Aa), the covalent or supramolecular ligands and spacers (L), the ligand coordinating 
the metal ion (red crescent), the metal ion catalyst (red ball). The dashed lines represent non-covalent 
interactions, and the plain lines represent covalent interactions. 
 
Aa
Aa
Aa
Dative Covalent
Aa L
Supramolecular
L
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In the dative anchoring, a binding site is built inside the natural enzyme structure to 
accommodate the transition metal catalysts (Figure 1). Several amino acids are 
known to establish dative bonds with transition metal catalyst through N, O and S 
coordination. Thus, the protein scaffold can be arranged into an efficient three-
dimensional binding site. Two techniques have been used: the repurpose of a natural 
enzyme metal binding site or the creation of a new catalytic binding site.12 
 
Almost a third of enzymes in nature are metalloenzymes.13 They have naturally 
evolved to hold the characteristics for an efficient metal binding in their structures 
(e.g. Zn-dependent alcohol dehydrogenases, Fe-containing cytochromes, Cu-
laccase…). Thus, natural metalloenzymes are perfect candidates for the substitution 
of their native metal by a transition metal catalyst.  
The technique consists in removing the natural metal from the enzyme (i.e. dialysis) 
and mixing the new metal ion with the apoprotein. In 1976, Kaiser and Yamamura 
first reported this technique using a Cu(II) ion to substitute the zinc of a Zn(II)-
dependent carboxypeptidase A.14 The newly engineered AM was able to catalyse the 
oxidation of ascorbic acid. Several other studies involved different enzyme scaffolds, 
including a Zn(II)-carbonic anhydrase with Mn(II) replacing the native metal,15,16 Pd2+ 
ions inserted inside an apo-ferritin17,18 or two Cu2+ embedded in a repurposed di-Zn 
metallo-β-lactamase.19 All these enzymes showed new to nature catalytic reactivity. 
This strategy is however limited in the scope of the binding site where only 
metalloenzymes with a proper coordination motif for a metal can be used. In 
addition, the enzymes need to be separated from their natural metal with certainty. 
If the metal is not removed, the new transition metal cannot be inserted. Finally, 
metal substitution enhances the non-specific metal binding to other potential binding 
sites. 
 
One strategy to overcome the limitation of scaffold scope is the screening of existing 
protein binding sites for a potential binding of transition metals.12 Ward and co-
5 
 
workers used this technique to create a new to nature OsO4-streptavidin AM, after 
the screening of five potential proteins.20 The second option for the creation of dative 
anchoring sites is the de novo design of a metal binding protein. A new metal-binding 
site is formed by the incorporation of the appropriate amino acids (or unnatural 
amino acids) via site-directed mutagenesis. This strategy significantly increases the 
choice of scaffolds. 
An example of direct metal incorporation was provided by Reetz and co-workers, who 
created a Cu(II)-binding site inside the thermostable enzyme tHisF.21 They first 
inspected the protein crystal structure to target amino acids for the conventional site-
specific mutagenesis. The authors introduced a His/His/Asp coordinating 
environment in the TIM-barrel of the tHisF to welcome the Cu(II) ion. The resulting 
AM was able to perform a new Diels-Alder reaction with moderate enantioselectivity 
(46 % ee).  
To expand the opportunities of metal coordination in scaffolds, researchers have also 
developed unnatural amino acids. As an example, Roelfes and co-worker inserted in 
vivo the unnatural amino acid bipyridyl alanine (BpyAla) inside their extensively 
studied AM scaffold, the lactococcal multidrug resistant receptor (LmrR, Figure 2).22 
This dimer receptor forms a hydrophobic pocket that fits both the metal complex and 
the substrate. Insertion of BpyAla coordinates the binding of Cu(II) ion to perform a 
Friedel-Craft reaction catalysis with up to 94 % ee. 
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Figure 2: Representation of the LmrR engineered in vivo with incorporation of BpyAla residues to 
create AM. After coordination of the Cu(II) ion, an example of its new to nature catalysis of Friedel-
Crafts alkylation reaction is presented. Adapted from Roefle article.23 
With help from computational design RosettaMatch,24 Baker and co-workers also 
created a new AM using BpyAla, aspartic acid and glutamic acid residues as metal-
binding amino acids (Figure 3).25 Experimental confirmation revealed a crystal 
structure of the designed protein, with the BpyAla binding Co2+ or Ni2+. 
A) B)   
Figure 3: Reproduction of Baker and co-workers designed protein.25 A) Solved crystal structure of their 
designed protein with Co2+ B) and Ni2+.  
The development of methodologies for the de novo binding site design has been 
extensively studied to increase the potential of AMs engineering. However, the 
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engineering of a new binding site must not prefer the metal binding over other 
structures the scaffold needs to accommodate, like the substrates and any potential 
cofactors. In addition, accommodation of the new binding site can be a challenge for 
the overall structural stability. 
 
In this second approach, a synthetic ligand linked to a metal catalyst is covalently 
bound to an exposed amino acid inside a protein scaffold (Figure 1). This results in 
the most stable and the most common linkage between two structures. Besides, this 
strategy provides high flexibility in the scaffold and transition metal choice. 
This bioconjugation still implies requirements. First, a suitable reactive residue 
(generally nucleophile cysteine or lysine) must be present in the binding site while 
similar reactive residues have to be removed. Secondly, the ligand should possess a 
reactive functional group able to make the irreversible connection reaction (e.g. 
nucleophilic attack, disulphide bond, cycloaddition). Finally, the enzyme cavity must 
be large enough to contain the whole metal complex with the ligand linker and the 
substrate.11 
Kaiser and co-worker first reported the potential of a synthetic ligands covalently 
bind to a protein scaffold.26 They used the nucleophilic activity of the single cysteine 
in papain to selectively alkylate a brominated flavin α-haloketone (Figure 4, A). This 
resulted in an oxidoreductase catalysing the oxidation of dihydronicotinamides. 
Distefano and co-workers first started to explore enantioselective catalysis with 
covalent binding of a metal catalyst. They focused on the adipocyte lipid-binding 
protein which structure contains only one cysteine.27 They bioconjugated the 
iodoacetamido-1,10-phenanthroline ligand and metalated the bioconjugate with 
Cu(II) (Figure 4, B). The resulting AM catalysed amide and ester hydrolysis with high 
enantioselectivity (more than 90 % ee).28 
Based on these preliminary results, several groups have tested multiple ligands and 
protein scaffolds for covalent bioconjugation. Reetz and co-workers developed a 
series of maleimide-substitutes bypiridine ligand metalated with Pd, Cu and Rh 
(Figure 4, B and C). They proved the alkylation with first the papain cysteine29 and 
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then inside the tHisF thermostable enzyme.30 Salmain and co-workers then 
bioconjugated a Ru(II)η6-arene complex inside papain protein with significantly 
better catalytic activity on Diels-Alder reaction than preliminary work from Kaiser and 
co-workers (Figure 4, D).31 Lewis and co-workers32 and Hayachi and co-workers33 
designed a maleimide-substituted terpyridine ligand metalated with Mn and Cu 
respectively (Figure 4, E). They both bioconjugated inside the nitrobindin protein to 
produce AMs catalysing oxygenations and Diels-Alder reactions. Meanwhile, Banse 
and co-worker bioconjugated a Fe(II) amine/pyridine ligand complex with the only 
cysteine available inside the bovine β-lactoglobulin (Figure 4, F), resulting in a 
peroxygenase.34  
 
Figure 4: Representation of ligands structures used in literature to make covalent linkage in order to 
anchor metal ions inside a host to form AMs. 
Some non-maleimide based ligands have also been reported. For example, Kamer 
and co-worker bioconjugated a phosphine-based ligand, metalated with Rh or Pd, 
inside the photoactive yellow protein (Figure 4, G).35,36 Gebbink and co-workers 
reported the bioconjugation inside a lipase cutinase of a Grubbs type metal catalyst: 
Rh(NHC) or Ru(NHC) (NHC= N-heterocyclic carbene).37,38 The authors used a 
phosphonate lipase inhibitor as ligand to covalently bind the Grubbs catalyst through 
active site-directed hybridization of a serine residue in the lipase (Figure 5). The 
resulting AMs catalysed the hydrogenation of olefin and ketone, the ring-closing 
metathesis of diallyl tosylamine and the cross-metathesis of allylbenzene. 
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Figure 5: Reaction scheme of the bioconjugation of lipase cutinase hybrid, adapted from Gebbink and 
co-worker.37 
These authors also realised that the chain length of their ligand was important. With 
a short linker, no metathesis activity was spotted. 
However, since Distefano works, little or no enantioselectivity has been detected 
with all engineered AMs. The importance of the ligand size and binding position is 
essential for selectivity. Lu and co-worker followed a rational design approach on the 
anchoring location and movements of a covalently bound ligand.39 They studied a 
MnSalen complex bioconjugated inside an apo-myoglobin (Mb) (Figure 6, B).40 The 
authors predicted, by computational modelling, several ligand location prior to 
mutating the targeted residues inside the heme cavity.  
A)  
B)  
Figure 6: MnSalen complex inside apo-Mb protein scaffold, reproduced from Lu and co-workers.40 A) 
MnSalen complex B) Computer model of MnSalen dual anchoring in Mb, overlayed with the protein 
natural heme cofactor. 
10 
 
The resulting optimised AMs carried a dual anchoring to two mutated cysteine 
residues. The experimental work showed a clear increase in asymmetric sulfoxidation 
(up to 83 % ee). In addition, any changes in anchoring positions revealed significant 
changes in the reaction rate and enantioselectivity. On sulfoxidation of thioanisole, 
the MnSalen complex alone yielded 1 % ee-(S), a single anchoring yielded 12 % ee-(S) 
and for the dual anchoring 66 % ee-(S) was recorded. The two-point covalent 
anchoring may have decreased the complex movement within the scaffold, 
enhancing selectivity.  
This hypothesis was later confirmed by Lewis and co-workers,41 who introduced a 
histidine residue to coordinate their metal catalyst in a two-point anchoring. The 
authors extended activity and selectivity of propyl oligopeptidase AMs by an active 
site mutagenesis. Roelfes and co-workers clearly confirmed the impact of the 
anchoring position on the conversion and enantioselectivity by a mutagenesis study 
of their Cu(II)-LmrR AM.42,43 The environment around the metal complex catalyst, 
provided by the protein scaffold, is key to an efficient catalysis.23,43  
Overall, the covalent anchoring of a metal catalyst introduced non-natural reactions, 
increasing reaction scope of enzymes, while adding high enantioselectivity and 
robustness of the complex metal-enzyme. However, the covalent anchoring of a 
metal complex presents challenges. For example, a single residue is needed for the 
bioconjugation. Prior steps are thus necessary to mutate any potential other reactive 
amino acid in the host scaffold, with caution for the structural stability. Besides, the 
chemical reaction endured by the enzyme during bioconjugation also threaten the 
integrity of the scaffold. Finally, the ligand size may limit the encapsulation inside the 
protein scaffold. 
 
Covalent and dative strategies are limited by the need of specific amino acids and 
restricting chemical reactions. Another strategy for the incorporation of a metal 
complex catalyst is the supramolecular anchoring (Figure 1). In this approach, the 
metal catalyst is anchored by strong and specific non-covalent linkage inside the 
protein. These types of linkages involve no electron sharing, but weaker interaction 
forces such as hydrophobic, electrostatic interactions or hydrogen bonding.  
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This supramolecular strategy has several advantages: there is no need for a coupling 
chemical reaction, no need for modifications of the enzyme scaffold, diversity in the 
nature of the metal catalyst and enzyme structure and easier optimisation of the 
engineered AMs.44 There are however some drawbacks in the design of 
supramolecular AMs. For example, the strength and selectivity of the non-covalent 
bindings are a challenge, with possible formation of unexpected bindings inhibiting 
the enzyme activity. 
The supramolecular binding approach can be divided in two strategies: the metal 
complex is directly bound to the protein scaffold or a ligand linker bind the metal 
complex to the scaffold. 
 
Unlike metal binding using dative interactions, the metal complex binding involves 
supramolecular interactions with a ligand coordinating the metal ion. These 
interactions are often labile, and the slightest modifications in the ligand structure 
results in an entire change of reactivity. 
The apo version of heme proteins were among the first to be shown to accommodate 
non-natural metal complexes, which were non-covalently bound in place of heme.  
Watanabe and co-workers introduced several metal complexes inside a suitable 
mutant of apo-Mb protein.45 They generated artificial sulfoxidases by the 
introduction of a Mn(III)/Cr(III)-salophen Schiff bases (Figure 7). The planar structure 
of the metal complex results in similar binding as the natural cofactor heme. 
 
Figure 7: Example of Cr(III)-salophen catalyst complex, reported from Watanabe and co-workers.45  
Hartwigs and co-workers created several AMs using protoporphyrin and 
mesoporphirin IX (PIX) as metal coordinating ligand. They reconstituted apo-(PIX)-
proteins by replacing the natural iron metal. In the apo-Mb scaffold, they inserted a 
protoporphyrin IX metalated with different metals (Co, Cu, Mn, Rh, Ir, Ru and Ag).46 
After optimisation by targeted mutations of the active site, the best AM selected was 
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the Ir(Me)-PIX-Myo, catalysing the epoxidation of olefin (up to 82 % ee) and C-H 
intramolecular insertion of diazo substrate (up to 86 % ee). Based on this work, 
Hartwig and co-workers recently replaced a cytochrome P450 heme by the Ir(Me)-
PIX catalyst, using molecular evolution.47 The new AM showed non-natural reactivity 
of intramolecular C-H amination of sulfonyl azides (Figure 8).  
 
Figure 8: C-H amination reaction scheme catalysed by the best Ir(Me)-PIX CYP119 enzyme variant. 
Figure adapted from Hartwig and co-workers.47 
Another scaffold for metal complex binding is the LmrR, extensively studied by 
Roelfes and co-worker. The authors recently reported the binding of Cu(II)-
phenantroline catalyst inside the interface cavity of the receptor (Figure 9).48 The 
hydrophobicity of the cavity and two central tryptophans favour a planar 
coordination of the metal complexes. They thus started to evaluate the activity of 
several bidentate aromatic nitrogen Cu(II) complexes. The engineered AMs were able 
to catalyse a Frieldel-Crafts alkylation of indoles with high enantioselectivity (up to 
93 % ee).  
 
Figure 9: Representation of supramolecular assembly of Cu(II)-phenantroline complex catalyst inside 
LmrR, with an example of its new to nature Frieldel-Crafts alkylation of indole. Adapted from Roelfes 
and co-workers.23 
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The Roelfes group later bonded a hemin complex inside LmrR for an AM catalysing 
cyclopropanation reactions with enantioselectivity (51 % ee).23 
 
In the previous non-covalent metal complex binding strategy, modifications to the 
ligand coordinating the metal will automatically change the binding to the scaffold 
and thus the activity and selectivity of the AM. In turn, the binding of the metal 
complex might affect its chemical abilities.  
One way to decouple the catalyst from the binding process is to add an anchoring 
ligand in between. This approach also brings challenges: the ligand must bind strongly 
enough to the scaffold and the metal position must allow reactivity and selectivity. 
One of the first and the most studied scaffold to generate non-covalent AM is the 
avidin (Av) or streptavidin (Sav). This approach relies on the naturally strong non-
covalent interaction between the protein (strept)avidin and its natural coenzyme 
biotin (1012 - 1015 M-1 affinity).49 The concept was first described by Wilson and 
Whitesides in 1978.50 They embedded the achiral [Rh(nbd)(diphosphine)]+ complex 
(nbd= norbomadiene) within avidin to generate an artificial hydrogenase (Figure 10). 
To this end, the authors substituted the biotin anchoring ligand with a diphosphine 
to coordinate Rh(I). The resulting AM catalysed the reduction of α-acetamidoacrylic 
acid with enantioselectivity 41 % ee-(S). 
 
Figure 10: Presentation of the first AM based on Av/Sav technology, catalysing the hydrogenation of 
α-acetamidoacrylic acid. This AM was composed of a biotinylated Rh catalyst non-covalently bound 
inside avidin. Figure adapted from Wilson and Whitesides.50 
Later, Chan and co-worker reported similar conclusions using chiral biothinylated 
Rh(I)-pyrphos complex linked to biotin and embedded within avidin.51 The resulting 
AM catalysed the asymmetric hydrogenation of itaconic acid (37 % ee-(S)). 
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In recent years, the biotin-(strept)avidin technology has been extensively developed 
by Ward and co-workers. They started in 2001 by changing the scaffold of the protein 
to Streptavidin (Sav), easily recombinantly expressed in E. coli. The authors then 
applied combined optimisations. A chemical optimisation of the synthetic ligand gave 
a small library of metal catalyst complexes.49 Besides, genetic modifications created 
a library of Sav mutants, changing the surrounding of the metal catalyst.52 
Combination of both first and second coordination spheres optimisations engineered 
a small library of efficient AMs.  
Ward and co-workers initial experiments bound biotinylated Rh-diphosphine 
complexes ([Rh(COD)Biot], COD= 1,5-cyclooctadiene) within Sav, to build an artificial 
hydrogenase catalysing the hydrogenation of N-protected dehydroamino acids. They 
then chemically optimised the first-generation catalyst by adding amino acid linkers 
between biotin and the metal complex (18 biotinylated catalysts designed, Figure 
11). They also realised saturation mutagenesis for the creation of a Sav mutant 
library. The combined strategy improved the catalytic selectivity up to 96 % ee-(R)  
and 95 % ee-(S)  with [Rh(COD)Biot-Phe-2]-Sav(S122G).53,54,55 
 
Figure 11: Examples of biotinylated metal complexes, designed to be non-covalently embedded inside 
Sav to build artificial hydrogenases. [Rh(COD)Biot-1] is constructed with the first generation of 
diphosphine ligand. The other complexes were then optimised with amino acid spacers.49,55 
Following their success in hydrogenation catalysis, Ward and co-workers applied the 
biotin-streptavidin technology to one fundamental chemical reaction: the 
asymmetric transfer hydrogenation of carbonyl. In addition, the authors investigated 
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the versatility of their AMs to imitate the ketone oxidoreduction of a natural enzyme. 
They selected the piano-stool catalyst complex, which was used by Noyori to catalyse 
the prochiral ketone reduction and the oxidation of secondary alcohol.56 Ward and 
co-workers embedded diamine biotinylated d6 piano-stool complexes inside Sav 
(Figure 12).57 They again combined chemo-genetic optimisations to create a library 
of improved AMs.58,59 
 
Figure 12: AM model for the enantioselective transfer hydrogenation of carbonyl, adapted from Ward 
and co-workers.58 The ligand biotin (blue) is separated from the d6 piano-stool metal complex (red) by 
different spacers (green). The prochiral substrate receives two hydrogens without coordinating with 
the metal.   
The common transition metals rhodium (Rh), iridium (Ir), and ruthenium (Ru) were 
used with different arene-cap. Variation in the capping impacted the 
enantiopreferences. In addition, distinct genetic mutations on the scaffold showed 
an impact on stereoselectivity when cationic residues were around the metal.52 The 
best enantioselectivity was obtained with a [η6-(p-cymene)RuCl-Biot] - Sav S112Y 
mutant for 97 % ee-(R) and [η6-(benzene)RuCl-Biot]  Sav S112R mutant for 70 % ee-
(S). For the reverse reaction, only the oxidation of sec-phenethyl alcohol was 
catalysed using the biotinylated amino-sulfonamide Ru(II) catalyst embedded within 
avidin protein.60 
Ward and co-workers then utilised similar biotinylated d6 piano-stool catalysts for the 
creation of artificial cyclic imine reductases library (Figure 13). The chemo-genetic 
optimisations, coupled to computational design, enabled the selection of the best 
AMs with improved enantioselectivity: 85 % ee-(R) salsolidine with [Cp*IrCl-Biot] - 
Sav S112R-N118P-K121A-S122M-L124Y and 78 % ee-(S) salsolidine with [Cp*IrCl-Biot] 
- Sav S112A-N118P-K121A-S122M and an enhanced substrate scope.61,62,63,64 
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Figure 13: An example the asymmetrical reduction from cyclic imine to amines, catalyse by an AM 
based on the biotin-Sav technology. 
Notably, Ward and co-workers used in silico studies to introduce a suitable histidine 
residue in the active site. The mutation provided a dual anchoring of the metal 
through a new dative bond, improving the activity and selectivity. The synthesis of 
this AM and the structural characterisation confirmed the computational design.65 
The authors applied the Biotin-Sav technology to numerous reactions, including 
notably olefin metathesis with Grubbs like catalysts,66 sulfoxidation with Mn-salen 
catalysts67 or phosphino-palladium catalysed Suzuki reactions.68 
A collaboration with Rovis led to an AM catalysing the enantioselective 
benzannulation reaction (Figure 14). For a new C-C bond formation a C-H bond needs 
to be first activated by deprotonation from a base in excess. The authors induced an 
intramolecular deprotonation by introducing with site-directed mutagenesis a 
carboxylate residue in the active site.69 
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Figure 14: Enantioselective benzannulation catalysed by a new Sav-AM, adapted from Ward and co-
workers.69 A) Synergistic action of a basic residue introduced by site-directed mutagenesis with a 
biotinylated RhCp*Cl catalyst non-covalently bound to Sav. B) Reaction scheme of the synthesis of 
dihydroisoquinolones by benzannulation reaction catalysed by the new Sav AM.  
In nature, numerous enzymes are collaborating for the synthesis of products via 
metabolic pathways. However, if a non-natural occurring reaction is wanted in these 
cascade reactions, a free metal catalyst would not be able to stand alone. In their 
recent work, the Ward group hypothesised that AMs could be an attractive solution 
to protect metal catalysts during cascade reactions. To prove this, they first combined 
an artificial imine reductase with a natural amine oxidase (monoamine oxidase, 
MAO). However, the imine reductase was poisoned by hydrogen peroxide produced 
by the MAO. They thus introduced a third enzyme, a catalase (Figure 15).70 Using a 
[Cp*Ir(biot)Cl] – Sav S112T imine reductase, conversion was observed toward (R)-
salsolidine with 99% ee. Upon varying the AM, further cyclic imines or ketones could 
be reduced. 
 
Active site
tailoring
AM minimally
active
Highly active 
AM
A)
B)
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Figure 15: Representation of the double deracemization with MAO/artificial imine reductase 
(ATHase)/catalase, reproduced from Ward and co-workers.70 
Interestingly, artificial imine reductases have also been applied in NADH regeneration 
within cascade reactions. NADH is an expensive cofactor and thus its regeneration 
has been investigated intensely.71,72 Ward and co-workers used [Cp*Ir(biot)Cl] – WT 
Sav coupled with the 2-hydroxybiphenylmonooxygenase (hbpA) and formate as the 
hydride source to regenerate NADH cofactor.70  
Furthermore, Ward group teamed with Hollmann and co-workers to regenerate NAD 
mimics in a cascade using formate as hydrogen source.73 The regeneration cascade 
was tested on five NAD mimics, using the iridium biotinylated-Sav coupled with an 
ene-reductase of the Old Yellow Enzyme family (TsOYE). Only one mimic reduced with 
enantioselectivity (up to 98 % ee-(R)) and high turnover number (100-1000 TON).  
Subsequently, Ward and co-workers developed a cascade of reactions in vivo, with 
the biotin-(strept)avidin technology. Using their library of artificial imine reductases, 
they screened for an AM able to use the natural NAD(P)H cofactor as the hydride 
source for transfer hydrogenation reactions (a critical parameter to work in vivo).74 
The authors engineered several in vivo cascades with natural enzymes and catalysed 
several reaction types (e.g. hydride transfer reaction, olefin metathesis).75 As an 
example, they designed a gene switch inside a mammalian cell that was activated by 
a molecule produced with their AM (engineered HEK-293T mammalian cells).76 The 
gene activation then upregulated the expression of a bioluminescent nanoluc 
marker. One challenge of the system was the required integration of AM inside the 
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cells. The authors optimised their AM with a cell penetrating poly(disulfide) (CPD), in 
order to maximise the uptake of the AM. After addition of AM substrate, the 
luminescence in the presence of both AM-(CPD) and Hek-293T cells was significantly 
superior to the cells alone or to the cells with AM without CPD. Ward and co-workers 
highlighted the importance of cell penetration for AM used in vivo. They later 
succeeded in showing the expression and the activity of AMs in the periplasm77 and 
at the surface of E. coli.78 
Following the success of biotin-(strept)avidin technology and to increase the scope 
of scaffolds, other proteins have been studied for supramolecular anchoring. In a 
similar concept, the identification of high affinity between the scaffold and the 
potential ligand anchor is essential. For example, Mahy and Ricoux group studied the 
neocarzinostatin scaffold, naturally evolved to strongly bind testosterone. They 
coupled the testosterone with Fe(III)79 Zn(II)80 and Cu(II)81 to create AMs catalysing 
respectively the oxidation of thioanisole, the hydrolysis of phosphate ester and the 
Diels-Alder cyclisation reactions. However, in all these models, low enantioselectivity 
was observed. 
Ward and co-workers also worked successfully on another type of host protein: 
human carbonic anhydrase II (hCAII). The protein is known to bind aryl sulfonamides 
cofactors. The authors bound several sulfonamide-substituted Ir d6 piano-stool 
catalysts [(η5-Cp*)Ir(pico)Cl], to generate artificial transfer hydrogenases, with weak 
enantioselectivity (68 % ee-(S) salsolidine, Figure 16A).82,83 Later, through 
computational modelling using Rosetta Design, they genetically optimised their AM 
model based on the crystal structure (PDB 3ZP9).84 This resulted in a more tightly 
bound catalyst by new packing interactions and a stabilisation of the protein 
backbone through H-bonds. The catalyst was embedded in a fixed orientation within 
the protein. Experimental tests showed an increase in the affinity of [(η5-
Cp*)Ir(pico)Cl] for the enzyme in all the new designs. Besides, activity and 
enantioselectivity were significantly improved from the first model (up to 92 % ee-(S) 
salsolidine). In a similar rational design method, Ward and co-workers also 
introduced a Grubbs-Hoveyda catalyst to engineer artificial metathesases (Figure 
16B).85 
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A)    
B)  
Figure 16: Two AMs adapted from Ward and co-workers. A) AM for the transfer hydrogenation of 
salsolidine. The bidentate ligand (blue) anchor the IrCp* metal complex inside hCAII.83 B) AM for ring-
closing metathesis. The arylsulfonamide ligand (blue) is anchoring the Grubbs-Hoveyda type catalyst 
inside hCAII.85  
Following a similar strategy to biotin-Sav, Tanaka and co-workers developed an AM 
based on the supramolecular interaction albumin-coumarin. They linked a Ru catalyst 
to a coumarin anchor, binding strongly inside the albumin hydrophobic pocket. The 
anti-cancer therapeutic potential was highlighted along with the interesting 
biocompatibility of this human based AM.86 
The supramolecular anchoring strategy is a dynamic and self-adjustable system, 
conductive to wide optimisation opportunities. The different designs of AMs proved 
how changing the active site around the metal (second coordination sphere) 
impacted the activity (e.g. charged residues might decrease imine reductases 
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activity). Modifications of the features in direct coordination with the metal (first 
coordination sphere) also impact activity and selectivity (e.g. arene capping). A tightly 
bound catalyst seemed to react better than a loose one. All these conclusions showed 
how the design of non-covalent AMs can be challenging. Any subtle changes that can 
occur in the contacts between the anchoring ligand and the scaffold must be taken 
into accompt. These previous works also bring forward how understanding the 
structure of the scaffold and the position of the metal catalyst is critical.  
 
A critical requirement in the design of AMs is the selection of a suitable enzyme 
scaffold to interact with the metal catalyst and the substrate during the catalytic 
reaction. This project will focus on the reduction of carbon-heteroatom double bonds 
by modification of natural reductases.  
 
One of the most prevalent biocatalysts for the reduction of carbonyls is the 
nicotinamide-dependent alcohol dehydrogenase (ADH),87 present in many organisms 
(human, animals, bacteria, yeast…). ADHs detoxify alcohol in the mammalian 
organisms, and they are part of the fermentation process in yeast and bacteria. 
Another interesting fact about ADHs is the broad range of substrates they accept. 
ADHs have been classified in three subfamilies depending on their amino acid chain 
length and structure: The short-chain dehydrogenases / reductases (SDRs), the 
medium-chain dehydrogenases / reductases (MDRs) and the long-chain 
dehydrogenases / reductases (LDRs). The common structural feature to all ADHs is 
the Rossman-fold element, defined by a three-layered arrangement of a beta sheet 
composed of six beta strands surrounded by two alpha helices. This strand topology 
is the typical binding site for the NAD(P)H natural cofactor.88 
ADHs catalyse the reversible oxidation of primary and secondary alcohols to 
aldehydes and ketones via transfer hydrogenation reaction, using the cofactor 
NAD(P)H / NAD(P)+ as an electron acceptor/donor. The presence of natural, stable, 
and operative cofactor-enzyme interactions is interesting for the supramolecular 
anchoring strategy. 
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The two ADHs used as scaffold in the project are part of the MDRs sub-family: the 
horse liver alcohol dehydrogenase (HLADH) and the Thermoanaerobacter brockii 
ADH (TbADH). Both are zinc-dependent enzymes. 
 
The HLADH crystal structure has been resolved since 1976 by Eklund and co-workers 
(PDB 4XD2, Figure 17).89 Mammalian ADHs are dimer structures, built on two 
domains: the C-terminal domain, composed of the Rossmann fold motif (cofactor 
binding site), and the N-terminal catalytic domain for the substrate binding. Two zinc 
ions were identified in the HLADH structure. The first Zn2+ is coordinated by four 
cysteines (C97, C100, C103 and C111) and is used for the structural stabilisation of 
the enzyme. The second zinc ion is a catalytic Zn2+, tetrahedrally-coordinated by 
C174, C46, H67 and a molecule of water which is replaced by the hydroxyl group of 
the alcohol substrate during catalysis. This Zn2+ ion is located at the intersection of 
the cofactor and the substrate binding pocket.90,91  
 
Figure 17: Horse liver ADH (HLADH) structure (PDB 4xd2) with NAD(H) cofactor (green) at the domain’s 
interfaces. Zn2+ are displayed in red spheres.92 
 
The catalytic mechanism of HLADH implies a hydrogen transfer between the natural 
NAD+ cofactor and the alcohol substrate (Figure 18). The oxidation reaction starts by 
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the binding of NAD+ into the cofactor pocket,91 followed by the alcohol substrate 
binding to Zn2+ via displacement of a molecule of water. An extended connection is 
then established:  the 2-OH of the nicotinamide ribose is hydrogen bonded to H51 
which engages a cascade of proton transfer to deprotonate the zinc-bound 
alcoholate and transfer the hydride toward the nicotinamide ring of NAD+. 
 
Figure 18: Catalytic mechanism of HLADH based on proton-relay, reproduced from Lee and co-
workers.93  
After the dissociation of the aldehyde product from Zn2+ and replacement by a water 
molecule, the reduced NADH form leaves with the opening of the cofactor binding 
pocket.  
The reverse hydride transfer reaction is also observed from the reduced NADH 
cofactor to the carbonyl carbon of an aldehyde, liberating the NAD+ oxidized form.94 
 
24 
 
 
The different ADHs possess distinct specificities for their natural cofactor. Some are 
more active with NAD(H), one of the most important cofactors found in cellular 
mechanisms (e.g. gene expression, cell death, signal transduction),95 while others 
prefer NADP(H) (Figure 19). The human liver ADH and HLADH use NAD(H).96  
A)  
B)  
Figure 19: Structure of the ADHs natural cofactors A) NADH and B) NADPH. The structure is divided in 
two parts: the adenine ring and the nicotinamide ring, used for the catalytic activity. The two parts are 
linked by a diphosphate group. Their oxidized forms are respectively NAD+ and NADP+. 
Upon the binding of NAD(H) cofactor, a drastic change in domain conformation closes 
the cofactor binding site and brings NAD(H) closer to the catalytic site.97 
Inside the narrow cofactor binding pocket, the adenine ring of NAD(H) is placed in a 
hydrophobic cleft, pointing toward the solvent. The ribose hydroxyls are hydrogen 
bonded to an acid aspartic residue side chain, the D223 (Figure 20). The middle 
pyrophosphate group is bound through its oxygens to two arginines side chains. The 
nicotinamide is composed of one pyridine ring (N-ring), important for the catalytic 
reactivity, and an amide group interacting with F319, A317 and V292 residues. 
Hydrophobic interactions between one face of the N-ring and V203, V292 and T178 
residues place the nicotinamide part close to the active site and Zn2+.91 The correct 
binding position of the nicotinamide ring is particularly important for the catalytic 
activity.  
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Figure 20: Schematic representation of binding interactions between HLADH crystal structure (PDB 
4xd2) and NAD+: amide binding (blue), nicotinamide ribose binding (green), pyrophosphate binding 
(red) and adenine ribose binding (orange). 
The specificity of ADHs for the two cofactors has been explained in several studies by 
comparison of catalytic activity. However, the catalytic activity only gives an 
indication of binding but not a precise affinity strength or insights in the binding 
process. 
Fan and co-workers showed that the presence of D223, in the active site of HLADH 
acts as a charge repulsive for NADPH.98 The presence of a phosphate on the ribose 
just in front of the aspartic acid residue leads to an electrostatic repulsion, preventing 
the correct position of NADPH. To support their theory, the corresponding amino acid 
(D201) in the yeast ADH I was mutated into a glycine. They realised steady-state 
kinetic studies on ethanol oxidation. The results highlighted changes toward an equal 
use of NAD+ and NADP+. The authors suggested that D223 was responsible of the 
exclusion of NADP(H) cofactors. 
More recently, a study compared HLADH to the complex NADPH-ADH8 (ADH from 
amphibian Rana perezi), the only vertebrate ADH specific to NADPH.99 In ADH8, 
contacts along the binding pocket remain identical to HLADH at the exception of a 
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cleft in place of D223. The small pocket is composed of neutral and basic amino acids 
(G222, T223, H224, K227 and L199), allowing the insertion of the NADPH phosphate. 
This study confirms again Fan’s conclusions that D223 is responsible for the NADH 
specificity in ADHs. The presence of the phosphate group in NADP(H) leads to 
electronic and space clashes inside liver ADH, probably reducing the binding affinity 
and thus the activity. 
 
Tetrameric type of ADHs can also be found, mainly in fungal, bacterial or yeast 
enzymes.96 TbADH is a tetrameric alcohol dehydrogenase from the bacteria 
Thermoanaerobacter brokii, first described in 1980 by Lamed and Zeikus (Figure 
21).100 Each monomer are composed of a Rossmann fold cofactor binding site 
connected to a catalytic site by an α–helix.97 
Like most of the alcohol dehydrogenase, TbADH activity depends on a Zn2+ ion located 
in the catalytic site. In contrast to HLADH, Zn2+ is bound to four amino acids: C37, H59, 
E60 and D150 (replaced by a molecule of water in HLADH).93  
 
Figure 21: Holo-TbADH crystal structure at 2.5 Å (PDB 1YKF) with its natural cofactor (green) and the 
Zn2+ ions in red spheres.97 
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TbADH is also well known for its high stability: the enzyme is stable at high 
temperature (up to 93 °C) and shows resistance to organic solvents.97 
 
The TbADH mechanism follows an alternative model to the one explained in HLADH 
(Figure 22). The catalytic Zn2+ forms two penta-coordinated complexes with water 
and substrate, and no extended proton relay transfer are necessary.93  
 
 
Figure 22: Reproduction of the catalytic mechanism of TbADH from Lee and co-workers. Int.1 and Int.2 
are the two intermediates penta-coordinated.93 
The binding of NADP+ forms the first penta-coordinated zinc complex, with the 
addition of a water molecule (Int.1). A tetra coordinated Zn2+ ion is back with the 
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dissociation of E60. The subsequent binding of the alcohol substrate leads to the 
second intermediate penta-coordinated (Int.2). The hydride transfer is then 
completed and yield the cofactor reduced form NADPH and the aldehyde/ketone 
product. The detachment of the product induces the association of E60 to provide 
the original tetra-coordinate zinc complex. 
 
Only 27 % of TbADH sequence is identical to eukaryotes enzymes, including HLADH. 
The majority of the similarities is concentrated in the cofactor binding site (43 % 
identity).101 Nonetheless, TbADH is among the few ADHs dependent to NADP(H). The 
specificity for NADP(H) cofactors over NAD(H) is explained in the binding site 
composition and support the previous explanations of HLADH specificity 
(section1.3.2.2, page 24). 
Frolow and co-workers affirmed the specificity for NADP(H) cofactor relies on four 
residues: G198, S199, R200 and Y218 (Figure 23).97 First, the G198 replaces the D223 
residue found in all NAD(H)-dependent enzymes, including HLADH. As discussed 
previously, this aspartic acid creates charge repulsion with the phosphate ribose of 
NADP(H). G198 residue is composed of a smaller side chain, fitting the extra 
phosphate. The three other residues are then making hydrogen bonds with the extra 
phosphate of NADP(H). Through the adenine part binding, the whole cofactor is 
stabilised and more efficient. 
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Figure 23: Interactions of TbADH (PDB 1ykf) with NADPH: amide binding (blue), nicotinamide ribose 
binding (green), pyrophosphate binding (red) and adenine phosphate ribose binding (orange).97 
Upon binding of the cofactor, the four catalytic domains of the monomers initiate a 
movement that slightly changes conformation.97 As a consequence, the whole 
tetramer structure expends. In contrast, HLADH is subject to more drastic changes of 
the rigid body, narrowing the pocket.  
The cofactor binding diagram clearly shows less hydrogen bonds than in HLADH one 
(Figure 20). Here, only one amino acid binds to the amide and the ribose hydroxyl, 
and only two residues exchange hydrogen bonds with the pyrophosphate. The more 
intensive binding is held by the adenine part, explaining again the specific affinity of 
TbADH for NADP(H) cofactor. 
 
The high cost of NAD(P)H cofactors have led studies to seek for alternative, less 
expensive NADH mimics.102 Generally, the mimics were designed with the 
replacement of the adenosine-phosphate-ribose part. 
At first, Ansell and co-workers designed a cofactor analogue called CL4, based on the 
nicotinamide ring substituted by triazines (Figure 24).103 They tested CL4 inside 
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HLADH for the oxidation of butan-1-ol. Compared to NAD+ cofactor, the authors 
obtained a lower efficiency (low Vmax and high KM). 
 
Figure 24: CL4 mimic is an analogue of NADH cofactor, designed by Ansell and co-workers. Only the 
nicotinamide ring was preserved and substituted by triazines.103  
Later, Fish and co-workers synthesised an even more truncated NADH biomimetic, 
with a benzyl group in place of the adenine, pyrophosphate and ribose parts (1; 
Figure 25).104,105 Several mimics were then synthesised, which kept the same model: 
a N-ring substituted by a benzyl group in place of adenine and pyrophosphate parts. 
 
Figure 25: 1-Benzylnicotinamide, used by Fish and co-workers to mimic NADH cofactor. 
The authors implied a recognition by HLADH and a catalytic activity of these mimics, 
using the reduction of several achiral ketones as model. For example, a yield of 90 % 
with 93 % ee was obtained with the mimic 1, while NAD+ obtained 91 % yield and 93 
% ee. They thus concluded that only 1,4-dihydronicotinamide part is necessary in the 
recognition and the binding to the cofactor binding site.  
However, these results have since been challenged by Paul and Hollmann, who linked 
the reactivity of these NAD+ mimics to the presence of NADH inside a non-pure 
HLADH protein.106 They later used a purified HLADH with the similar synthetic mimic 
1 and assumed from their preliminary results that the enzyme cannot bind the mimic. 
The authors suggested that some functional groups of NADH which were truncated 
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(mainly ribose or pyrophosphate) might play a relevant role in the affinity toward 
HLADH, and therefore the catalytic activity. 
Hollman group later investigated several NADH mimics in a flavin-dependent ene-
reductases (ER) for ketone and aldehyde reduction (Figure 26).107 Their results were 
equivalent to those with the natural NADPH cofactor, or even better. 
 
Figure 26: NADH mimics reduced form, tested inside ER enzymes by Hollman and co-workers for 
oxidoreduction reactions.107 
However, attempts with the same mimics on HLADH ended with no activity 
detected.108 
To the best of our knowledge, no literature evidence shows NAD(P)H cofactor mimics 
assays inside TbADH. The only interactions of mimics inside TbADH are found in Dr 
Mattias Basle’s thesis.109 He explored the binding of cofactor mimic 1 and its oxidised 
form inside both HLADH and TbADH, through activity and inhibition tests. The 
conclusions displayed no interaction between both enzymes and the derivatives.  
 
Artificial metalloenzymes is a prosperous strategy in biocatalysis. The engineering of 
these catalysts depends on multiple factors, among which the selection of a proper 
enzyme scaffold to stabilise the metal catalyst and the substrate in a catalytic 
orientation. In this project, the transfer hydrogenation of imines was selected as the 
chemical reaction targeted for the AM. 
Zn2+-dependent ADH enzymes activate the reduction of carbonyls by hydrogen 
transfer reaction, but despite their structure similarity with ketones, imines do not 
get reduced by ADHs. The stability, the structure, and the large substrate scope of 
ADHs make them interesting for the design of AMs. 
In addition, the natural NAD(P)H cofactor has already evolved to tightly bind inside 
ADHs, which represents an advantage for the supramolecular binding of a metal 
catalyst. For now, the literature indicates a lack of activity of short synthetic mimics 
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inside ADHs. This poor activity may be the result of a lack of crucial bounds inside the 
cofactor binding site, however this has never been confirmed by affinity studies in 
ADHs. A strong knowledge of NAD(P)H binding mode is thus required to improve the 
design of synthetic cofactors and increase affinity for ADHs.  
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The second requirement for the engineering of an AM is the choice of the metal 
catalyst, in agreement with the project objective: the modification of the previously 
described natural ADH for the transfer hydrogenation of carbon-heteroatom double 
bonds.  
 
The reduction by hydrogen transfer consists of an intermolecular transfer of 
hydrogen with its electron pair to an activated carbon. This process results in an 
oxidoreduction. These reactions are frequent in nature, where enzymes use organic 
hydride sources in cofactors such as the NADH or flavin adenine dinucleotide 
(FAD).110 Nature inspired chemists to create new organocatalysts, metal catalysts and 
biocatalysts for industrial applications. In 1903, Bergdolt and co-workers first 
reported the hydrogen transfer between two molecules catalysed by palladium.111  
The challenges of this reaction are the design of an efficient catalyst with enhanced 
yield and better enantioselectivity. 
 
 
In 1925, the first metal-catalysed transfer hydrogenation of a carbonyl compound 
was developed independently by Meerwein and Schmidt112 and by Verley.113 They 
reduced ketone and aldehyde in their corresponding alcohol using an aluminium 
alkoxide (now called the Meerwein–Ponndorf–Verley reduction reaction).  
Later, increased activity was discovered using transition metal catalysts. Rh, Ru and 
Ir have been extensively studied for their reactivity. Notably, Mason and co-workers 
used Ir complexes to catalyse the reduction of cyclohexanone to the corresponding 
alcohol, using water as the hydrogen source.114 Besides, Sasson and Blum developed 
Ru complexed with phosphine to successfully catalyse the transfer hydrogenation of 
ketones.115,116 However, in all these models, enantioselectivity was still a challenge 
and the production of chiral compounds required difficult purification steps. 
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The major breakthrough in asymmetric hydrogenation came from Knowles117 and 
Noyori,118 separately developing chiral complexes showing enantioselectivity on 
carbonyl and imines reduction by hydrogen transfer (respectively Rh(DIPAMP) and 
Ru-BINAP). Noyori and co-workers proved the transfer hydrogenation of ketone using 
Ru-d6 piano-stool complexes, but also the versatility of the catalyst by catalysing the 
oxidation of secondary alcohol (Figure 27).56 Later, Noyori reported the first imine 
reduction in 1996, by developing a piano-stool π-complex [Ru-TsDPEN] (TsDPEN= N-
(p-toluenesulfonyl)-1,2-diphenylethylenediamine) in combination with formic acid / 
Hϋnig’s base as hydrogen source.119 The importance of the η6-arene and the diamine 
ligand for the high selectivity and the broad substrate scope was proven.120 
 
Figure 27: Asymmetric transfer hydrogenation of carbonyl, catalysed by Noyori's chiral Ru complexes. 
The metal complex favoured transition state is depicted underneath the reaction scheme. Adapted 
from Noyori’s work.118  
The development of these transition metal catalysts started the race toward more 
efficient chiral selectivity of products for industrial applications. The most successful 
catalysts are based on Ru(II), Rh(III) and Ir(II) half-sandwich p-complexes, with a chiral 
bidentate ligand and an arene or Cp* (η5-pentamethylcyclopentadienyl) cap.121 The 
success of these catalysts comes from the achiral ligand for selectivity and the 
transition metal ion in low oxidation state for the control of activity. The hydrogen 
source comes from molecular hydrogen or organic hydrogen (e.g. formic acid, 2-
propanol). 
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Recent studies focus on a more environmentally friendly use of these transition metal 
complexes. Chiral arene Ru, Rh and Ir catalysts have been reported to catalyse the 
transfer hydrogenation of ketone and imine in aqueous media.122,123,124,125 A tosyl 
substituted chiral diamino ligand coordinates the transition metal ions (Figure 28). 
Sodium formate is use as the source of hydrogen. When high quantities of formate 
are used, the catalytic rate is increased. 
 
Figure 28: Hypothetic catalytic mechanism for the enantioselective transfer hydrogenation of imine, 
using a biotinylated Ru bidentate catalyst in aqueous solution with sodium formate as hydride source. 
Adapted from Suss-Fink and co-workers postulated mechanism.124  
Even closer to nature, examples from Ward74 and Soetens126 use similar metal 
catalyst with NADH cofactor as the hydrogen source. More recently, the change of 
metal to Osmium resulted in the reduction of pyruvate in vivo, in cancer cells.127 
 
For greener perspectives, organocatalysts are an ecological alternative to the use of 
metal ions in transfer hydrogenation reactions.110 
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List and co-workers128 with MacMillan and co-workers,129 reported separately the 
first metal-free transfer hydrogenation reaction (Figure 29). They used several 
ammonium salt as efficient catalysts, in combination with the Hantzsch ester as a 
hydrogen source mimicking the NADH cofactor.  
 
Figure 29: Transfer hydrogenation of double bonded carbon, catalysed by iminium combined with 
Hantzsch ester, separately reported by List and MacMillan groups.128  
Both groups later introduced asymmetry in a variety of their reactions.130,131,132 By 
introduction of chiral phosphate anion, List group proved a high enantioselectivity 
with a large scope of substrates containing C=C and C=N. They later extended their 
reaction scope toward the reduction of carbonyls by re-introducing the metal catalyst 
Cu(II)-bisoxazoline.133  
Even if less reactive than transition metal catalysts, organocatalysts are sometimes 
more stable than enzymes or organometallics, like in solid state reactions.110 
 
 
Enoate-reductases (ER) are the preferred natural catalysts for the C=C reduction by 
hydrogen transfer.87 However, their dependence on expensive NAD(P)H cofactors 
represents a major challenge for industrial applications, which is balanced by 
additional efforts to externally recycle the cofactor. New alternatives are the 
development of AMs. 
Hollmann and co-workers107 and Qian and co-workers134 created mimics of NADH 
inside the Old Yellow Enzyme family, to replace the expensive NAD(P)H in the 
catalysis of hydrogenation reactions (examples in Figure 26, page 31). 
Ward and co-workers reported on the hydrogenation of acetamidoacrylic acid using 
Sav AMs, from a library of Rh(diphosphine)(cod) biotinylated catalysts.54,53 The study 
37 
 
showed the importance of the metal catalyst structure. A more flexible linker 
between the metal and biotin catalysed the hydrogenation with better 
enantioselectivity than more rigid linkers. 
 
Dehydrogenases are the preferred enzymes to reduce carbonyls. Their large 
substrate scope and their high enantioselectivity (frequently surpassing chemical 
catalysts) make them the prime choice of chemical substitute.87 However, as seen in 
ERs, their dependence on the expensive cofactor NAD(P)H is a bias in their use at big 
scale. Alternatives rely again on recycling the cofactor or generating artificial 
dehydrogenases with low-cost catalysts. 
Noyori’s catalyst has been inserted within diverse AMs for the transfer hydrogenation 
of carbonyl. Salmain and co-workers used papain and bovine β-lactoglobuline 
proteins as host for several d6-Rh-bipyridines complexes.135,136 The resulting AMs 
catalysed the hydrogenation of cyclic ketones and NAD+ cofactor. 
A big step forward came from Ward and co-workers, who developed a now well-
known AM based on Sav, for the efficient reduction of ketones.57 They synthesised 
biotinylated catalysts composed of the aminosulfonamide Ru η6-arene complex 
attached to the biotin molecule and introduced into Sav (Figure 27, page 34). This 
new AM proved to be efficient in the asymmetric reduction of ketones with high 
enantioselectivity (94 % (R)). 
 
Chiral amines are important constituent of bioactive molecules derived from natural 
or chemical sources, with applications in chemical industries such as the fragrance, 
pharmaceutical or agricultural industry.137 
An efficient route to chiral amines is the reduction of imines. Natural imine reduction 
is performed by imine reductases (IREDs), discovered by Nagasawa and co-workers138 
in 2011, which marked the beginning of their exploitation. Notably, the work of both 
Hauer and-co-workers139 and recently Turner and co-workers140,141,142 extended the 
investigations on IREDs structures, substrate scope and activity. Specific (S) and (R) 
IREDs were identified, and their substrate explored. 
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The best artificial imine reductase reported for the transfer hydrogenation of imine 
comes from Ward and co-workers work on biotin-streptavidin. Investigations on the 
chemical part (optimisation of ligands and metal centres) and on the genetic side (2nd 
coordination sphere mutations), improved the scope of the reaction.10  
The authors identified the best complex for imine reduction as an Ir piano-stool inside 
streptavidin Sav112 mutant. Both (R)-salsolidine (95 % ee) and (S)-salsolidine (86 % 
ee) enantiomers were synthesised (Figure 13, page 16).64  
Based upon this work, Rimoldi and co-workers validated the use of a different ligand 
(1,3 aminosulfonamide) for the development of imine reductases.143,144 These AMs 
have then been applied to reaction cascade with natural enzymes, and coupled to 
the regeneration of NADH.70,74 
In recent work, Ward and co-worker changed the scaffold for the asymmetric 
hydrogenation of ketones and imines by using the hCaII. With the help of 
computational modelling, they built competent mutants of hCaII with Ir complexes.84 
Another strategy, by Duhme-Klair and co-workers, used a sulfonamide Ir(III)-complex 
catalyst inserted into the iron-siderophore periplasm binding protein (CeuE) of 
Campylobacter jejuni, to create an artificial transfer hydrogenase (Figure 30).145 The 
iron-siderophore anchoring part allowed for a reversible attachment of the transition 
metal. Low efficiency was observed for the reduction of imine (36 % ee-(R)) but the 
AM assembly had the advantage to be reversible and controlled. 
A)  
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B)  
Figure 30: Artificial transfer hydrogenase created by Duhme-Klair and co-workers, combining CeuE 
protein and a sulfonamide-Ir(II) complex. A) Catalyst engineered for the synthesis of salsolidine. In 
blue is highlighted the iron-siderophore ligand, and in red the Ir-complex catalyst. B) Design of the 
siderophore (blue) anchoring the iridium catalyst (red) inside CeuE. Adapted from Duhme-Klair and 
co-workers145  
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The biocatalysis field is in constant evolution with the improvement in protein 
engineering technologies, offering great possibilities for the design of tailored 
catalysts. The traditional design and optimisation of enzymes largely centred around 
two main approaches: directed evolution and rational design (Figure 31). The 
engineering of enzymes relied mostly on experimental studies. However, nowadays, 
the use of experimental procedures tends to be supplemented by computational 
techniques. Even though the methods still need improvements, computational tools 
can provide cheaper and quicker access to knowledge on structures and chemical 
reaction mechanisms.146 
 
Figure 31: Scheme of two approaches of protein engineering: rational design and directed evolution. 
Adapted from Gruber-Khadjawi and co-workers representation.147  
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Computational protein design has been applied either to re-design native proteins 
towards different substrate ranges, selectivity, or new functionalities; or to de novo 
engineer active sites from scratch.147   
 
The directed evolution strategy explores enzymes residues to modify and stabilise a 
new system. Based on the “Darwin evolution” method, libraries of mutant enzymes 
are built by random mutagenesis to screen for an efficient and selective enzyme 
(Figure 31, B). Limits are encountered with this technique: tunable enzymes are 
required and a scaffold with a basic targeted catalytic activity is necessary. In 
addition, the randomness of this technique creates huge libraries of mutants that can 
overwhelm the experimental capacities in their preparation and screening. 
Introducing a new non-natural catalytic activity is a challenge with directed evolution 
method alone.148 
Rational design is based on the knowledge of the protein structure, the catalytic 
reaction targeted, and any structure-function relationships (Figure 31, A). In the best 
case, the structure can be determined by X-ray crystallography or NMR spectroscopy, 
and additional kinetic experiments provide data on the mechanism of reaction. These 
data are then used to investigate promising binding sites or to spot specific amino 
acids of importance for anchoring and catalytic activity. By structural guided 
mutagenesis, rational design directly targets specific amino acids (from active or 
allosteric sites) responsible of an anchoring, an activity, or a structural modification. 
This technique allows to narrow the enzyme libraries toward a small number of more 
efficient mutants.149 As an example, Wu and co-workers recently redesigned 
computationally an aspartase from Bacillus sp. YM55-1, introducing a non-natural 
activity and enlarging the substrate scope to build a small library of β-lyase. This 
enabled them to bypass multiple experimental trial and error.150  
However, this methodology also shows some weaknesses. The rational design 
technique relies on prediction and knowledge of enzyme characteristics through its 
rigid crystal structure. It could thus fail to include the fine flexibility and interactions 
needed to achieve a high catalytic activity.  
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The latest studies in enzyme engineering tend to use a combination of both rational 
design and directed evolution for a complementary engineering of efficient artificial 
enzymes. 
 
Figure 32: Combination of Rational Design and Directed: studied enzyme structures and properties are 
used to select hot spot amino acids (rational design). These are replaced by all possible amino acids to 
create a smaller and efficient library (directed evolution). The library is screened, and the best variant 
is selected. Adapted from Gruber-Khadjawi and co-workers representation.147  
 
Impressive results have been achieved with rational design of artificial enzymes. Lu 
and co-workers extensively studied the repurposing of enzymes by structure 
knowledge design guided. They engineered de novo metal binding site by 
modification of the heme cavity of myoglobin.148,151 Through site directed 
mutagenesis, the authors introduce a copper binding site and create an efficient 
artificial enzyme able to reduce O2 into water.  
In a similar way, Lin and co-workers modified the Mb to a dye-decolorizing 
peroxidase.152 However, the resulting rationally designed AMs generally showed 
weak activity and selectivity. To accommodate the new function, the enzyme scaffold 
needs random mutations that are too difficult to predict. This is were directed 
evolution enters as an essential optimisation step. 
The combined method of rational design / directed evolution has been extensively 
used. Baker and co-worker engineered an artificial organophosphate hydrolase from 
a native zinc adenosine deaminase.153 Starting with computational modelling, they 
introduced mutations predicted by Rosetta software to create an initially low-active 
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AM. Based on this raw AM, random mutations increased the activity by around 2.500-
fold. Similarly, Kim and co-workers changed the catalytic activity of an existing 
protein by inserting a β-lactamase activity inside a glycoxalase II.154 They first 
extensively redesigned the active site with removal and insertion of entire loops. 
They then used directed evolution to fine-tune the new catalytic activity for a 
resulting AM which completely lost its original activity.  
On a reverse strategy, Ward and co-workers investigated chemical and genetic 
optimisations to build a library of artificial imine reductases inside hCAII and screened 
for activity and selectivity. The best selected mutant ([(η5-Cp*)Ir(pico)Cl] - hCAII) 
crystal structure was then studied with Rosetta software. This software also used in 
previous examples, and extensively in other studies, is a computational package of 
macromolecular modelling, design and docking.155 Ward and co-workers then applied 
site-directed mutagenesis on targeted residues to enhance activity and selectivity.84  
These example highlights how rational design and directed evolution can be 
combined in a circle of optimisations.  
This combined strategy was also applied to a more challenging AM engineering 
approach: the de novo design, or the creation of protein from scratch. Hilvert and co-
worker developed a highly active and enantiospecific artificial zinc-dependent 
esterase.156 Beginning with the de novo design of a homodimeric helix-turn-helix 
peptide, they built a four-helix-bundle protein with Zn(II). After several rounds of 
genetic optimisation, they obtained a mutant catalysing the hydrolysis of p-
nitrophenyl acetate, with 10 000-fold activity increase. Based on their de novo 
protein, they recently predicted mutations through DFT calculation to create a diels-
alderase by improving the substrate binding and transition state stabilisation. Several 
turns of directed evolution then improved the activity.157 
 
 
Computational tools can help in many ways in the redesign or the de novo 
construction of enzymes: from sequence homology to ligand binding analysis or 
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protein structural stability, computational expertise is essential for enzyme 
engineering. 
As seen previously in the works done by Ward and co-workers, chemical and genetic 
optimisations are strategies of choice for the conception of AMs. However, this 
introduces a large amount of complexity in the computational design. The 
combination of cofactor, substrate and scaffold residues demand a lot of 
configuration and scaffold conformation exploration. Thus, computational 
techniques have evolved to use different powerful computational algorithms to take 
in consideration the function, the structure stability and the evolution of a protein.158   
Starting with structurally unknown proteins, homology models can be built from high 
similarities with structurally characterised relatives.158 Several algorithms know a 
high success in the protein structure prediction. For example, I-Tasser specialised in 
protein folding recognition or de novo modelling, and the software AlphaFold 
succeeded in the accurate prediction of protein fold and function from amino acid 
sequence alignment and comparison with proteins libraries.159,160 
In AMs design, molecular modelling is the most applied technique. This approach 
regroups several methods to calculate the energies of a molecule in function of its 
geometry and its interactions with other molecules. The methods accuracy and 
approximations vary, where an accurate method needs high computational power, it 
will explore smaller space while for larger systems less accurate methods will be used. 
The challenge is then to select the right method by assessing the information needed 
and the technique cost.12  
For the study of molecular interactions between a protein and its substrate /co-
factor, docking is the most accessible and most prominently used approach (using 
molecular mechanic (MM) principles). The knowledge of the binding and release 
thermodynamics of these complexes uses more sophisticated methods, like free 
energy perturbation (FEP), for a calculation of the binding free energies, or the 
Molecular Dynamic (MD) simulations, used to understand the protein stability and 
flexibility. Finally, the catalytic mechanism is analysed with very accurate methods 
named quantum mechanics (QM) or a combination of QM/MM. 
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Quantum mechanics (QM) methods describe accurately the electronic structure of a 
system, the chemical states of a reaction and the reaction mechanism. Two main 
families of QM methods have been applied to AM design: the Hartree-Fock (HF) and 
the density functional theory (DFT).12 
The HF method determined the molecular electronic wave function of a system, built 
on the molecular orbitals. It approximates all interactions between electrons to a 
general wave function. Post-HF add electronic methods which present more accurate 
but also more resource consuming methods. 
For DFT methodologies, the electronic calculations rely on the electron density. The 
approximate energy is calculated as a function of the electron density. DFT is an 
approximation method without any addition of time-consuming post-HF methods, 
and it can be used on a system with transition metal catalysts. 
QM techniques are highly accurate to reproduce the electronic properties of a 
molecule. However, they are also highly time-consuming and computationally costly. 
QM methods are mainly used in small systems, for example a combination of the 
cofactor, the substrate, and few residues around.  
 
Molecular mechanics (MM) are used to model and describe large systems with 
reasonable accuracy, such as whole enzymes in water. This method relies on classical 
mechanics described by force fields. Unlike QM method, the electrons are not 
separated from the nuclei, and the molecules are represented by atoms and bonds. 
Force fields only describe two molecular systems by defining intra-molecular bonding 
terms (bonds, angles, dihedral angles) and intra- and inter-molecular non-bonding 
interactions (van der Waals and electrostatic interactions). MM methods represent 
much quicker and cheaper alternative, however, no electron transfer, and thus no 
chemical reactions can be described. These methods are compensating the limit of 
QM calculations: the ability to work on complete biological systems. 
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In biochemical interaction prediction, the simplest and most widely used MM 
technique is the computer-based docking screens. Docking is often utilised in drug 
design for the optimisation of lead ligands (molecules in complex with biomolecules) 
by prediction of stable ligand-protein complexes and the estimation of the binding 
affinity.  
The docking methodology generates and evaluate ligand poses (orientation and 
conformation within the protein) to predict experimental binding modes and 
affinities. An algorithm evaluates the complementarity between a high-resolution 
structure and the molecules docked. Ligand poses are ranked through a score 
representing their stability and binding affinity.161  
The docking methodology can be classified into three main classes that incorporate 
different levels of complexity to the protein and the ligand flexibility:162  
- Rigid docking: within a rigid docking, both the enzyme and the ligand are kept 
rigid. Therefore, no alternative conformations are handled, and only 
translational and rational freedom of the ligands are explored. 
- Semi-flexible docking: several algorithms are used for the generation of ligand 
poses (e.g. systematic algorithms, stochastic or deterministic methods) which 
considers the conformational changes of the ligand besides the rotational and 
translational freedom. The protein is kept rigid. 
- Flexible docking: the flexibility of the ligand is conserved while several 
parameters can set flexibility in the protein (e.g. residues side-chain and 
backbone flexibility, small overlaps between the protein and the ligand atoms).  
To evaluate the binding affinity of the ligands poses, a scoring function is used. This 
adds favourable binding energies (e.g. hydrogen bonding, hydrophobic interactions) 
to a so-called binding score. Several methods of scoring function are available to 
predict the binding affinity (e.g. empirical scoring, force-field based, knowledge-
based).163 
Although the docking technique tries to reproduce the more accurately possible 
experimental results, some improvements have yet to be made, especially in the 
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binding affinity prediction. Basic scoring functions struggle to reflect experimental 
data and more sophisticated ones are too computationally expensive. Protein 
flexibility is also a challenging point. Most of the docking studies keep the structure 
rigid or slightly flexible, where, in nature, allosteric movement can impact the binding 
process.164 
For a better understanding of the full ligand binding process, MD simulations are a 
more suitable method. Combined with FEP evaluations, the method gives higher 
accuracy for binding affinity of protein-ligand and protein-protein complexes.165 In 
MD simulations, kinetic and potential energies are calculated, giving better insights 
than the static docking.12 MD simulations are also used to analyse at atomic 
resolution the flexibility and stability of protein and ligand-protein complexes, 
however at a higher cost.166  
 
At the interface of chemistry and biology, a hybrid QM/MM technique enables the in 
depth treatment of enzyme regions (binding sites) with a QM method coupled with 
an MM treatment of the entire protein structure.167 This is an attractive strategy to 
accurately understand the details of a catalytic site and the reaction chemistry, with 
the treatment of the whole enzyme at a cheaper cost than with QM method alone. 
Apart from mutant libraries creation or analysis of conventional enzymes, QM/MM 
is useful for the design of AMs. It is now frequent to combine QM/MM and docking 
or MD simulations for the exploration of specific binding properties, the prediction 
of energies or even the selection of suitable anchors.168 
 
Computational methods have now been extensively used for enzyme engineering. 
For example, Kamerlin and co-workers used the empirical valence bond approach on 
the human diamine oxidase to understand its mechanism.169 This method accurately 
investigates chemical reactivity, using MM representation in combination with QM 
electronic structure. This provides a fast and extensive knowledge of a chemical 
reactivity. Mulholland and co-workers also used QM/MM calculations to determine 
the mechanism of benzyl hydroxylation by the human cytochrome P450 2C9.170 
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Substrate unbinding kinetic was studied by Damborsky and co-workers using free 
energy calculation in their protein model haloalkane dehydrogenase.171 All these 
information allow the identification of hit residues to modify for biocatalysis 
improvement. 
The following section will focus on the use of computational tool for the engineering 
of AMs. As described before, the activity and selectivity of an AM are controlled by 
the binding of the metal catalyst and the substrate to the protein scaffold. Thus, the 
design of AMs involves modifications of the first coordination sphere (metal catalyst 
and residues in direct contact) and/or the second coordination sphere (enzyme 
scaffold). Another AM engineering approach is the de novo design, where new 
enzymes are entirely built from scratch. Computational modelling stands here as a 
critical tool to understand structural and biochemical processes, at low experimental 
cost. 
 
A fundamental aspect of AMs engineering is the binding of the metal catalyst inside 
the scaffold. Molecular docking is often the first method of choice for the design of 
anchors binding to proteins, like in structure-based drug design.  
Lu and co-worker used docking models for their initial AM to understand the covalent 
anchoring of their metal catalyst. They predicted the best fit inside the scaffold and 
then created a new AM with increased activity thanks to a tighter ligand affinity (dual 
anchoring).40  
Protein-ligand docking studies have also been extensively used to understand 
experimental results. For example, Ricoux and co-workers ran docking experiments 
to explore their AM poor enantioselectivity (13 % ee).79 Conclusions of the docking 
calculations identified a solvent exposed metal catalyst, due to a large occupancy of 
the cavity by the anchoring ligand. The substrate access to the metal was then less 
controlled and could explain the low enantioselectivity observed experimentally. 
Ward and co-workers also used docking to gain insight on the localisation of their 
metal complex catalyst.85 
However, limitations to the docking approaches can be highlighted. Docking methods 
lack predictions of the dynamics of binding processes. They also poorly incorporate 
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the solvation and desolvation effects, which makes binding affinities prone to errors, 
particularly by neglecting entropic effects. Besides, the associated scoring functions 
use simple potential energy functions related to well parametrised force field, thus 
lacking contributions like polarisation effects and detailed estimation of proton 
affinity. Finally, transition metal catalysts are not yet routinely handled by docking. 
Standard molecular docking is not able to account for the change of electronic states 
and coordination of the metal or any conformational impact on residues during the 
binding process. In several studies the transition metal has been considered rigid, 
using a “dummy” atom with no impact on the scaffold upon binding.40,79,172  
Refinement after protein-ligand docking with MD simulations or QM/MM 
calculations is then used for a more accurate process.173,174 
A case protocol is described by Maréchal and co-workers.175 The authors combined 
docking with QM/MM approaches for the introduction of Fe(Schiff base)-salophen 
inside a heme oxygenase. Their objective was to check out the changes induced upon 
binding of the complex during the activation process. First, based on the crystal 
structure, the authors optimised the Fe(Schiff base)-salophen using QM calculations. 
They proved that the experimental structure was indeed the resting state of the AM. 
They then docked the metal complex inside the haem cavity and studied the poses 
to identify all residues making contacts with the metal catalyst. Finally, to analyse the 
electronic transition and activation process, they generated all coordination possible 
of the complex residues-metal catalyst in the previously docked poses by refinement 
through QM/MM calculation. The results showed how the resting state (with a 
distorted metal complex binding) and later the activation process were driven by 
changes in the first coordination sphere. 
A similar protocol was also followed by Ward and co-workers to analyse the catalytic 
mechanism of their first Sav artificial imine reductase and refine the structure.176 
To further maximise enantioselectivity, computer modelling also facilitates 
investigations of the second coordination sphere upon metal complex-scaffold 
binding. Ward and co-workers, in collaboration with Baker group, tailored the second 
coordination sphere around a metal catalyst with the protein design software Rosetta 
Design.84 To enhance the modest catalytic activity of their artificial imine reductase 
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([(η5-Cp*)Ir(pico)Cl] - WT hCAII), they selected and mutated specific amino acid 
residues in the protein-ligand binding interface. Their goal was to firmly anchor the 
metal catalyst in one location that favour the interactions with the substrate. Based 
on the AM crystal structure (PDB 3ZP9), four mutants were developed to improve 
affinity between metal catalyst and protein. Later characterized experimentally, the 
designed mutants showed increased affinity to a 50-fold, activity to a 10-fold and 
enantioselectivity to 96 % ee-(S) salsolidine.  
The other essential aspect of AMs design is the substrate binding to the enzyme. 
Molecular docking is again a gold standard to understand the interactions upon 
binding. Coupled with QM techniques, docking also helps to understand the catalytic 
pathway and any interactions between the substrate and the metal catalyst. 
Ricoux and co-worker engineered a Mn(III)-meso-tetrakis(p-carboxyphenyl) 
porphyrin inserted within a xylanase. They analysed through docking the epoxidation 
of aromatic alkenes substrate.177 The first molecular docking run was to identify the 
characteristics of the metal complex binding to the xylanase. Several aromatic 
substrates were subsequently docked inside the previous best docking pose. 
Adequate new poses were selected with proximity between the metal and the alkene 
double bond. Some residues in the active site pocket were spotted as regulators of 
the substrate access to the active site and the proximity with the metal catalyst. 
These results were later confirmed by experimental tests.  
Furthermore, computational modelling has also been used for the identification of 
novel substrates for AM. An example is the work of Ménage and co-workers on their 
artificial monooxygenase.178 The authors developed four AMs from a transport 
protein NikA, using supramolecular anchoring of several iron metal complexes. They 
then docked a set of sulfides substrates to identify catalytic oxidation of their hybrids. 
The molecular docking concept was then proven by experimental tests on the 
selected substrates.  
 
Computational modelling tools are already used in combination with directed 
evolution to either design catalyst-scaffold-substrate bindings or increase the activity 
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and selectivity of AMs. However, one domain is still challenging for computational 
modelling: the de novo design of AMs from scratch. 
A typical protocol starts with defining a catalytic reaction and its mechanism. Then, a 
“theozyme” is modelled quantum mechanically: a minimum three-dimensional 
model of an active site structure is defined, composed of a cofactor, a substrate and 
the amino acids surrounding. The QM method calculate the optimal arrangement of 
the active site to stabilise the transition state of the targeted reaction. Using 
explorative algorithm, this model is then compared to existing protein in order to 
define a scaffold.179,180 
Some first approaches have already been developed. Baker and co-workers used the 
most common Rosetta software pack to design an enzyme model for Diels-Alderase 
reaction.181 RosettaMatch was first used to find a corresponding scaffold to the 
theozyme and RosettaDesign followed to optimise the transition state structure of 
each matches. The rigidity of the predicted models differs from the conformation 
changes of a scaffold during catalytic process, and a refinement is generally executed 
with QM/MM calculations. 
Other studies have followed a similar protocol for different reactions. For example, 
Bolon and Mayo worked on hydrolysis reactions,182 Houk and co-workers on Kemp 
elimination183 or Baker and co-worker on Morita-Baylis-Hillman reaction.184 Clearly, 
the computational strategy alone is not able to produce a sustainable level of activity 
for the new artificial enzymes compare to other catalyst types. Further studies from 
these groups combined subsequent computational optimizations and directed 
evolution, to create hybrids with enhanced effectiveness.153,185,186 These results are 
still challenged due to the simplicity of the catalytic reactions targeted, and thus the 
luck could also be considered in the success of such strategy.12 
When considering artificial metalloenzymes, the complexity of a de novo design is at 
a higher degree. As seen before, activity is regulated by the binding of the metal 
catalyst. Thus, the theozyme models would have to also account for the correct 
coordination of the metal inside the scaffold: first and second coordination spheres 
must be designed.  
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To date, no efficient de novo AM has been engineered from computational modelling, 
but enormous progresses have been achieved toward this objective. 
On the second coordination sphere design, models of protein folding were developed 
by Wolynes and co-workers187 and Baker and co-workers.188 Experimental results 
confirmed the predictions of the new protein folding. The design of the first 
coordination sphere has also been studied. Hellinga and co-workers184 achieved the 
introduction of a novel iron binding site inside an E. coli thioredoxin and Baker and 
co-workers introduce unnatural amino acids to engineer a new binding site.25  
Finally, the first de novo proto-enzymes have been reported based on a rough starting 
point, the Due Ferri (di-iron) helical bundle created by DeGrado and co-workers with 
mathematical equations.189 A di-iron oxidase, an oxygenase and a ferroxidase were 
engineered by DeGrado group using computational protein design (Figure 33, 
A)).189,190,191 By modelling the protein folding in concert with the metal binding site, 
the authors succeeded to insert within the four-helix bundle scaffold a transition 
metal cluster composed of four Zn2+ and 16 polar residue side chains (carboxylates 
oxygens, imidazole), all connected by hydrogen bonds (PS1, Figure 33 ,B)).192 The 
process used automated sequence design and Rosetta methodology on the Due Ferri 
starting point to develop the final proto-enzyme, followed by QM/MM methods to 
understand the engineered structures. 
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A)  
B)  
Figure 33: DeGrado de novo proto-enzymes. A) Top: Proposed mechanism of the catechol oxidation 
reaction catalysed by DF3. Bottom: Representation of a four chain DF structure (similar to DF3). B) X-
ray structure of PS1 (PDB 5WLM) with a close view of the zinc cluster. Figures adapted from DeGrado 
and co-workers.189  
 
Computational tools must be considered an important strategy for AMs engineering, 
in combination with experimental work. So far, in silico studies have proven to be 
useful for a large range of information (from coordinated interactions to binding 
process mechanism). The methods are in constant evolution to be more fine-tuned 
and more powerful, for the accurate prediction of all aspects of the biochemical 
transformations during a catalytic reaction.  
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Protein engineering is now an advanced biotechnological strategy. However, the 
introduction of non-native activity is still challenging. Artificial metalloenzymes (AMs) 
are becoming a powerful approach to address this question. The introduction of a 
metal catalyst in an enzyme scaffold leads to a renewable catalyst, able to catalyse 
green reactions efficiently and selectively. 
In the AM field, the supramolecular anchoring achieved a great success with the 
biotin-(strep)avidin and LmrR receptor technologies. However, no relevant evidence 
for other efficient supramolecular systems have been privileged yet. In addition, the 
use of enzymatic scaffolds has been overlooked compared to their non-enzymatic 
counterparts. The existing architecture of the enzymatic site within an enzymatic 
chassis can be advantageous. For example, the natural evolution of the pockets 
provides a proximity between cofactor and substrate, which can be exploited in the 
non-covalent binding of a metal catalyst. 
In previous works, the design of AMs has been supported by computational 
modelling, using predominantly docking to help in the optimisation of AMs. 
Computational docking is rarely used to design the initial AMs from the beginning, 
but more often to optimise and understand AM mechanism. Starting the engineering 
of AMs with computational modelling would be a gain of time and experimental 
resources.  
The aim of this project is to computationally design anchors for the binding of metal 
catalysts inside a cofactor pocket, as starting point to engineer new AMs. The focus 
of this work is to expand the enzyme functionality of alcohol dehydrogenases (ADHs) 
from reduction of carbonyls to the asymmetric reduction of imines, with high 
enantioselectivity. 
A literature search concluded that there was interest in imine reduction to chiral 
amine. These are important pharmacophores found as building blocks in many active 
molecules with applications in the chemical and pharmaceutical industries. The use 
of a d6 piano-stool transition metal was thus prioritised since such compounds are 
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highly active in imine reduction. The choice of ADHs as an enzymatic scaffold, for the 
reduction of imine, is based on the structural similarity of their natural ketone 
substrate C=O and the imine structures C=N. Furthermore, the natural evolution of 
the catalytic pockets in ADHs contributes to the strong binding affinity to their natural 
NAD(P)H cofactor, along with high stability and proximity to the substrate. This work 
sets out to create analogues of NAD(P)H as anchors for the transition metal catalyst. 
Two ADHs enzymes were selected for the AM scaffolds: the Horse Liver Alcohol 
Dehydrogenase (HLADH) and the Thermoanaerobacter brockii Alcohol 
Dehydrogenase (TbADH).  
 
 
The initial focus of this project is the computational design of appropriate small 
anchor molecules, with high affinity for the NAD(P)H binding pocket of the two 
selected ADHs. Docking methods will be set up to first assess the relative affinity of 
natural cofactors, mimics thereof and large libraries of existing compounds, within 
HLADH and TbADH. The objective is to gain detailed knowledge of the binding pocket 
and the non-covalent interactions essentials to ensure strong affinity of small 
molecules within ADHs. These conclusions will lead to the creation of a novel anchor 
structure model, with the required functionalities to enable the binding of a metal 
catalyst. A final computational modelling protocol will investigate the anchor binding 
and evaluate the impact of metalation on the binding orientation inside the pocket 
of ADHs. The resulting docking will provide a refined ranked list of molecules with 
high affinity and appropriate location. 
 
This objective includes the design of a short synthetic pathway and the creation of a 
library of small anchors. Based on the results predicted by the docking protocol, the 
anchors which demonstrated the highest affinity for ADHs will be selected for 
synthesis. All synthesised compounds will be metalated with iridium to give the 
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transition metal catalysts. Their catalytic reactivity will then be tested to ascertain 
their effectiveness in the transfer hydrogenation of imines. 
 
The final part of the project concentrates in the construction of AMs. To do so, a 
reliable method for the expression and purification of TbADH, HLADH and also a 
TbADH mutant which lacks the catalytic zinc ion will be used. The previously 
synthesised transition metal complexes will be non-covalently assembled inside the 
purified ADHs. The high affinity of anchors binding will be assessed by isothermal 
titration calorimetry and inhibition assays. The catalytic activity and selectivity of the 
resulting AM will be evaluated by HPLC analysis and will be compared to the free 
catalyst complexes. This will allow a critique of the computational results and 
therefore assessment of its capacity as a predictive tool to design AMs.  
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In the following chapter, the computational methods used throughout the in silico 
study are detailed. The chapter focuses on computational applications and their 
theoretical background without accounting for hardware considerations. The process 
toward the selection of molecules as metal anchors with high affinity for both HLADH 
and TbADH is described. 
The computational methods were developed to understand key features of the 
cofactor binding site of these enzymes and identify the strongest natural non-
covalent interactions, to promote the binding of synthetic molecules. Co-crystallized 
structures of HLADH and TbADH were selected for docking studies, based on previous 
crystal structures of purified enzymes in complex with their cofactor or substrate 
(respectively PDB 4XD2193 and PDB 1YKF97).  
 
 
For the design of molecular docking protocols, the Schrodinger suite of programs and 
the Maestro graphical interphase were used. The theoretical background for 
molecular docking was presented in the section 1.5.4.1, page 43. 
 
All compounds included in this work were prepared using Ligprep from Schrödinger 
suite,194 with OPLS3 force field.195 Generation of all possible protonation and 
ionisation states combinations was performed for each ligand by using Epik196 in 
aqueous solution at pH of 7.0 +/- 2.0. Whenever the ligand contained a ribose, the 
same stereochemistry as of the natural cofactor was kept. 
 
The crystal structures of the enzymes were obtained from the Protein Data Bank 
(HLADH PDB 4XD2193, HLADH with substrate PDB 4DWV197and TbADH PDB 1YKF97) 
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and prepared using the Maestro Protein Preparation Wizard in the Schrödinger 
suite.198 The structure integrity was analysed and missing hydrogen atoms and 
residues side chains were added to the structure by Prime-refinement199 throughout 
the pre-processing. During the refinement, water molecules with less than three 
hydrogen bonds to other atoms were removed, which resulted in no more water in 
the binding site. The selection of the position of hydroxyl and thiol hydrogens, the 
protonation/tautomer states and the “flip” assignment of aspartic acid, glutamic acid, 
arginine, lysine and histidine were adjusted at pH = 7.0 using PROPKA.200 Finally, the 
structures were minimized using the OPLS3 force field with a RMSD = 0.3 Å maximal 
displacement of non-hydrogen atoms as convergence criterion. 
The proteins were additionally prepared without the natural zinc ion in the active 
site, by removing it from the crystal structure using the Protein Preparation Wizard. 
Furthermore, several amino acids present in the active site were mutated to alanine: 
H67, C46 and C174 in HLADH and C37, H59, E60 and D150 in TbADH. These mutations 
allowed to lose the zinc ion and to make space at the catalytic site. 
 
In order to define the pocket of interest for the docking, a grid was set around the 
defined docking site. At the beginning of this work, the same grid preparation setup 
was chosen for all docking methods. The enclosure box was defined from the 
optimized protein structure at the centroid of the active site (10 Å radius around the 
co-crystallized ligand). No constraints were added. The standard settings of van der 
Waals scaling factor of 1.0 for nonpolar atoms was conserved. Nonpolar atoms were 
defined with absolute value of partial atomic charges ≤ 0.25. 
 
Prepared ligand conformers were flexibly docked into the receptor grid using Glide 
SP and XP procedures.201,202,203 In this method, the receptor was kept rigid.  
Glide docking uses a technique of exhaustive systematic search to predict 
orientation, conformation, and binding position of a ligand inside a receptor pocket. 
The following steps are undertaken during a Glide docking procedure: 
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1) Collection of ligand conformations (from exhaustive enumeration of ligand 
torsions) 
2) Initial screening inside the predefined grid space. This results in the selection 
of ligand poses (“poses” refers to the orientation, position, core conformation 
and rotamer-group conformation of the ligand inside the receptor). 
3) Refinement of pre-selected poses by analysis of ligand torsions in the field of 
the receptor. 
4) Minimization of ligand poses with full flexibility. A Monte Carlo procedure 
analyses nearby torsional minima and selects the minimum energy poses. 
5) Final scoring applied to the poses predict binding affinity (GlideScore). 
 
This is the classical method which uses exhaustive sampling method.201,202 The 
default parameters as defined in the Schrodinger program were kept, OPLS3195 was 
used as force field and the variation of conformation was applied.  
The four best docked structures were saved for each ligand, based on the Emodel 
score which allows a better discrimination between the conformers of a ligand (it 
combines the non-bonded interaction energy and the excess internal energy of the 
generated ligand conformation). Subsequently, the Glide score was the focus 
outcome of the Glide SP docking. Contrarily to Emodel score, the Glide score ranks 
the different ligands and maximizes the discrimination between ligands that bind 
strongly inside the pocket to the ones that have little affinity. Glide Score is an 
empirical scoring, taking in account the physics of the binding process (e.g. 
lipophilic-lipophilic, hydrogen bond, protein-ligand coulomb-vdW energies) and 
the displacement of water molecules by a ligand. It is an estimation of the ligand 
free energy binding (the more negative, the better). 
The Emodel score was used to select the best ligand conformer and then the Glide 
score ranked all these ligands structure for a determination of the best binder. 
 
Glide XP performs a more extended sampling methodology and has an optimized 
scoring function. It penalizes some false positives, which Glide SP does not eliminate, 
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by adding new elements in the scoring: desolvation penalties applied to polar and 
charged groups and recognition of groups that increase affinity.203  
Glide XP is more time consuming than the SP version. Therefore, this method is better 
when used on predefined ligand poses, after a pre-screening by Glide SP. The Glide 
XP score is more sophisticated by identifying better complementarities between the 
ligand and the protein (penalties are assigned to expected unfavourable energy 
complexes). 
 
The MM-GBSA method is a molecular mechanic energies method, coupled with 
generalized Born model surface area continuum solvation. This end point method is 
based on the end states difference of the free ligand, the free receptor, and the 
complex. It is an effective method with a satisfying compromise between a good re-
ranking of Glide XP docking poses and a lower time consumption, and is used to give 
an estimation of the binding affinity between a ligand and its receptor in a 
complex.204 The best ten XP scored poses where retained for MM-GBSA predictions. 
The relative free binding energy (ΔG) was calculated using Prime/MM-GBSA software 
from the Schrodinger Suite, according to the following equation: 
ΔG = EC – (EL + ER) (1) 
Where EC, EL and ER represent the free energy of a state (complex, ligand, and 
receptor respectively). The software uses different energy properties (structure, 
binding, and strain) to obtain totals energies applied to the different states: 
E = EMM + Gsolv – TS (2) 
Where EMM represents the molecular mechanics energy, Gsolv the solvation free 
energy and S the entropy of the system. The contribution of various factors is also 
considered (e.g. H-bond, vdW, solvation energy) in this protocol.205 The VSGB 
solvation model (Surface Generalized Born Model and Variable Dielectric) was 
selected to approximate the solvation free energy and correction of interactions (H-
bond, hydrophobic, π-π).206 The OPLS3 force field was applied and flexibility was 
added to residues at 5.0 Å from the ligand position in the binding pocket. A Prime 
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minimisation was used on the residues selected in the flexible region, without any 
constraints. 
 
For docking of metal, a challenge arises from the software being unable to handle 
ligand structures incorporating complexed metal ions. In the Schrodinger software, 
force field parameters available in Glide are designed to treat structures with zinc, 
copper, or iron only. However, this project deals with the treatment of transition 
metals such as iridium (Ir), rhodium (Rh) or ruthenium (Ru). To dock structures 
containing transition metal, the settings of the OPLS3 force field were modified. In 
this work, the experiments were attempted with metal complexes made of Ir.  
At first, structures containing Ir metal were created by using the Maestro interface to 
build a pyramidal metal centre, substituted by a pentamethylcyclopentadienyl 
moiety (Cp*, Figure 34). 
 
Figure 34: Iridium coordinated with chloride, bidentate sulphonamide ligand and Cp*. This transition 
metal complex was built using the Maestro building panel. 
Zero bonds order (no electron bonding) were applied to the Cp*metal ion ligand 
(dash lines, Figure 34). Force fields have difficulties to characterise metal 
coordination and there is no criterion for covalent bonds between metal and ligands. 
Thus, zero bond order connections represented the metal coordination geometry. 
The different metal ligands were left flexible. 
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In the chapter section involving the transition metal complex docking, the enclosure 
box was defined from the optimized mutated protein structures (HLADH H67A, C46A, 
C174A and TbADH C37A, H59A, E60A and D150A), by a selection of amino acid 
residues defining the centre of the box to be the area of the NADH nicotinamide ring. 
No constraints were added. Van der Waals scaling factor of 1.0 and partial charge ≤ 
0.25 were conserved. These grid modifications allowed to focus the binding of metal 
complexes around the catalysis area. 
 
The IFD method considers the receptor pocket to be flexible around the ligands 
docked.207 It combines Glide,202 to obtain the possible binding poses, and Prime199 
which associates conformational changes of the receptor structure (refinement of 
active site residues).208 The following steps were undertaken: 
1) Docking of the ligand with Glide 
2) Prime refinement to reorient amino acid side chains for each ligand pose 
found by Glide. 
3) Minimisation of residues and the ligand. 
4) Re-docking of the ligand in the receptor active site, using Glide, and 
minimisation and ranking of complex poses by IFDscore. 
The IFD parameters were defined as follows: Prime refine residues up to 5.0 Å to the 
ligand position. The first docking used Glide SP and subsequent re-docking steps used 
Glide XP for refinement, which gave a final Glide XP score for each ligand structures. 
 
The most employed method to predict biomolecular interactions between a protein 
and a molecule is the docking.12 By providing binding structures and binding scores, 
docking tools give an insight into the pocket geometry, the binding conformation, the 
chemical interactions and an approximation of the affinity.  
However, precautions are to be taken in the interpretation of docking results, 
especially in the catalytic domain. The approximation resides mainly on the scoring 
function, which lack certainty in the representation of binding affinity.  
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Docking studies are a promising tool to predict ligands configurations and their 
affinity to a protein binding site. A docking protocol was prepared to filter the ligands 
that bind with high affinity to the enzymes out of large sets of structures and bound 
conformations: 
 
Figure 35: Established docking protocol used to filter various ligands in order to select lead structures. 
The two Glide dockings give a rough ranking of structures, followed by a refinement using MM-GBSA 
method. 
The protocol started with a raw filtering of the NAD(P)H, fragments of the cofactors 
and libraries of ligands structures inside HLADH and TbADH cofactor binding site. 
First, the Glide SP method was applied, followed by Glide XP (elimination of false 
positives). This rough ranking of structures separated the binding ligands from the 
less or non-binding ones. However, this score had a too low accuracy for a 
hierarchical separation inside the group of binding ligands and for the determination 
of a potential lead compound. Estimation of the free binding energy of enzyme-ligand 
complexes would provide more information on the affinity for a ligand, the stability 
of a system and a more precise ranking. As an example, molecular dynamic (MD) 
simulations combined with free energy perturbation (FEP) are a powerful tool to 
retain accurate binding affinities. This strategy is more accurate toward experimental 
data than Glide scores. However, MD simulations are also time expensive, and thus 
difficult to use on a vast number of ligands.209 
An interesting alternative was the Molecular Mechanics Generalized Born and 
Surface Area (MM-GBSA) method, for the estimation of binding free energies. The 
Ligand and protein preparation
Glide SP docking
Glide XP on 30 best Glide SP 
ligands
Prime/MM-GBSA calculations on 
10 best poses from Glide XP
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resulting final scores predicted the relative binding affinities and provided a ranking 
between selected binding ligands. 
The quality and efficiency of this protocol was tested by re-docking the co-crystallized 
NAD(H) cofactor inside the protein and comparing the docking poses through 
calculations of root mean square deviation (RMSD) by using the superposition panel 
in Maestro. A good docking pose is highlighted by an RMSD value < 2.0 Å from the 
co-crystallised cofactor (Table 1).210 
Two HLADH structures were used in which the enzyme was crystallised with only the 
cofactor NADH (PDB 4XD2211) and with the cofactor NAD+ plus an alcohol substrate 
(2, 3, 4, 5, 6-pentafluorobenzyl alcohol, PDB 4DWV197). In each crystal structure type, 
another round of docking was conducted without the catalytic zinc ion to evaluate 
the impact of Zn2+ removal on the orientation and binding affinity of the ligands. This 
gave more information on whether binding space can be increased in the absence of 
the Zn2+, to allow its replacement by a different transition metal complex. The results 
are presented in Table 1 below:  
Table 1: Cofactors docking scores represented by Glide XP (kcal mol-1) and MM-GBSA calculations (ΔG 
in kcal mol-1). The RMSD values compare the dock poses to the co-crystallised cofactors in the X-ray 
structures. 
Enzyme PDB Ligand 
Resolution 
(Å) 
Glide 
XP 
Score 
RMSD 
(Å) on 
Glide XP 
pose 
MM-
GBSA 
RMSD (Å) on 
MM-GBSA 
pose 
HLADH 
4XD2211 NADH 1.1 
-14.8 0.32 -80.6 0.33 
HLADH 
no Zn2+ 
-15.1 0.41 -83.6 0.37 
HLADH + 
substrate 
4DWV197 NAD+ 1.14 
-11.7 0.61 -101.2 0.98 
HLADH + 
substrate 
no Zn2+ 
-13.1 0.49 -124.6 0.97 
For all HLADH structures, the superposition displayed a RMSD values < 2.0 Å, attesting 
accurate docking poses. The correct re-docking of NADH/NAD+ gave confirmation of 
an efficient docking protocol for HLADH in silico study, which was able to relocate the 
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cofactor in its original position and conformation. The superimposition of the docked 
structure and the crystal structure of NADH inside HLADH is shown in Figure 36. 
 
Figure 36: NADH (blue) re-docked inside HLADH and superposed to the co-crystallised cofactor 
(green). Hydrogen bonding contacts are represented in dashed lines and the amino acids in contact 
with the ligands are labelled and shown in pink. 
The removal of Zn2+ led to no variation of values or orientation inside the binding site, 
and only a slight improvement in the binding free energy was seen with MM-GBSA 
calculations. These first results implied little impact of Zn2+ in the binding of cofactors. 
As suggested in the literature, Zn2+ is used to act as Lewis acid and activate the 
carbonyl for hydride transfer.91 Thus, based on literature and first docking 
conclusions, the zinc role is mainly of catalytic nature and may have no influence on 
the cofactor binding.  
In summary, the designed docking protocol was proven accurate for the analysis of 
ligands inside the different HLADH structures. The following results were obtained 
using this protocol on various ligand structures inside the two HLADHs crystal 
structures. 
Zn2+
PHE 319ALA 317
VAL 292
ILE 269
ARG 47
VAL 203
ASP 223
ARG 369
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After validation of the protocol, docking of other molecule structures was performed 
and compared to co-crystallized NAD(H) cofactors. The experiments started with 
fragments of NAD(P)H cofactors, followed by NADH mimics from the literature and 
previously designed compounds in the laboratory, to end with a screening of large 
compound libraries. The aim of this methodology was to understand key features of 
the cofactor binding pocket and to discriminate the influence of different fragments 
from the relatively big cofactor structure. The diversity of structures explored within 
the screening of large compound libraries further helped to better understand the 
potential of the cofactor binding pocket environment to host alternative molecules 
with different functionalities.  
 
The various natural cofactors in reduced and oxidised states (NADH, NAD+, NADP+ 
and NADPH) were compared for the evaluation of differences in their binding 
affinities to HLADH.  
Table 2: Cofactor docking inside HLADH (PDB 4XD2). Glide XP score (kcal mol-1) and the free binding 
energy ΔG (kcal mol-1) from MM-GBSA calculations are presented for all cofactors. The lower the score, 
the better the binding affinity. 
Enzyme 
NADH NAD+ NADPH NADP+ 
XP Glide ΔG XP Glide ΔG XP Glide ΔG XP Glide ΔG 
HLADH -14.8 -80.6 -11.5 -92.7 -14.9 -73.5 -11.1 -83.4 
HLADH 
no Zn2+ 
-15.1 -83.6 -12.0 -125.7 -13.2 -70.3 -11.8 -99.1 
The comparison of these results led to a more complex picture of binding. According 
to both scores, the binding of cofactors NADH and NADPH were of similar order, with 
a slight preference for NAD(H) binding. A minor binding difference was observed with 
Glide XP score between the oxidised and the reduced forms of the cofactors. Then, 
in the MM-GBSA calculation, the ranking established a significantly better affinity for 
complexes with oxidized forms (NAD+, NADP+).  
All NAD(H) nicotinamide ring structures appeared flat inside the pocket of HLADH. 
However, the QM calculation works of Meijers and co-workers demonstrated a 
distortion of the pyridine ring in NADH, later followed by Rubach and Plapp 
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calculations, suggesting a boat like conformation during the transition state (Figure 
37A).212,213 The docking results might indicate that the force field parameters were 
not accurate enough to describe the difference between the oxidised and reduced 
structures (difference in solvation free energy of the cation), which in turn might lead 
to inaccuracies of the docking scores in comparison. Thus, the comparison between 
docking of reduced and oxidised cofactors needs to be treated with caution at this 
stage. 
To the best of our knowledge, there is no direct information available in the literature 
about binding affinity studies to HLADH of the two cofactors NADH and NADPH. 
Examining the work detailed in literature (section 1.3.2.2, page 24), a specificity of 
HLADH to NADH was estimated, but it is unclear whether NADPH does not bind inside 
HLADH or bind in an inactive conformation. The literature still suggests the binding 
of NADPH is hindered by a repulsion between the ribose phosphate and D223.214,215 
A tendency to bind NADH better than NADPH was also found in both docking 
approaches. From the visual analysis, a slight difference was showed between NADPH 
and NADH position and contacts, with the adenosine ribose phosphate group of 
NADPH orienting the ribose away from D223 (Figure 37B). 
A) B)  
Figure 37: A) Superposition of the crystal nicotinamide ring of NADH (yellow) and the structure from 
QM calculations (cyan) from Meijers and co-workers B) Superposition of NADPH cofactor (blue) with 
the NADH (green) from docking experiment. The highlighted D223 repulsed the NADPH ribose 
phosphate from the adenine group. By contrast, the ribose of NADH made contacts with D223.  
In general, all the cofactors bound with significant high affinity values, predicting a 
relative high affinity to HLADH. These results gave a reference for further studies of 
different ligands structures. However, more experiments will be necessary to inform 
Zn2+
Asp
223
68 
 
if the binding affinity ranking between the different cofactors in the docking 
simulations is of quality.  
 
From the literature, it is unclear whether strong NADH binding is due to the 
adenosine fragment, the nicotinamide part or both. The screening of molecules 
fragments is helpful in order to better understand key binding interactions. As the 
molecules are smaller, they explore a larger part of the binding site. These smaller 
structures are likely to form few bonds with the target binding site, but these links 
have to be strong to form a stable complex.216 Thus, this fragment screening was 
applied to obtain a better idea on which NADH part is responsible for the affinity 
inside HLADH. 
The NAD(P)H cofactor was split into two fragments between the two phosphate 
groups (Figure 38): the nicotinamide riboside structures bearing modifications at the 
ribose primary hydroxyl group (fragments 6 to 8) and the adenosine fragments with 
or without the corresponding ribose monophosphate (fragments 9, 10, 11 and 12, 13 
and 14, respectively). 
 
 
Figure 38: Fragments of NAD(P)H structure based on the nicotinamide and adenosine parts, designed 
for the docking inside HLADH. 
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Table 3: Glide XP (kcal mol-1) and MM-GBSA (ΔG in kcal mol-1) results ranked by HLADH XP score. The 
highlighted numbers represent the best scores. The location of fragments compared to NADH is 
presented in the last column.  
Fragments 
HLADH HLADH without Zn2+ Similar location to 
NADH (w/wo Zn2+) 
XP Glide ΔG XP Glide ΔG 
NADH -14.8 -80.6 -15.1 -83.6 - 
NAD+ -11.5 -92.7 -12.0 -125.7 - 
6 -10.9 -62.5 -8.8 -70.9 Yes/yes 
9 -10.6 -55.4 -8.6 -69.9 No/no 
8 -10.3 -40.5 -8.6 -58.1 No/yes 
11 -9.2 -39.8 -6.6 -40.3 No/no 
7 -8.7 -53.3 -6.7 -58.9 No/no 
12 -8.7 -24.4 -6.1 -22.5 No/no 
14 -8.6 -23.6 -7.4 -41.1 No/yes 
10 -7.5 -36.1 -7.3 -40.3 No/no 
13 -6.5 -41.9 -7.9 -40.4 No/no 
Docking scores of all fragments presented in Table 3 displayed lower affinity than the 
entire NAD(H). Fragment 6 which contained a ribose moiety modified with a 
phosphate group at the primary hydroxyl, presented the lowest free energy binding 
using both Glide XP and MM-GBSA methods.  
The visual analysis showed a general location of the fragment in the end of NAD(P)H 
pocket facing the active site, which is naturally occupied by the cofactor nicotinamide 
ring and the pyrophosphates groups. More precisely, nicotinamide fragments (6 to 8) 
were roughly located in the nicotinamide binding region, featuring similar contacts 
(Figure 39). 
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Figure 39: Nicotinamide mononucleotide fragment (NMN, fragment 6, blue) superposed to NADH 
(green). The H-bonds are in dashed yellow lines, while the amino acids (pink) in contact with the 
ligands are labelled. 
When no phosphate groups were present in the ligand structure, a shift of the 
nicotinamide ring was observed towards a hydrophobic pocket further from the 
normal position of NADH (e.g. with fragments 7, Figure 40). This pocket is positioned 
on the other side of the Zn2+, constituting the binding site of the substrate.217 
 
Figure 40: The nicotinamide fragment 7 (blue) superposed with NADH (green), slide inside the 
hydrophobic substrate binding pocket. 
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On the other hand, in the best scored adenosine fragments (9 or 11) the ribose was 
positioned at the native NADH nicotinamide ribose position, making similar hydrogen 
bonds with V268, V294 and I269 (Figure 41). 
     
 
Figure 41: Example of adenosine monophosphate fragment 9 (blue) superposed to NADH (green), and 
its interaction residues (pink). 
All adenosine fragments were in the ribose and nicotinamide ring area, with few 
interactions made by their hydroxyl or phosphate group.  
In general, scores obtained with all the fragments were of comparable values. This 
highlighted a similar affinity, confirmed by the same interactions detected in all the 
3D structures. The fragment docking approach gave first insights in the importance 
of each NAD(P)H part. Adenosine and adenosine 3’-monophosphate showed little 
affinity for their respective sites. This suggested that adenosine fragments were least 
responsible for NADH affinity.  
Considering the better scores when they were present, the ribose and 5’-phosphate 
groups seemed to lead to better binding affinity on any of the fragments. 
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Literature reports suggested that benzyl nicotinamide structures and nicotinamide 
mononucleotide (NMN, fragment 6) were active NADH mimics with HLADH.104 On 
the other hand, other reports implied no activity with benzyl nicotinamide in 
HLADH.218 The affinity of these mimics for HLADH are still under debate. 
Following the results of fragments docking, the nicotinamide part was presented as 
the important part for binding. Thus, the NADH nicotinamide ring was used as frame 
for the design of ligands to dock inside HLADH, alongside mimics from Fish and co-
workers and M. Basle work (Figure 42).104,109 The oxidised form was applied for all 
structures, as a slight affinity advantage was shown in the validation of the protocol 
with the natural cofactors (section 3.3.1.3, page 66). 
 
 
Figure 42: Designed ligands for further docking screening. Structures 1, 15 and 16 are based on 
previous work from literature.104,109 Structures 17 to 22 are based on NMN fragments, supplemented 
with a sulphonamide bidentate ligand for structures 19 to 22.  
The first set of ligands (1; 15; 16) were composed of a nicotinamide ring to which a 
benzyl group was added, based on the previous designs of mimics from Fish and 
Hollmann work (Figure 25, Figure 26, page 31).104,107 These analogues already 
synthesised and tested for inhibition in our laboratory, gave a reference for the 
docking results. For ligand 16, a sulphonamide group was also included, that later 
should support the transition metal for the imine reduction.124 
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Based on the structure of NMN, a second set of ligands was then created using a 
ribose and a phosphate group (ligands 17 to 22, Figure 42). The amide group was 
substituted with a phenyl to highlight the effect of a hydrophobic group in this part 
of the structure (ligands 17, 18). The sulphonamide complex was also added to the 
structure (ligands 19, 20 and 21, 22). These molecules were designed to test the 
impact of ribose and phosphates on affinity and the fragments 6 and 8 were kept as 
reference. All stereochemistry of the ligand structures were kept identical to the co-
crystallised NADH cofactor. To investigate the possible impact of docking parameters 
concerning Zn2+ interactions on ligands, both HLADH with and without Zn2+ were used 
for the docking, applying the docking protocol established earlier. 
Table 4: Presentation of Glide XP (kcal mol-1) and MM-GBSA (ΔG kcal mol-1) docking scores for the 
designed compounds and NAD(P)H inside HLADH with and without Zn2+. The ligands are ranked by XP 
results in HLADH. The highlights represent the best scores. The location of ligand nicotinamide ring is 
compared to NADH for both docking inside HLADH and HLADH without Zn2+.  
Ligands 
HLADH HLADH without Zn2+ Similar position 
to NMN 
(w/wo Zn2+) XP Glide ΔG XP Glide ΔG 
NADH -14.8 -80.6 -15.1 -83.6 - 
NAD+ -11.5 -92.7 -12.0 -125.7 - 
18 -9.9 -53.5 -10.5 -65.7 yes/yes 
19 -9.8 -65.2 -7.7 -81.9 no/no 
17 -9.7 -63.1 -10.2 -82.3 no/yes 
20 -9.2 -46.2 -12.2 -81.8 no/yes 
22 -8.4 -42.7 -9.2 -70.9 yes/yes 
6 -6.8 -67.3 -8.6 -70.2 yes/yes 
15 -6.7 -43.1 -5.9 -70.4 no/yes 
16 -6.2 -50.3 -2.8 -77.9 no/no 
8 -4.1 -62.5 -6.5 -71.4 yes/yes 
21 -4.0 -57.0 -5.8 -41.0 yes/no 
1 -3.7 -47.4 -4.2 -62.8 yes/yes 
The docking results showed similar Glide XP ranking between both HLADHs while 
MM-GBSA scores resulted in higher values for HLADH without Zn2+. 
The benzyl-modified ligands (1; 16) resulted in significantly lower binding affinity 
inside both HLADH crystal structures compared to all other molecules, as shown by 
74 
 
their lowest rank with Glide XP (Table 4). The location of the nicotinamide ring was 
identical to NADH ring; however, the benzyl group was placed inside the substrate 
pocket. In addition, the ligands displayed a limited number of specific bonds (e.g. H-
bonds) with the protein, mainly between the sulphonamide and the amide group 
with valine residues in the pyrophosphate binding area (Figure 43). However, this 
situation was not acceptable for the final objective to construct a binding metal 
catalyst, due to the sulphonamide support taking the space of the anchoring part and 
thus positioning the metal toward the exit of the cofactor binding pocket.  
 
 
Figure 43: Best scored docking poses of ligand 15 and 16 (blue) superposed to NADH (green). The 
benzyl was inserted in the substrate hydrophobic pocket. The ligands bound to valines (pink) with their 
amide and sulfonamide group. 
VAL 292
Zn2+
VAL 268
Zn2+
75 
 
The lack of contacts and a wrong position of the ligand prevented a strong affinity 
toward HLADH and a right positioning to a catalytic activity. These docking results 
confirmed previous conclusions of inhibition assays from M. Basle,109 along with the 
work of Hollmann and co-workers218 who suggested a low affinity for the synthesised 
ligands toward HLADH.  
The second set of ligands (17 to 22) was docked to establish the ribose and phosphate 
groups importance in the binding location and affinity. The structures were ranked at 
the top with the best XP and MM-GBSA scores (Table 4). When looking at the poses, 
all the ligands inserted their sulphonamide in the substrate hydrophobic pocket 
ahead of NADH pocket, using the phosphate and the ribose for H-bonds interactions 
(Figure 44).  
 
Figure 44: 3D structure and corresponding interaction diagram of ligand 20 (blue). Phosphate and 
ribose made interactions that reversed the structure’s orientation, inserting the sulphonamide group 
Zn2+
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inside the substrate pocket, ahead of the NADH binding pocket. Arg: arginine, Asp: aspartic acid, Cys: 
cysteine, Gly: glycine, Ile: isoleucine, Leu: leucine, Lys: lysine, Met: methionine, Phe: phenylalanine, 
Pro: proline, Ser: serine, Thr: threonine, Val: valine. 
The docking poses of the best structures suggested again a phosphate and sugar 
impact in affinity, confirming the previous NADH fragments docking results. The 
presence of a ribose and a phosphate completely reversed the ligand structure 
orientation by positioning the sulphonamide inside the substrate hydrophobic 
pocket, contrary to ligand 1 or 15 whose benzyl anchoring part was in the substrate 
pocket. 
To conclude on these first screenings inside HLADH, all best fitting ligands showed 
similar features:  
- Ribose and phosphate groups are important for the binding.  
- Several functional groups (carboxyl, amine, and hydroxyl) in the structure’s 
core make hydrogen bonds all along the binding pocket (especially in 
ribose/pyrophosphate area with valine and arginine residues).  
- A hydrophobic part (aromatic rings, aliphatic chain, halogens) docks in the 
substrate pocket, lined with hydrophobic residues.  
These findings led to a series of new questions arising: can we use the substrate 
pocket for ligand binding, or is this area too important for the catalytic reaction? 
When the substrate is present, is there enough space remaining to include a metal? 
New docking experiments should be conducted with the presence of a substrate 
preventing any docking inside its pocket, to confirm the previous interaction 
hypotheses and optimize them.  
 
A crystallized structure of HLADH complexed with NAD+ and 2, 3, 4, 5, 6-
pentafluorobenzyl alcohol (PDB 4DWV) was prepared with and without Zn2+ ion.  
By avoiding occupancy of the substrate binding pocket, the study of this crystal 
structure might provide more information on major contacts inside the cofactor 
binding site.  
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The docking protocol was verified in the previous section (3.3.1.1, page 63) for this 
new HLADH structure, and the RMSD scores validated the protocol. Similar steps to 
the previous docking were then applied with the docking of NAD(P)H cofactors and 
their fragments. 
Table 5: Glide XP (kcal mol-1) and MM-GBSA (ΔG in kcal mol-1) results inside HLADH with substrate, 
ranked by XP score. The highlighted numbers represent the best scores. The location of fragments is 
compared to the co-crystallised NAD+ in the last column. HLADHsubst refers to the crystal structure 
containing a substrate (PDB 4DWV). 
Fragments 
HLADHsubst HLADHsubst without Zn2+ Similar location to 
NAD+ (w/wo Zn2+) 
XP Glide ΔG XP Glide ΔG 
NADH -14.6 -60.8 -14.1 -80.5 - 
NADPH -12.9 -95.2 -14.6 -90.2 - 
NAD+ -11.4 -101.2 -13.1 -119.9 - 
NADP+ -11.9 -77.9 -14.5 -73.4 - 
6 -8.9 -50.6 -10.2 -94.2 yes/yes 
9 -8.2 -24.3 -4.8 -33.8 yes/yes 
8 -7.8 -47.9 -10.1 -63.9 yes/yes 
7 -7.8 -34.9 -6.4 -93.9 no/yes 
10 -6.8 -38.9 -7.2 -42.3 no/no 
11 -6.7 -28.1 -5.6 -45.5 no/no 
13 -7.1 -35.5 -5.4 -36.0 no/no 
12 -6.4 -38.3 -7.4 -41.8 no/no 
14 -6.9 -46.8 -7.5 -34.3 yes/no 
This new docking showed similar conclusions as the earlier docking in HLADH without 
the substrate, in terms of score and visual analysis: 
- Lack of discrimination between NADH and NADPH, and between their reduced and 
oxidised forms. 
- NADH fragments location was restricted to middle and top areas of the binding 
pocket and fragment 6 (NMN) was clearly selected as the best score (Figure 38).  
- Similar to the NAD+ co-crystal, contacts were made by the ribose and phosphate 
groups with arginine and valine residues, confirming the importance of the 
nicotinamide area in the cofactor pocket. 
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The same ligands (1 to 22; Figure 42) were docked again inside the binding site in the 
presence of the co-crystallised substrate (see Table 6). 
Table 6: XP (kcal mol-1) and MM-GBSA (ΔG in kcal mol-1) docking results, for designed ligand inside 
HLADH including co-crystallised substrate with and without Zn2+. The ligands are ranked by XP results 
and the highlights represent the best scores. The location of ligand nicotinamide ring is compared to 
the NAD+ co-crystal. HLADHsubst refers to the crystal structure containing a substrate (PDB 4DWV).  
Ligands 
HLADHsubst HLADHsubst without Zn2+ 
Similar orientation than 
NMN 
XP Glide ΔG XP Glide ΔG 
NADH -9.8 -60.8 -14.3 -54.1 - 
NAD+ -11.4 -101.2 -13.1 -119.9 - 
22 -9.0 -58.0 -9.0 -35.3 No/no 
20 -8.2 -36.8 -8.0 -29.2 No/no 
18 -8.2 -48.8 -10.4 -93.7 no/no 
17 -7.7 -48.8 -8.1 -93.5 Yes/yes 
21 -7.3 -36.1 -6.7 -55.2 No/no 
16 -7.1 -44.8 -6.6 -62.2 No/no 
15 -5.0 -36.2 -1.8 -58.6 No/no 
1 -4.5 -41.1 -5.2 -77.3 Yes/yes 
19 -4.3 -43.5 -6.9 -48.6 No/no 
The ligand structures with phosphates and ribose groups scored again best with both 
Glide XP and MM-GBSA (17, 18, 22), while the benzyl-substituted nicotinamide 
structures 1 ranked among the last. This again confirmed previous docking results 
with HLADH alone.  
When a phenyl or a sulphonamide group was added to the nicotinamide ring position 
(18, 20), compounds reversed their orientation towards the adenine part location 
while keeping the ribose and phosphate contacts (Figure 45). This was probably due 
to the additional phenyl ring not able to accommodate inside the substrate pocket. 
Therefore, the residue D223 in the adenine section of the cofactor pocket interacted 
with the nicotinamide pyridinium by making a salt bridge.  
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Figure 45: A) Docking poses of ligands 18 and 20 (blue), compared to crystal structure NAD+ 2 (green), 
in presence of the substrate (red). B) Pose of ligand 20 (blue) superposed with NAD+ 2 (green). C) 
Interaction diagram represents ligand 20 contacts with the amino acids inside NADH binding pocket. 
The red box represents interaction similar to NADH pyrophosphate and the orange box the NADH 
adenine ribose interactions. Arg: arginine, Asp: aspartic acid, Asn: asparagine, Gly: glycine, Ile: 
isoleucine, Leu: leucine, Lys: lysine, Phe: phenylalanine, Pro: proline, Thr: threonine, Val: valine. 
No significant differences appeared for structures without hydrophobic substituents 
inside HLADH with substrate, where they remained in a NADH like position. However, 
an inversion was observed for bigger and more hydrophobic structures (ligands 16 to 
18) which arranged their hydrophobic part toward the outside of the pocket, while 
keeping the phosphate and ribose interactions.  
This docking with substrate confirmed the previous conclusion settled: the ribose and 
the phosphate seem to be the decisive groups in NADH structure, while several links 
with arginine (R369 and R47) and valine residues (e.g. V294, V292 and V268) are of 
importance for a good affinity. Moreover, supplementary hydrophobic substituents 
linked to the nicotinamide ring must be avoided for their risk of insertion into the 
substrate binding pocket. This might block the substrate normal binding and change 
the right orientation of the ligand toward the substrate. Finally, the nicotinamide ring 
showed no interaction in all the different docking experiments. This heterocycle 
might thus not be essential for the binding inside HLADH.  
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A virtual screening study was conducted using libraries of ligands to enhance the 
variety of structures docked inside HLADH. This will highlight the structural 
characteristics of a ligand with affinity for the enzyme cofactor pocket, and the 
residues used for the interactions. Around 8000 structures of available chemical 
compounds and their conformers were docked within both HLADH and HLADH with 
substrate. The online available Schrodinger library of lead like ligands and the ZINC 
library were used (ZINC12; Glide Drug-like Ligand Decoy sets).219 
 
The first ten best binding ligands showed similar XP and MM-GBSA values as the 
NADH cofactor inside HLADH. They docked with a MM-GBSA score between -89.0 
kcal mol-1 and -59.4 kcal mol-1, where NADH was of -80.6 kcal mol-1 and NAD+ -92.7 
kcal mol-1. 
 
Figure 46: Interaction diagram of best MM-GBSA scoring ligand in HLADH cofactor binding pocket. 
Similar interactions as phosphate (red box), ribose (green) and nicotinamide (blue) groups of NADH 
were spotted. Arg: arginine, Asp: aspartic acid, Cys: cysteine, Gly: glycine, His: histidine, Ile: isoleucine, 
Leu: leucine, Met: methionine, Phe: phenylalanine, Ser: serine, Thr: threonine, Val: valine. 
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In a general visual analysis, the docking of libraries inside HLADH again validated the 
previous conclusions. The best ranked ligands shared two important features in their 
structures: a hydrophobic part with naphthalene or aliphatic chain and a hydrophilic 
centre composed of amino, carboxyl or hydroxyl groups. 
The hydrophobic elements were always positioned in the hydrophobic substrate 
pocket (Figure 46) while the hydrophilic groups formed several interactions with 
residues in the cofactor pocket. A recurrence of three or four links was spotted 
between carboxyl/hydroxyl groups and R369, R47 and/or V203, V292.  
On the other hand, the lowest ranked structures were mainly composed of 
hydrophobic groups with aromatic rings and heterocycles.  
 
The same ligands libraries were screened inside HLADH with substrate. The docking 
showed a good correlation between the two HLADH structures with and without Zn2+; 
the score values and the structures were found similar (hydrophilic groups and 
heterocycles).  
Compared to HLADH without substrate, lower MM-GBSA scores were obtained 
(between -38.4 kcal mol-1 and -67.5 kcal mol-1).  
The first visual impact of these ranking differences was seen in the ligand’s structure 
shape, where hydrophilic groups were even more frequently present. For example, 
hydrophobic groups frequent in previous HLADH alone docking were generally 
replaced by heterocycles (Figure 47). The substrate pocket being occupied, the 
hydrophobic part was reduced in the selected structures. The ligands docked inside 
the cofactor pocket only, by contacts from the nicotinamide and phosphate area 
(Figure 47). Almost no interactions were present in the adenine area. 
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Figure 47: Selection of the ligands poses from libraries with the best XP and MM-GBSA scores, and 
their corresponding interaction diagrams inside the cofactor binding pocket of HLADH. Ligands (blue) 
are superposed to NAD+2 (green) with substrate (red). In the diagrams, the similar interactions as the 
NADH pyrophosphate group are represented in red boxes and the nicotinamide in blue. Arg: arginine, 
Asp: aspartic acid, Cys: cysteine, Gly: glycine, His: histidine, Ile: isoleucine, Leu: leucine, Lys: lysine, Phe: 
phenylalanine, Ser: serine, Thr: threonine, Val: valine. 
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Schrodinger and ZINC libraries also provide fragments sets of ligands, which can be 
used for a more precise screening of important areas.  
The analysis of fragments docking confirmed the previous findings: the general 
localisation of the fragments was identical to the pyrophosphate position of the co-
crystallised NADH (Figure 48). They also formed similar interaction with V294, V203 
and R47, R369. 
 
Figure 48: Pose and interaction diagram of the best scoring fragment from the online libraries (blue). 
The interactions mimicked NAD+ ribose (green box) and phosphate interactions (red box). Arg: 
arginine, Cys: cysteine, Gly: glycine, His: histidine, Ile: isoleucine, Ser: serine, Thr: threonine, Val: valine. 
Zn2+
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In HLADH with substrate, all best poses always made interactions with V203 and 
V292, V268 and V294 in addition of two hydrogen bonds with R47 and R369 inside 
the cofactor pocket. Other less frequent links could also be spotted with glycine, 
cysteine, or histidine residues. Additional extra links with residues were observed 
compared to the docking in HLADH alone, where the hydrophobic cleft of the 
substrate added some affinity for the ligand docking. 
The lowest ranked ligands obtained XP scores around 0.796 and 1.134 (Figure 49) and 
were typically hydrophobic structures, with few interactions.  
 
Figure 49: An example of the lowest ranked structure from Schrodinger library, with few interactions. 
Arg: arginine, Asp: aspartic acid, Cys: cysteine, Gly: glycine, His: histidine, Ile: isoleucine, Leu: leucine, 
Lys: lysine, Phe: phenylalanine, Pro: proline, Ser: serine, Thr: threonine, Val: valine. 
 
Despite the variety of ligands tested in this first docking studies, similar structures 
and interactions were found to be an advantage for the affinity inside HLADH. Those 
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docking studies provided insights into the NADH structural motifs and the cofactor 
pocket residues relevant for an efficient binding: 
- The adenosine moiety and the nicotinamide ring did not improve binding 
significantly.  
- The phosphate group and the ribose nicotinamide seemed to be the most 
important groups in the NADH structure for high affinity, by building strong 
H-bonds. 
- Key residues in the cofactor pocket for strong affinity include mainly arginines 
(R47, R369) and valines (V203 and V294). Two interactions frequently 
observed with the arginine residues implied even better scores and ranking 
for the ligands.213 
- The substrate pocket was useful for hydrophobic contacts. It may bring higher 
affinity and stability to the complex catalyst-enzyme. For example, a 
hydrophobic area in the ligand could relocate its metal closer to the substrate. 
On the other hand, this means such ligands would occupy the natural 
substrate binding site, which might prevent further substrate binding 
necessary for the anticipated catalysis. 
 
 
Based on the structural characteristics observed during the first docking experiment, 
a small anchor library was designed. To screen this new library and define a smaller 
set of lead structures, a second and improved docking strategy was developed.  
In the pharmaceutical industry, computational docking is generally used to identify 
inhibitors of proteins by favouring best binding structures. Hence, the affinity 
between a protein and its ligand is the principal parameter studied.162 In that way, 
during the first part of this computational study, the structures were ranked based 
on their binding energies.  
However, for this project objective, not only binding affinity but exact binding 
orientation were of major importance to find a suitable hit anchor for a metal 
complex catalyst. The anchor must place the metal exactly towards the substrate 
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pocket to deliver a catalytic activity. During these new docking studies, precision in 
the affinity, the location and the orientation of the structures must be considered.  
The new scheme of computational docking calculation started on structures without 
the transition metal, by the traditional Glide SP and XP docking screenings (Figure 
50). These experiments delivered a raw filtering of the small library of anchor 
structures. The change in the protocol was the final step with the introduction of 
Induced Fit Docking (IFD) treating the whole structures of ligands (anchor and metal 
complex). Indeed, Glide XP or MM-GBSA used in the previous docking study were not 
able to handle the Cp* metal complex inside the enzyme. A higher flexibility of the 
protein scaffold was needed in order to allow the Cp* group insertion at the interface 
between cofactor and substrate binding sites. Therefore, MM-GBSA docking was 
replaced by the more accurate IFD method.207 
 
Figure 50: The protocol designed for the second set of docking experiments, with a first rough 
screening using Glide score and a refinement using IFD calculation with some enzyme flexibility in the 
final step. 
In addition to the Glide XP score representing the affinity of ligands for HLADH, a new 
scoring was to be defined, characterising the orientation and location of ligands. 
Filters were created to evaluate various poses and explain the choice of structures 
among the ligand libraries. The location and the orientation of the ligand inside the 
HLADH binding site were evaluated as follows: 
Location: (x3) 
- 0: not in the pocket 
90 
 
- 1: in the entrance (adenine part) 
- 2: in the adenine-phosphate area 
- 3: in the pyrophosphate area 
- 4: in the nicotinamide ribose area 
- 5: perfectly follow the NAD area 
Orientation compared to NADH: (x4) 
- 0: turned upside down 
- 2: when several poses of ligand with some in reverse and some in similar 
position to NAD 
- 5: same orientation as NAD 
Energy binding scores (XP Score) (x2) 
The three factors were also ranked for their importance and impact. Thus, the pose 
of the structure was the most important parameter and both location and orientation 
were privileged over the affinity approximation. The resulting final score for each 
structure allowed a ranking and selection of several potential hit metal catalysts.  
HLADH with substrate crystal structure and lacking Zn2+ was used (PDB 4DWV). 
 
In the first set of docking calculations, phosphate and ribose groups were found the 
most important part of NADH for maximising binding affinity, as they form several H-
bonds with arginine and valine residues. On the other hand, the adenine part and the 
nicotinamide ring were considered not essential for the binding affinity.  
Based on these results, functional groups that mimic or strengthen the interactions 
between phosphate/ribose group and residues like R47, R369, V203 and V268 were 
selected. (Figure 51).  
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Figure 51: The prototype of the new high affinity ligand structure was based on the nicotinamide part 
of NAD(P)+ cofactor. The phosphate and ribose represent the anchoring part and can be replaced by 
shorter and simpler hydrophilic groups (blue). A sulphonamide bidentate metal ligand with and 
without its typical aromatic ring (red), is inserted at various positions on the nicotinamide ring. 
In view of the first docking results, a new anchor structure library was created (Figure 
52). Hydroxyl and carboxylic acid groups were used as principal groups to mimic the 
phosphate and ribose part of NADH. The strategy followed for the anchoring part 
design begun by a polyol structure, which mimics the two hydroxyl groups of the 
nicotinamide ribose. Modifications were then brought to the length, position, 
number, and nature of the functional groups. For example, carboxylic acids (as 
mimics of the phosphate) were added in various positions and in combination with 
other amino or hydroxyl groups. Finally, the original nicotinamide mononucleotide 
fragment was also added and slightly modified (ligand R2, R12, R13). The 
stereochemistry was kept unrestricted.  
92 
 
 
 
Figure 52: Selection of the functional groups (R) composing the new library of ligands. They were 
created using variation of structure length and hydrophilic groups combinations.  
The literature models for efficient transition metal complexes in the catalysis of imine 
reduction included one aromatic ring.124 Therefore, these various new functional 
groups were inserted into structures composed of two rings (pyridine and aromatic 
ring) as well as on a single ring, to evaluate the impact of structures length on affinity 
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(Figure 53). As highlighted earlier, the nicotinamide demonstrated little effects on 
the affinity. Thus, the nature of the ring was varied between a pyridine and a phenyl.  
Finally, the structures were designed with all possible insertion types on the rings 
(ortho, meta and para position). 
 
Figure 53: Model of ligand structures for the second docking screening, where R represents the various 
substituents (see Figure 52) and both phenyl and pyridine rings were used. The sulphonamide served 
as support for the metal complex and was inserted in ortho, meta or para position in the aromatic 
ring. 
These modifications led to a library composed of 477 newly designed ligands.  
 
Following the anchor library creation, the docking experiment started with a raw 
filtering with Glide SP and Glide XP methods. The structures docked at these stages 
were composed of only the anchor and the sulphonamide metal support (Figure 53).  
The aim of this docking approach was to reduce the number of potential ligands used 
as anchors, guided by their affinity scores and poses. A suitable pose was defined by 
a similar orientation and location as NADH inside the pocket. This resulted in a first 
overview of the R substituents impact on the affinity for HLADH. 
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Figure 54: General process of the Glide SP / Glide XP / IFD created protocol and the selection of ligands 
structures at each step. 
After the Glide SP filtering, the 40 best scoring ligands were selected, then the 40 best 
ligand poses were retained and were tested in the Glide XP docking (Figure 54). 
Figure 55 represents an example of an acceptable and a rejected pose. 
A)  
Library 477 structures
80 structures:
- 40 best score
- 40 best poses
53 structures
7 hits
Substrate
ALA 317
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B)  
Figure 55: Superposition of A) Anchor R10 (blue) with XP score of -10.3 kcal mol-1 in an efficient pose, 
with NADH (green) and B) Anchor R1 (blue) with XP score of -10.7 kcal mol-1 in a reversed pose, with 
NADH (green). The sulphonamide would locate the metal toward the solvent. 
From the Glide XP resulting ligands, the scores and the poses were manually checked 
for all the 80 structures. Only the ligands showing an acceptable orientation and 
location, suitable for the catalytic activity, were selected. Therefore, from the 80 
ligands ran through Glide XP docking, 53 ligands were selected (Figure 54) and the 
metal complex IrCp* was added (Figure 56). 
 
Figure 56: Model of ligands from the library previously created (R in Figure 52), in complex with the 
iridium transition metal. 
 
At first, Glide XP docking was attempted on the selected ligands including the metal 
complex, using the previous parameters and grid setup. However, the space in the 
pocket was too small to allow any valid poses by this method. 
Sulfonamide
VAL 292
PHE 319
Substrate
ARG 47
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IFD calculations were then conducted. This technique gave flexibility in the protein 
scaffold by refinement of the residues around the ligand (see details in section 3.2.2, 
page 62). The previous Glide docking grid was used to run the IFD calculations. From 
the 53 poses entered, 45 poses were recovered after IFD calculation among which 34 
structures had only one aromatic ring connected to the metal support. Only few 
poses were obtained for the ligand with two aromatic rings. The structures were too 
elongated and complicated to be synthesised and none of them showed a top score. 
Based on these results, only the structures with a single aromatic ring were 
considered for the rest of the project. 
The poses, direction, orientation, and affinity scores were treated following the filters 
created previously (section 3.3.5.1, page 88). Figure 57 presents the results of the 
filters applied to the 34 ligand poses from IFD calculations. 
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Figure 57: Graph representing the final score (y axis) obtained from the affinity score and the 
structures poses score (orientation/location) after HLADH docking. All the designed ligands (x axis) are 
represented with various metal complex insertions (ortho, meta, para) and the C-ring mode (orange) 
or the N-ring (blue). 
The analysis of the obtained scores gave a quick overview for the docking process 
conclusions. From view of the substitution position at the aromatic rings no para 
substituted ligand reached an advantageous high score, while the number of highly 
scoring phenyl-based ring structures was similar to pyridine counterparts. This 
indicates no discrimination between the two in terms of binding affinity. However, it 
is relevant to highlight that one ligand structure was best ranked for only one type of 
ring. For example, ligand R9 and R10 obtained only best scored poses for the C ring, 
whereas if no impact of the ring occurs, both N and C ring structures should show the 
same score.  Finally, the ranking of ligand structures depended mainly on the nature 
of the R substituent.  
The applied filters naturally discredited wrong poses, for example structures with the 
metal opposite to the substrate or with few contacts. Figure 58 depicts the structure 
of ligands R2 and R5, which ranked with highest and lowest score, respectively.  
A)  
IrCp*
Substrate
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B)  
Figure 58: A) Ligands R5ortho (XP= -4.0 kcal mol-1, blue) with a wrong orientation for catalysis 
(superposed to NADH green). B) Ligand R2ortho (XP= -6.1 kcal mol-1, blue) with a suitable pose toward 
the substrate (red). 
From the second docking screening, several best scoring ligands were selected: R2, 
R3, R9, R10, R14, R19 and R25 (Figure 59).  
 
IrCp*
Substrate
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Figure 59: Set of lead catalyst structures, selected based on the IFD results. The anchoring part of these 
products should be suitable for the anchoring of the iridium transition metal inside HLADH. 
Among these structures, the anchoring part of R2 represented the nicotinamide 
mononucleotide part of NADH cofactor. The presence of this ligand was not 
surprising and confirms the finding of the initial docking, which highlighted ribose and 
phosphate as essential for the binding affinity. 
In other hit structures, hydroxyl and carboxylic acid groups appeared as a recurrent 
substituent, found in almost all structures. These observations matched with the first 
aim, the substitution of ribose (by hydroxyl) and phosphate (by carboxylic acid). 
Conversely, ligands without carboxylic acid group, including R1 or R18 (Figure 53), 
presented no available pose. Ligands with only one functional group (e.g. ligand R5) 
were ranked with a weak score and wrong poses (Figure 58). The interaction diagram 
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and 3D poses of the hits ligands confirmed previous conclusions on the contacts with 
HLADH scaffold (examples in Figure 60; Figure 61; Figure 62):  
A)  
 
B) 
 
Figure 60: Ligand R25, with a C-ring and a meta insertion of the metal complex. A) Superposition of 
R25 (blue) with NAD+ (green). B) Interaction diagram of R25 inside HLADH cofactor pocket. Arg: 
arginine, Asp: aspartic acid, Cys: cysteine, Gly: glycine, His: histidine, Ile: isoleucine, Leu: leucine, Lys: 
lysine, Ser: serine, Thr: threonine, Val: valine. 
Substrate
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A)  
B)  
Figure 61: Ligand R2, with a C-ring and a meta insertion of the metal complex. A) Superposition of R2 
(blue) with NAD+ (green). B) Interaction diagram of R2 inside HLADH cofactor pocket. Arg: arginine, 
Substrate
ARG 369
ARG 47
LYS 228
VAL 268
VAL 203ILE 269
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Asn: Asparagine, Asp: aspartic acid, Gly: glycine, His: histidine, Ile: isoleucine, Leu: leucine, Lys: lysine, 
Ser: serine, Thr: threonine, Val: valine. 
A)  
B)  
Figure 62: Ligand R9, with a C-ring and an ortho insertion of the metal complex. A) superposition of 
R9 (blue) with NAD+ (green). B) Interaction diagram of R9 inside HLADH cofactor pocket. Arg: arginine, 
Ala: alanine, Glu: glutamic acid, Gly: glycine, His: histidine, Ile: isoleucine, Leu: leucine, Phe: 
phenylalanine, Ser: serine, Thr: threonine, Val: valine. 
Several interactions were observed between the sulphonamide group and the 
important arginine residues. Additionally, new contacts with other residues were also 
spotted: K228, H51, S48 or various glycines. 
Substrate
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Following the selection of the best residues, a validation of the protocol was 
performed to avoid any false positive or negative results. In the first section, the 
docking protocol was already validated by using the RMSD method (section 3.3.1.1, 
page 63). This part focuses on the accuracy of the selection method applied. 
 
As mentioned earlier, several ligands scored highly only with one type of the aromatic 
ring, obtaining no or poor results with the other ring structure (Figure 57). However, 
similar poses detected for C- and N- ring structures suggested that the nicotinamide 
ring showed no real impact in the affinity for HLADH pocket.  
In order to understand these differences between the two types of rings and validate 
the process, a new set of IFD calculations with similar filters were carried out with 
two structures containing the two ring types (Figure 63).  
 
Figure 63: Comparison of IFD scores between the same catalyst structures with either a N or C-ring. 
The structures used for the new IFD experiment showed scores similar with both 
rings, confirming that the nature of the ring had no effects in affinity. Thus, to 
understand the low scores in the original calculations, the whole process containing 
XP and SP docking selections was analysed in detail.  
In the first Glide filtering, many selected structures (e.g. ligand 10) appeared with 
only one type of ring. The other structures were generally ranked too low to be 
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considered in the 80 first selected structures. The reason behind this lies in the 
representative XP scores lying so close together that some structures with similar but 
slightly lower scoring fell below the cut-off for selection at this step.  
Another explanation involved the conformation of the structures. Some ligands (e.g. 
R2 or R9) were selected with both N and C ring after the SP / XP docking. However, a 
superposition between the two structures showed a difference in the conformation. 
During IFD calculations, a rigid treatment of the ligand was kept (while allowing 
flexibility for the enzyme) and the previous selected conformations stayed 
unchanged inside the pocket. In the end, the filters resulted in a bad scoring of the 
conformation for one of the structures. Thus, the differences in scores were due to 
different ligand conformers selected in the previous step, and not the nature of the 
ring.  
In order to verify these hypotheses, the IFD approach was repeated for several other 
ligands structure, randomly checked for their differences between C and N ring IFD 
scores. All of them resulted in similar scores for both ring types when the same ligand 
conformation was used in the IFD input.  
To conclude on this protocol validation, the nature of the ring had no impact on the 
binding process and the structure selection. 
 
The best scores obtained by the selected metal lead structures were then compared 
with several of the previous Glide XP results.  
- IFD result (metal ligands) vs Glide XP docking (only sulphonamide anchor):  
The Glide XP scores achieved by the docking of anchors are slightly higher 
than the IFD scores obtained for the corresponding metal ligands. For 
example, ligand R10 scored -10.3 kcal mol-1 without the metal complex (XP 
docking) while ligand R10 = -7.0 kcal mol-1 with the IrCp* (IFD calculation). 
This score variation highlighted a more important number of contacts made 
with surrounding residues (Figure 64). Especially, the sulphonamide and 
amine functions were free during XP docking, allowing hydrogen bound to be 
created, contrary to IFD experiments where they were engaged in IrCp* 
complex.  
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A) B)  
Figure 64: The number of contacts compared between A) an anchors R10 with only sulphonamide 
support and B) metal complex catalyst. 
- IFD results for metal catalysts against NADH cofactors:  
The NADH cofactor scored always better than XP or IFD docking of the 
catalysts, predicting a better affinity of the natural cofactor for HLADH. 
- IFD results of metal catalysts against benzylnicotinamide ligands (R= Benzyl):  
The benzylnicotinamide anchor structure previously used were metalated to 
match the structure of the hit ligand. Thus, both N and C ring were used, and 
a sulphonamide support was added to the aromatic ring. The best Hollmann 
ligand obtained a low score of -4.5 kcal mol-1, with all structures in reversed 
position. These results were lower than the lead ligands (around -9 kcal mol-
1), meaning a poorer affinity.  
 
Fragments of the hit structures were tested through the second docking protocol and 
compared to the cofactors NAD(P)H (Figure 50, Table 7). Only the ring and the 
functional group R were employed to determine the impact of the anchoring part. 
 
Figure 65: Truncated hit ligands used for enhanced affinity tests. They were composed only of an 
aromatic ring and the R anchoring part. 
This test gave another indication on the affinity strength of the substituents. 
ARG 47
Gly 202
ALA 317
VAL 292 
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Table 7: Glide XP results (kcal mol-1) of fragment into HLADH, and their position compared to the 
natural cofactor. 
Ligands XP scores Pose compared to NAD+ 
NADH (1) -14.3 - 
NADPH (3) -9.7 - 
NAD+ (2) -13.3 - 
NADP+ (4) -14.5 - 
1 -3.5 reversed structure/ no contact 
R2 -8.6 similar location / contacts 
R14 -8.2 
similar location /contacts 
similar to ribose and 
pyrophosphate of NAD+ 
R9 -7.4 same as R14 
R10 -6.6 same as R14 
R25 -6 same as R14 
R19 -5.3 same as R14 
The hit structures were not at the level of the natural cofactors due to missing 
hydrogen bonding interactions. Yet, as a shorter structure, the truncated hit structure 
still obtained acceptable scores, between -8 and -5 kcal mol-1. Furthermore, they 
clearly showed better scores than the benzylnicotinamide ligands 1, which 
experimentally obtained low affinity for HLADH.106 Inhibition assays from M. Basle’s 
thesis also concluded to a lack of interactions with the HLADH for all the different 
benzyl ligand.109 
The selected ligand presented lower affinity than the natural NADH cofactor. 
Nevertheless, they were the best structures tested by docking, with significant higher 
affinity compared to existing NADH mimics from literature. 
 
 
Before proceeding with the synthesis of the lead anchor structures, another alcohol 
dehydrogenase (ADH) enzyme was tested.  
The Thermoanaerobacter brockii alcohol dehydrogenase (TbADH) is an NADP-
dependent, zinc ADH from bacteria, currently studied in the laboratory for covalent 
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anchoring.97 The accessibility to this enzyme, a known higher thermostability than 
HLADH, the resistance to organic solvent and a broad substrate specificity made 
TbADH another interesting target for the engineering of AMs.101  
Anchor structures previously designed were also tested inside TbADH cofactor 
binding pocket to evaluate prospective affinities. This enzyme structure could also 
become an alternative at HLADH scaffold if no efficient experimental results were 
found. 
 
 
The TbADH crystal structure was without substrate (PDB 1YKF).97 The docking setup 
was exactly similar to the one used earlier for HLADH. Re-docking of crystal ligand 
NADP+ gave an RMSD < 2 Å, validating the protocol for this enzyme.  
Table 8: Docking of NAD(P) cofactors in TbADH, following a docking protocol set in the previous section 
(3.3.1.1, page 63). The Glide XP scores are in kcal mol-1. 
Enzyme NADH NAD+ NADPH NADP+ 
TbADH -11.2 -8.0 -11.6 -11.7 
TbADH 
no Zn2+ 
-10.5 -8.7 -12.3 -11.1 
Similar to HLADH docking experiment, the Glide scores were not able to clearly 
discriminate between NADH and NADPH cofactors, except for a lower affinity with 
NAD+ (Table 8). TbADH sequence identity is only about 27 % with HLADH,97 with the 
greatest similarity in the cofactor binding pocket. However, the literature suggests a 
specificity for NADPH favoured by the adenine binding to three amino acids (S199, 
R200 and Y218). In HLADH, this space is occupied by an aspartic acid (D223), repelling 
the phosphate.215 
 
The anchor library designed for HLADH was docked inside TbADH with the previous 
protocol starting with Glide docking and followed by IFD calculations for the metal 
complexes (Figure 66). The TbADH crystal structure was prepared like HLADH, the 
zinc ion was removed and all three amino acids around (C37, H59 and D150) were 
mutated to alanine. 
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Figure 66: Graph representing the final score (y axis) obtained from the affinity score and the 
structures poses score (orientation/location) by IFD calculations in TbADH. All the designed ligands (x 
axis) are represented with various metal complex insertions (ortho, meta, para) and the C-ring mode 
(orange) or the N-ring (blue). 
In TbADH, more structures were ranked with a better score after application of the 
filters than previously in HLADH. This could be explained by the presence of a 
substrate in HLADH, reducing the space for Cp* group compared to TbADH free of 
substrate. Thus, the limit was raised to a score of 40 for ligand to be selected as a hit 
(against 30 for HLADH). A broader range of structures in the right catalytic location 
and orientation were selected as hits: R1, R2, R9, R10, R11, R12, R13, R14, R15, R16 
(red structures have also been selected in HLADH docking). 
This table compares the scores and ranking of TbADH and HLADH for their hit 
anchors: 
Table 9: Comparison of hit anchors in TbADH and both HLADH with and without substrate. The ranking 
of the structures is made by their filters score. XP score (kcal mol-1) obtained from IFD calculations is 
also shown.  
Hit 
structures 
TbADH 
XP score 
Hit 
structures 
HLADH no 
substrate 
XP score 
Hit 
structures 
HLADH 
XP score 
R1 -14.0 R16 -10.4 R9 -7.0 
R14 -11.7 R13 -8.8 R10 -7.2 
R9 -10.3 R16 -9.4 R16 -7.3 
R13 -11.2 R3 -7.8 R2 -6.1 
R2 -12.0 R14 -9.6 R19 -6.2 
R16 -10.3 R6 -9.2 R14 -8.6 
R10 -10.0 R12 -8.0 R25 -5.1 
R12 -10.0 R10 -8.4 R21 -5.0 
R15 -11.0     
R11 -11.8     
The two studies in HLADH showed lower affinity scores for the anchors than TbADH. 
The affinity was even lower in the substrate presence, maybe again due to less space 
for Cp* or because of amino acids conformation in the “close mode”, refraining the 
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binding of ligands. Indeed, according to literature, more amino acid movements are 
observed in HLADH scaffold upon the binding of cofactors. The scaffold conformation 
“close” around the cofactor, which can explain the difficulties of binding for Cp* 
(especially in crystal structure with substrate).91 In TbADH, the main conformation 
changes are localised in the adenine binding area for the specificity for NADP 
cofactor.97 
In conclusion, TbADH seemed to be less discriminating, accepting a broader range of 
ligands. Within the first nine hit structures, TbADH and HLADH without substrate 
shared identical ligands (Table 9). Besides, four ligands were common to the three 
enzymes and part of the hit anchors previously selected: R10, R14 and R16. The visual 
analysis in HLADH showed similar H-bonds made by these anchors and the co-
crystallised cofactor. The conclusion of docking in TbADH again highlight that all the 
previously mentioned catalysts (R10, R14 and R16) made similar contacts with TbADH 
scaffold than NADP+. 
With the selected hit anchors also in TbADH docking top ranking, this enzyme can be 
another scaffold to use for AMs engineering. Therefore, the synthesised anchors will 
be tested into both HLADH and TbADH (available in the laboratory) to compare their 
affinity for the enzymes and validate the docking protocol. 
 
Molecular docking was used as a tool to design metal complexes, able to strongly 
bind inside HLADH. A first docking protocol was developed and validated for the 
classical determination of the binding affinity of natural NAD(P)H cofactors, previous 
NAD(P)H mimics and ligands libraries. Various enzyme residues and functional groups 
were then highlighted as necessary for a strong affinity. These findings enabled the 
creation of a NAD(P)H analogue model and the design of a small library of potential 
metal catalyst. A second docking protocol was developed, which analysed these new 
metal catalysts for their affinity, but more importantly, for their orientation and 
location toward an optimal catalysis. It is decisive to present the metal complex 
towards the substrate pocket, but without blocking the substrate binding site.  
112 
 
This new process allowed the selection of a set of metal complexes ranked with the 
best docking and location score. The affinity approximation of the metal catalysts was 
lower than the natural cofactor. However, the selected metal catalyst ranked better 
than benzyl nicotinamide ligands, already tested experimentally with a low affinity 
for HLADH. Finally, theses catalysts were also tested in TbADH and reported similar 
results than HLADH docking. TbADH was also selected as another potential scaffold 
for AM. Amongst the selected lead catalysts, some with the best scores in both 
enzymes (R2, R9, R10 and R14) are already favoured for the next synthesis step. 
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The previously designed and computationally tested metal catalysts were composed 
of three main parts. First, a N-sulfonyl-ethylenediamine moiety, derived from the 
Noyori’s catalysts, coordinates the transition metal.56 Several studies have shown 
that N-sulfonyl-ethylenediamine complex of Ru and Ir were the most efficient 
catalysts for the aqueous asymmetric transfer hydrogenation of imines.83,118,123 The 
second part of the catalysts consisted of the functionalised aromatic ring, acting as 
an anchor to the nicotinamide-binding pocket of alcohol dehydrogenases (ADHs). 
From the docking calculations, there were no significant differences in the affinity to 
ADHs between compounds bearing pyridine and phenyl rings. Thus, the phenyl ring 
was preferred for an easier and quicker synthesis. The third part of the catalysts was 
a supramolecular ligand, with features to bind inside ADHs natural cofactor binding 
pocket with high affinity (e.g. hydroxyl, carbonyl). Following the computational work, 
lead structures of ligands were selected based on their docking scores and their 
optimal binding orientation. The meta-position of N-sulfonyl-ethylenediamine 
moiety was preferred to mimic the position of the amide in the natural NADH 
cofactor. A multistep retrosynthetic workflow was then designed toward the 
production of these metal catalysts (Scheme 1). 
The retrosynthesis proposed was developed to fulfil two parameters: 1) a divergent 
synthesis promoting the creation of a ligand library through the functionalisation of 
a single intermediate 2) a short synthesis, yielding the metal catalysts in few steps.  
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Scheme 1: Retrosynthesis designed to produce the previously selected hit metal catalysts structures. 
The starting structure was a tosyl ring holding a functional group (Scheme 1, R2). The 
first step was to protect the N-sulfonyl-ethylenediamine by a tert-butyloxycarbonyl 
protecting group (Boc), a common protection for amines. The Boc protecting group 
can be cleaved under strong acidic conditions and resists to basic conditions and 
nucleophilic attacks. From previous protocols with similar N-sulfonyl-
ethylenediamine, this protection has been used for further modifications of the 
aromatic ring without impact on the amine.57,220  
The second step was the development of a small library of structures by substitution 
or addition of new functional groups (Scheme 1, R1). Finally, a metalation reaction 
was promoted to obtain an iridium metal catalyst for supramolecular anchoring into 
ADHs. 
A divergent synthetic pathway was then designed. The main objective was to 
synthesise a N-sulfonyl-ethylenediamine intermediate containing a reactive 
functional group able to be modified into different ligands. Based on the structures 
suggested by the docking studies (R2, R9, R10, R14), three metal catalyst complexes 
were targeted: R14, 32 and 35 (Scheme 2). The number and diversity of hydrophilic 
functional groups and the anchor’s length was an attractive parameter for future 
affinity investigations. Compound R14 was thus privileged over R9 and R10 because 
its variety of carbonyl and hydroxyl group combinations, to mimic the binding of the 
ribose and phosphate of NADH. The presence of several hydrogen bond donor and 
acceptor groups made these ligands potential better supramolecular anchors 
compared to phenyl substituted compounds studied previously.108 Besides, unlike 
complicated structures (e.g. the NMN ligand R2, Figure 59),221 the selected ligands 
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allowed for a short synthesis route of 4 - 6 steps, consuming less time and being cost 
effective. 
The designed synthetic pathway was based on the functionalisation of a the tert-butyl 
(2-((3-acetylphenyl)sulfonamido)ethyl)carbamate intermediate 30, through a Claisen 
condensation, to form the key ethyl4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl) 
sulfamoyl)phenyl)-2,4-dioxobutanoate 31. After applying subsequent Claisen 
condensation222 or reduction reaction, this key structure can be converted into the 
different target molecules: 
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Scheme 2: General synthetic pathway for the production of metal catalysts. Reagents and conditions: 
a) Boc2O, DCM; b) triethylamine, Boc-ethylenediamine, DCM; c) (i) SOCl2, CH3NHOCH3, Et(NPr-i)2, dry 
DCM; (ii) CH3MgBr, dry THF; d) CH3Li, DEE; e) t-BuOLi, dry THF; f) (i) TFA, DCM, (ii) NaOH, MeOH/H2O, 
(iii) [IrCl2Cp*]2, Et3N, MeOH; g) (i) NaOH, MeOH/H2O, (ii) TFA, DCM h) (i) NaBH4, MeOH, (ii) [IrCl2Cp*]2, 
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Et3N, MeOH; i) t-BuOLi, ethyl propionate, dry THF; j) (i) NaBH4, MeOH, (ii) TFA, DCM, (iii) [IrCl2Cp*]2, 
Et3N, MeOH. 
 
 
The first steps of the synthetic pathway were focused on the preparation of the 
ketone intermediate 30, from which a Claisen reaction led to the key compound 31, 
a common product to the different metal catalyst synthesis.  
Commercial chlorosulfonyl benzoic acid 27 was used as starting material, because no 
chlorosulfonyl acetophenone was commercially available (Scheme 3). Compound 27 
was treated with a protected N-Boc ethylenediamine in the presence of 
triethylamine, according to several literature protocols.220,223,224 This step 
functionalised the aromatic ring with the N-sulfonyl-ethylenediamine protected by 
tert-Butyloxycarbonyl (Boc). The choice of a Boc protection allowed to keep intact 
the future metal coordinating group. The planned steps involved basic conditions 
(Claisen reactions), and no strong acidic conditions, which are known to remove the 
Boc protection.  
Product 28 was obtained in 92 % yield after purification. This compound 28 was part 
of the designed ligands in the previous docking study (R23, Figure 52). The structure 
ended ranked with less affinity than the selected hits anchors. However, to validate 
the docking method, the affinity of 28 anchoring part can be tested against future 
compounds.  
 
Scheme 3: The 3 steps synthesis of ketone 30. 
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From the benzoic acid 28, the ketone intermediate 30 was synthesised in two steps 
according to the Weinreb-Nahm ketone method.225,226 Based on this method, the 
benzoic acid 28 was first activated by conversion into a Weinreb-Nahm amide 29, 
with a 36 % yield. Subsequent treatment of the amide 29 with a commercial Grignard 
reagent led to the ketone 30. The final step was performed in a dry solvent under 
inert atmosphere, to bypass possible reaction of the methyl magnesium bromide 
solution with water. The pure intermediate 30 was obtained with a 54 % yield from 
the N-Boc Weinreb amide 29. The starting material amide was also recovered from 
purification with 14 % yield. The two steps overall yield was of 20 %. The limiting step 
was the activation of the acid in the Weinreb amide. In literature, the resulting amide 
was not purified, so the amide 29 was then used in the next step without purification 
(3 g of acid 27 gave 1.7 g of ketone 30).  
 
Compound 31 represented a challenge to succeed in the route to the future metal 
catalysts library. The synthesis of 31 was performed by Claisen condensation of 
diethyl oxalate with ketone 30 to give a β-diketoester functional group (Scheme 4).227 
The general conditions involved the use of a base to create an enolate anion, which 
would perform a nucleophilic attack on the carbonyl functionality of the ester. 
 
Scheme 4: Claisen condensation scheme of ketone 30 and diethyl oxalate, for the synthesis of product 
31. 
Diethyl oxalate was chosen to react with the ketone 30 to achieve the targeted 
carbonyl pattern. A range of experiments was performed with variations of the 
conditions adapted from literature (Table 10).  
In an initial attempt, the sodium ethoxide (NaOEt) was selected as a base, according 
to previous work on diketoesters synthesis.227,228 Following the established protocol, 
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NaOEt was first utilised at 1 eq (1, Table 10). The analysis by thin layer 
chromatography (TLC) showed only the presence of the starting material after 16 
hours of reaction. Verification of the 1H-NMR spectrum confirmed that the mixture 
was composed of the starting material, with presence of signals attesting for only 
few, uninterpretable by-products. No changes were observed after increasing the 
NaOEt concentration up to 4 eq.227 Thus, according to other literature examples,229 
the solvent was changed to control its impact on the reaction (3, Table 10). The 
starting material and the previously described by-product were again detected in the 
1H-NMR spectrum, with high amount of a new by-product with signals at 4.39 ppm 
and 1.40 ppm. Unfortunately, the reaction did not provide the expected β-
diketoester 31. 
It was decided to change the base to sodium hydride (NaH), which is commonly used 
for Claisen rearrangements (4, Table 10).230,231,232 NaH concentration was raised until 
disappearance of the starting material on TLC analysis. After study of the 1H-NMR, 
the expected product was detected in low yield (12 %), with a mixture of by-products 
and starting material. Optimisation was needed to obtain the desired compound 31 
with a relevant yield. 
Table 10: Claisen condensation reaction between ketone 30 and diethyl oxalate under various 
conditions. 
Entry Base Eq. Solvent 
Reaction 
time 
Outcomes 
1 NaOEt 1 Et2O Overnight 
Starting material + by-
products 
2 NaOEt 4 Et2O Overnight 
Starting material + by-
products 
3 NaOEt 2 Methanol Overnight 
Starting material + by-
products 
4 NaH 5 Et2O Overnight 
Product 31 + by-product 
and starting material 
A report by Ji and co-workers233 demonstrated a low yield of their expected β-
diketoester when following the NaOEt-mediated sterically hindered Claisen 
condensation (Scheme 5). The authors explained that by-products observed in their 
1H-NMR spectra came from a retro-Claisen condensation and a self-Claisen 
condensation: 
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Scheme 5: Representation of a retro-Claisen reaction and a self-Claisen condensation mechanism, 
adapted from the proposed mechanism by Ji and co-workers.233 
The by-products 1H-NMR spectra, described in their paper, correspond to the by-
product signals found in the performed NaOEt attempts of Claisen condensation (1 
to 3, Table 10). When using NaOEt or NaH to condense ketone 30 and diethyl oxalate, 
the formation of β-diketoester was followed by additional reactions generating the 
observed by-products, without possible isolation of the β-diketoester 31 (Scheme 6).  
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Scheme 6: NaOEt catalysed Claisen condensation between ketone 30 and diethyl oxalate. 
Representation of the by-products created by self-Claisen condensation and retro-Claisen reaction, 
based on Ji and co-workers proposed mechanism (Scheme 5).233 
Ji and co-workers suggested the base plays an important role in the stabilisation of 
the reaction intermediates (Scheme 7). By creating a stable six-membered enolate, 
the base should avoid the side reactions previously mentioned.  
 
Scheme 7: Example of the stabilisation mechanism of t-BuOLi mediated Claisen condensation, adapted 
from suggestions by Ji and co-workers.233 
Thus, the authors proposed to use lithium bases instead of sodium-based ones. Due 
to the strong affinity of lithium for oxygen, the base was able to form a cyclic enolate 
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lithium salt, which circumvented second reactions. Their protocol used the tert-
butoxide (t-BuOLi) base (Scheme 8). Following a similar protocol, the β-diketoester 
31 was obtained with an overall 26 % yield.  
 
Scheme 8: Adapted protocol for the synthesis of product 31 by Claisen condensation. 
TLC analysis showed two distinct spots, corresponding to the two enolic forms trans 
and cis of the β-diketoester 31, later purified by column chromatography (86 % cis-
31b and 14 % trans-31a mass). The cis-enol was the most present and the most stable 
form due to the six-membered ring formation with intramolecular hydrogen 
bond.234,235  
The 1H-NMR spectrum of both compounds 31a and 31b showed an integration of 
only one hydrogen for the peak at the vinyl position, confirming the presence of the 
enol form over the keto form of the β-diketoester (see Appendix 1). A different shift 
of the vinyl hydrogen and the aromatic ring signals was observed between the two 
spectra, which helped in confirming the cis and trans assignment (Figure 67). The 
vinyl proton in cis-31b showed higher signal frequency (7.1 ppm) than the trans-31a 
signal (6.7 ppm), due to the proximity of a carbonyl. The deshielding effect of the 
carbonyl was also observed for the aromatic proton singlet, which shifted to higher 
frequency in the trans-31a spectrum compared to the cis-31b.  
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Figure 67: 1H-NMR spectrum comparison showing the proton shift differences between the two 
tautomers of the β-diketoester 31: blue 31a and red 31b (full spectrum in Appendix 1). 
These experimental results were consistent with literature observations. The β-
dicarbonyls compounds exist in five tautomers: the ketone form, two cis-enol forms 
(with the intramolecular hydrogen migrating between the carbonyls) and two trans-
enol forms.234,235 The enol-enol migration of the intramolecular hydrogen between 
the two oxygens was too fast to be detected by 1H-NMR. Besides, in tricarbonyl 
product, the keto form is usually not found.229,235,236 Thus, only the enol form cis and 
trans were isolated. Both enol forms were used in the next step, the deprotection of 
N-sulfonyl-ethylenediamine. 
 
The deprotection of the Boc protecting group was the final step before the insertion 
of the transition metal. Usually, a Boc deprotection uses strong acids, such as 
trifluoroacetic acid (TFA) or hydrochloric acid (HCl).220,237 The protonation of the tert-
butyl carbamate induces the loss of a tert-butyl cation. The HCl/TFA anion 
decarboxylate the carbamic acid left, to result in the free amine later protonated 
under acidic conditions. 
Aromatic ring
α-Hb
CDCl3
α-Ha
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Scheme 9: TFA catalysed deprotection of Boc intermediates 28 and 30 to afford the deprotected 
carboxylic acid 36 and ketone 37. 
The N-Boc intermediates acid 28 and ketone 30 were deprotected by an excess of 
TFA, affording the products 36 (30 % yield) and 37 (65 % yield). The 1H-NMR spectrum 
validated the results with absence of the CH3 signal (see Appendix 1). These two new 
products were then used in the next step of metalation to create new catalyst 
complexes. 
To the best of our knowledge, the deprotection of Boc in a molecule with a 1,3-β-
diketoester has not been tested in the literature. Only one experiment was described 
in a patent from Boojamra and co-workers, using TFA reagent.238 Other successful 
examples also promoted deprotection with TFA in DCM on molecules containing 
hydroxy ethyl ester, substituted ketoesters or substituted 3,5-diketoester 
molecules.239,240,241,242 Thus, the TFA-mediated deprotection protocol used earlier 
was applied to the β-diketoester 31 (Scheme 9).  
The concentration of TFA was varied following recommendations from the authors. 
According to TLC monitoring, the reaction showed no changes at low concentration 
and no starting material was left at high concentrations of TFA (1, 2, Table 11). 
Unfortunately, the reaction did not proceed to the deprotection of Boc group. The 
1H-NMR spectrum of the crude mixture from high concentrations presented similar 
proton signals as the deprotected ketone 37, along with the degradation of N-
sulfonyl-ethylenediamine by loss of the relevant 1H-NMR signals. 
Based on several literature protocols, variations of conditions were attempted as 
displayed in Table 11.  
125 
 
Table 11: Different conditions applied for the Boc deprotection reaction of 31. 
Entry Reagent Eq. Solvent Reaction time Outcome 
1 TFA 12 DCM Overnight 
Degradation + 
Ketone 37 
2 TFA 8 DCM Overnight Starting material 
3 HCl 1 M 
Methanol, 
EtOAc, water, 
dioxane 
Overnight Starting material 
4 HCl 4 M 
EtOAc, 
methanol 
Overnight 
Ketone 37 + by-
products + starting 
material 
5 HCl Conc. Methanol Overnight 
Ketone 37 + by-
products 
6 H2SO4 1.5 Dioxane 6 h Starting material 
7 H3PO4 15 THF; DCM 1 day Starting material 
8 Iodine 1 DCM Overnight Starting material 
9 - - Water reflux  Starting material 
First, the acid reagent was replaced by HCl, the second most used acid in N-Boc 
deprotection. The concentration of acid and the solvent were varied based on several 
existing protocols (3 and 5, Table 11).220,243,244 Similar to TFA results, reactions with 
HCl in low concentration ended with the starting material while concentrated HCl 
degraded the product to the deprotected ketone 37. The 1H-NMR and ESI-MS analysis 
of the crude mixture using 4 M HCl in methanol or ethyl acetate showed a mixture of 
products. The deprotected ketone 37 was once again the main by-product spotted.  
To protect the sensitive part of the molecule, milder acidic conditions were tested. 
Various common protocols used H2SO4 or H3PO4 for successful N-Boc 
deprotection.237,245,246 However, in both cases, the starting material was detected in 
the 1H-NMR spectra. (6, 7, Table 11). Literature protocols using non-acidic conditions 
were then investigated.246,247,248,249 The use of aqueous reflux (100 °C) and of iodine 
proved no reactivity with the starting material observed by 1H-NMR spectra (8, 9, 
Table 11).  
Because the reaction conditions were not suitable to the current structure, it was 
decided to modify the product 31, while keeping an anchoring part able to bind 
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properly inside ADHs. Examples of a TFA catalysed reaction on diketones or ketoester 
structures substituted between the carbonyls by aryl, triphenylphosphine or carbonyl 
groups, were performed without changes in the diketone integrity.240,250,251 In order 
to test the potential effect of a substituent between the two carbonyls, a methyl 
group was added between the two ketones (Scheme 10). The choice of a methyl 
group, instead of the phenyl group, was made after Ji and co-workers never 
succeeded to mediate the Claisen condensation with a phenyl substituted ketone as 
starting material.233 Besides, the methyl also avoids the insertion of a large 
hydrophobic group, which might later impact on the affinity inside the enzymes 
cofactor pocket. As seen in the docking experiments, the anchor structure should 
increase its affinity when containing hydrophilic groups. 
From the Weinreb amide 29, the commercial Grignard reagent ethyl magnesium 
bromide was used instead of the previous methyl magnesium bromide.226 The 
conditions were kept as mentioned before, to synthesised the expected ethyl ketone 
39 with 50 % yield. 
 
Scheme 10: The two steps synthetic pathway to produce the ethyl4-(3-(N-(2-((tert-butoxycarbonyl) 
amino)ethyl)sulfamoyl)phenyl)-3-methyl-2,4-dioxobutanoate 40, following previously describe 
protocols. 
The previously optimised Claisen condensation conditions were used in the following 
step for the synthesis of the corresponding β-diketoester.233 The methyl substituted 
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β-diketoester 40 was obtained at 25 % yield, a similar yield than with the 
unsubstituted product. 1H-NMR spectrum displayed only the keto form over the enol, 
due to the presence of an alkyl substituent located between the two carbonyl groups 
(see Appendix 1).235,236  
For the deprotection step, higher concentrations than the previous TFA and HCl-
catalysed deprotections were needed before seeing the starting material consumed 
by TLC. Both resulting 1H-NMR spectra showed by-products mixture, with none of the 
expected β-diketoester signals. The by-products were difficult to determine with 1H-
NMR, and only the deprotected ketone 37 was identified again. The methyl group 
helped stabilising the structure, however, not enough to deprotect the N-Boc without 
degradation of the β-diketoester. In order to further stabilise the β-diketoester part, 
a phenyl group would be an alternative substitution for a higher potential of 
hindrance effect. However, this group can also be challenging in the binding to the 
ADHs cofactor pocket.  
After investigating on several reaction conditions and structure modifications, it was 
concluded that N-Boc deprotection of an aryl sulfonamide substituted with β-
diketoester was not achievable. Only one patent apparently succeeded in TFA 
deprotection.238  
Besides, Murray and co-workers proved degradation of a ketoester by TFA mediated 
decarboxylation.252 Munro and co-workers then proved degradation of a natural 
diketoester into the corresponding ketone, by using low concentration of TFA (0.05 
%).253,254 Based on their decarbonylation-decarboxylation explanation, Scheme 11 
presents a hypothesis for the degradation mechanism of compound 31. 
 
Scheme 11: Hypothesis of a degradation mechanism of compound 31 into the deprotected ketone 37, 
following a decarbonylation-decarboxylation combination.  
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Under acidic conditions, the protonation of carbonyl starts the nucleophilic attack by 
the deprotected ester hydroxyl, forming a five-membered ring. A combination of 
decarbonylation and decarboxylation forms the ketone. Meanwhile, the acidic 
conditions also deprotected the N-Boc, affording the ketone 37.   
 
Given that the Boc protecting group was not removed without degradation of the β-
diketoester, the focus was changed toward the ester deprotection instead. The size 
of Boc group is similar to the IrCp* normally introduced at this position, therefore, 
affinity experiments inside ADHs were deemed to provide information about the 
metal complex and the anchoring part of the structure. 
The saponification reaction was applied using basic conditions for the hydrolysis of 
the ester (thus avoiding any possible degradation of the β-diketoester from acidic 
conditions).255 
 
Scheme 12: Ester deprotection of product 31 through saponification reaction to afford the product 
38. The hydrophilic anchoring part was composed of ketones and carboxylic acid. 
The hydroxyl of NaOH works as a nucleophile and led, through ester deprotection, to 
the β-diketo acid 38 in a mixture with the N-Boc ketone 30. The presence of the 
ketone can be explained by two degradation reactions. Compound 31 could have 
underwent either the previously described decarbonylation-decarboxylation 
combination after ester deprotection (Scheme 11), or a retro-Claisen condensation 
presented in Scheme 13.256  
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Scheme 13: Proposed retro-Claisen condensation mechanism during the ester deprotection reaction. 
The high reactivity of the second carbonyl resulted in a nucleophilic attack by hydroxyl group, 
promoting a C-C bond cleavage and the production of an enolate, subsequently reprotonated to 
generate the ketone 30.  
The mixture was further purified by column chromatography and recrystallisation in 
hexane. The difficulty in the purification and the presence of by-products gave a low 
yield of 12 % of pure product. 1H-NMR spectrum proved the loss of the ethyl 
protecting group, confirmed later by mass spectrometry (see Appendix 1). This 
product was later tested for its binding affinity inside ADHs. 
 
Given the lack of stability of the β-diketoester functionality under acidic Boc 
deprotection conditions, a different protective group for the N-sulfonyl-
ethylenediamine was investigated in parallel. The benzyloxycarbonyl (Cbz) protecting 
group was chosen due to its stability under basic Claisen condensation condition and 
its ability to be deprotected without strong acidic conditions, which degrade the β-
diketoester. The usual Cbz deprotection conditions imply a catalysed reductive 
cleavage by hydrogen gas catalysed by palladium on carbon (Pd/C). To the best of our 
knowledge, no Cbz deprotection has been achieved with β-diketoester group in a 
molecule. The main risk was the hydrogenation of the aryl ketone as reported by 
Fadnavis and Radhika.257 
From the deprotected ketone 37, the protection of the primary amine by benzyl 
chloroformate, following the protocol from Song and co-workers,258 led to the pure 
Cbz-protected ketone 41 with 60 % yield (Scheme 14). 1H-NMR spectrum validated 
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the protocol by showing the signals representing the ketone, the typical Cbz aromatic 
ring and the ethylenediamine moiety. 
 
Scheme 14: Synthetic pathway using Cbz protection. The deprotected ketone 37 was first re-protected 
by Cbz group before the synthesis of the β-diketoester 42. The final step was the Cbz deprotection 
catalysed by Pd/C. 
The Claisen condensation of 41 with diethyl oxalate gave the Cbz-β-diketoester 42 
product with 69 % yield. This time, the two enols form cis and trans were not 
separated by column chromatography. The overall yield was higher than for the 
previously synthesised Boc-protected compounds (33 % and 37 %), indicating a 
possible impact of the protecting group geometry on the β-diketoester synthesis step 
(see Appendix 1 for 1H-NMR spectra).  
Following the protocol from Croft and co-workers,259 the Cbz protected ketone 41 
and the Cbz protected β-diketoester 42 were further subjected to deprotection, using 
a Pd/C catalyst under hydrogen atmosphere. 
The Cbz deprotection of the ketone 41 gave the deprotected ketone 37 with 39 % 
yield. 1H-NMR spectrum analysis showed no Cbz characteristic signals and the typical 
shift of the ethylenediamine protons due to deprotection.  
However, with the similar protocol used for the deprotection of ketone 41, attempts 
to deprotect the Cbz β-diketoester 42 resulted again in degradation. 1H-NMR 
spectrum showed the starting material along with a mixture of by-products. The 
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deprotected ketone 37 typical signals were spotted. One degradation hypothesis was 
first the decarboxylation of the ester induced by Pd/C, followed by the already 
described decarboxylation-decarbonylation combination (Scheme 11). Another 
possible explanation could be the Pd/C catalysed selective C-C bond scission of the 
diketone by H2 reaction, resulting in the ketone 37 (Scheme 15).260,261,262 
 
Scheme 15: Proposed mechanism for the hydrogenolysis by H2 of the β-diketoester anchoring part, 
catalysed by Pd/C.263 
Two triplets counting for four hydrogens (2.58 ppm and 2.84 ppm) were also 
identified in the spectrum at 45 wt% (Scheme 16). These signals corresponded to the 
hydrogenated aryl ketone to hydrocarbon, consistent with the literature on 
palladium preferential hydrogenolysis of aryl ketones.264,265,266,257  
 
Scheme 16: Example of observed by-products obtained from the Cbz deprotection of β-diketoester 42 
using Pd/C - H2 hydrogenation. 
Only 6 % of the starting material was recovered. 
 
Given the instability of the substituted β-diketoester, another strategy was the 
reduction of this entity prior to the amine deprotection. Accordingly, the reduction 
of the ketone functionalities to hydroxyls was selected as it should prevent the 
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decarbonylation-decarboxylation degradation and it would give access to the second 
anchor option: product 14, composed of a diol and a carboxylic acid (Scheme 2, page 
116). Besides, polyols showed stability under TFA treatment.267,268  
 
The prior reduction of the ketones, while keeping the ester intact, will be followed by 
ester deprotection to a carboxylic acid, to afford the final product 14. The esters are 
stabilised by the presence of the second oxygen atom with a lone pair of electrons, 
avoiding their reduction by weak reagents. The use of a weak reducing agent like 
sodium borohydride (NaBH4) was selected, as it promotes the reduction of ketones 
over esters.269  
Unfortunately, the treatment with NaBH4 of the β-diketoester 31 resulted in a 
mixture of several products. The 1H-NMR and COSY spectra showed a high proportion 
of the starting material (68 %) and a mixture of by-products was observed, among 
which a small portion of a β-diketoester with only the aliphatic ketone reduced. 
Thus, the second option chosen was to use a stronger reducing agent. Following the 
optimal conditions according to Ragavan and co-workers,270 lithium aluminium 
hydride (LiALH4, LAH) was tested under inert atmosphere (Scheme 17). Product 43 
was obtained with a 36 % yield.  
 
Scheme 17: The LAH-mediated reduction of compound 31 afforded the Boc-protected keto-diol 43. 
Both aliphatic ketone and final ester were reduced to hydroxyl groups. 
COSY-NMR and HSQC-NMR experiments confirmed the reduction of both ester and 
ketone (Figure 68 and Appendix 1). The ethyl ester signals were not present anymore 
and two new signals were detected at 3.67 ppm and 3.80 ppm (protons linked to C13, 
where 13 is the carbon number described in Figure 68). These protons suggested the 
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deprotection and reduction of ester into a hydroxyl. In COSY spectrum, these two 
hydrogen signals correlated to one new hydrogen at 4.87 ppm, representing the 
proton linked to C11. Then, another two hydrogens signal at 3.34 ppm and 3.19 ppm, 
corresponding to the two vinyl hydrogens hold by C10, coupled with the proton on 
C11. No hydrogen signal was displayed at the position C7, highlighting the presence of 
a carbonyl group.  
 
B)  
Figure 68: A) H-H coupling in product 43. The arrows represent the couplings made by the H11. B) The 
COSY-NMR spectrum of product 43 showed the couplings between H11 and H10 and between H11 
and H13, highlighted by circles.  
As stated by Ragavan and co-workers,270,271 the ester and the alkyl ketone were 
chemoselectively reduced to a hydroxyl, while the aryl ketone stayed intact. Their 
proposed justification to ensure the stability of the aryl ketone was based on the 
conjugation with the aromatic ring. This lower ketone reactivity avoided any 
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reduction, even with strong agents like LAH. Meanwhile, the aliphatic carbonyl 
functionalities underwent a reduction to form a diol.  
Following the successful reduction of the β-diketoester 31 to the ketodiol 43, the TFA-
mediated N-Boc deprotection was again attempted, using the previously described 
protocol. 
 
Scheme 18: TFA-mediated N-Boc deprotection of the ketodiol 43, using the previously described 
protocol. The resulting product 44 was a deprotected furan. 
This time, no degraded by-products or starting material were observed by TLC or 1H-
NMR. However, the expected final product 14 was not detected. The analysis of 1H-
NMR, COSY-NMR, and 13C-NMR spectra showed the presence of three new aromatic 
signals coupling together (between 6.59 ppm and 7.77 ppm, Figure 69 and Appendix 
1). Besides, hydrogen signals composing the ketodiol part of the starting material 43 
could not be found (C10, C11 and C13, Figure 68). The NMR spectra, supported by mass 
spectrometry, allowed to conclude on a cyclisation of the diol and ketone, due to the 
use of acidic conditions. The TFA-mediated cyclisation afforded the furan 44 with a 
70 % yield. 
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Figure 69: 1H-NMR spectrum of product 44. The three new observed aromatic signals correspond to 
furan hydrogens. 
A proposed explanation of the furan synthesis would be the occurrence of the acid-
catalysed Paal-Knorr reaction from 1,4-diketones, discovered in 1884 (Scheme 
19).272,273 Even though the reaction is known for more than a century, few studies 
have explored the reaction mechanism, and the pathway is still debated. A commonly 
accepted mechanism is the ring-closure of a rapidly formed monoenol. However, 
little experimental work has been carried out to validate this pathway based on 
hypothesis from pyrrole synthesis experiments.274,275 Based on experimental kinetic 
studies on furan, Amarnath and Amarnath later proposed a new mechanism involving 
a concerted cyclisation by attack of a protonated carbonyl group by the readily 
formed enol from the other carbonyl (Scheme 19).276 This is then followed by an 
irreversible dehydrative cyclisation to form the final furan. 
furan
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Scheme 19: Top: generally accepted Paal-Knorr mechanism for the acidic catalysed cyclisation of 
diketone into furan. Bottom: Reported Paal-Knorr pathway by Amarnath and Amanarth.276,277  
The synthesis of furan derivatives from alcohols was also demonstrated by Weedon 
and co-workers in acidic conditions, due to cyclisation of a 1,4-keto-alcohol 
intermediate, with no mechanism determination.278,279,280 Furthermore, the specific 
TFA-catalysed cyclisation of a tert-butyl acetoacetate was proven by Stauffer and 
Neier.281 
Based on literature results and mechanisms hypotheses, a proposed pathway for the 
TFA-catalysed cyclisation of product 43 is presented in Scheme 20. 
 
Scheme 20: Proposed mechanism of the TFA-catalysed furan cyclisation to form the furan product 44. 
The mechanism was based on reported Paal-Knorr pathways.276,277 
Based on Amarnath and Amarnath suggestions, the acidic condition led to the 
protonation of the aryl carbonyl, inducing the electrophilic attack of the 4-hydroxyl 
on the protonated carbonyl centre. The cyclisation was followed by irreversible 
dehydration due to aromatisation.  
The newly synthesised product 44 represented the perspective of a new catalyst 
complex and was used in the next step of metalation.  
In the previous TFA-mediated Boc deprotection attempts, the β-diketoester products 
31 and 40 and the ketoacid 38 did not undergo cyclisation.  
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First, they were all composed of a 1,3-diketone group and the Paal-Knorr reaction 
needs a 1,4-dicarbonyl reactant to cyclise. Thus, in the β-diketoester and the 
ketoacids groups, only the carbonyl from the ester and the carboxylic acid would have 
reacted with the aryl ketone. 
To the best of our knowledge, no evidence of an ester carbonyl involved in Paal-Knorr 
reaction was found in literature. Deprotection is necessary to obtain the reactive 
carboxylic acid. Stauffer and Neier showed an example of a furan cyclisation between 
ketone and carboxylic acid, using a TFA-catalysed reaction.281 Their tert-butyl 
acetoacetate products were deprotected by TFA to give the corresponding carboxylic 
acid, which attack the keto function, leading to a cyclisation. However, they 
confirmed the lack of reactivity when treating similar product as ketoacid 38 with 
TFA. The low electrophilic activity of the aryl ketone carbonyl is not enough for a 
possible attack of the carboxylic acid.   
 
To circumvent the cyclisation induced by acidic conditions, the Pd/C - H2 conditions 
were again tested for Cbz deprotection of the reduced β-diketoester. The Cbz 
protected β-diketoester 42 was first reduced by LAH, following the previously used 
protocol (Scheme 21). This time, after column chromatography purification, the Cbz-
ketodiol 45 was obtained with 15 % yield.  
 
Scheme 21: The LAH-mediated reduction of the Cbz-protected product 42 afforded the Cbz-protected 
keto-diol 45. Both aliphatic ketone and final ester were reduced to hydroxyl groups. 
The yield was influenced by the purification (recovery of impure product). For further 
optimisation of the reaction, a solution could be the use of a weaker reducing agents 
(NaBH4), or lower LAH concentrations (literature references advised 3 eq instead of 
the protocol 4 eq).282,283 
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The removal of the Cbz group was then performed using Pd/C - H2, applying the same 
condition as previously described:  
 
Scheme 22: Synthesis of the triol 46 by Cbz deprotection of product 45, using a reductive cleavage by 
hydrogen gas catalysed by palladium on carbon. 
The reductive cleavage of the Cbz group was successful, without Paal-Knorr 
cyclisation. The typical aromatic ring signals were not observed on the 1H-NMR 
spectrum (Appendix 1). Under these deprotection conditions, the reduction of the 
aromatic ketone was confirmed by NMR. A new hydrogen signal emerged in the 1H-
NMR spectrum, corresponding to the proton linked to C7, represented in Figure 70. 
A COSY-NMR spectrum confirmed the coupling between both C7 and C9 protons 
(circled, Figure 70). In addition, the absence of carbonyl signals was spotted on the 
13C-NMR spectrum.  
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B)  
Figure 70: A) H-H coupling in product 46. The blue arrows represent the couplings made by the H7. 
The red arrows represent the couplings made by the H10. B) The COSY-NMR spectrum of product 46 
showed the coupling of the new H7 with the two neighbours H9, highlighted by a circle. 
These data confirmed the catalytic hydrogenation of the aromatic ketone using Pd/C 
- H2 conditions, already described in literature.266,284 The final triol 46 was obtained 
with 74 % yield and taken to the next step. 
A 17 % yield of by-product was also found and characterised by ESI-MS and 1H-NMR. 
The product corresponds to the total reduction of the aryl ketone by hydrogenation 
from Pd/C - H2 conditions:  
 
Figure 71: By-product of the total reduction of 45 aromatic ketone, under Cbz deprotection conditions 
using Pd/C - H2. 
 
All deprotected N-sulfonyl-ethylenediamine products (36, 37, 44 and 46) were 
subjected to iridium metalation to form the final piano-stool complexes. The protocol 
was based on the modified work of Letondor and co-workers.58 The 
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pentamethylcyclopentadienyl iridium dichloride dimer ([IrCl2Cp*]2) was first 
suspended in methanol while the deprotected compounds, dissolved in methanol, 
were added to the suspension. A diphase water/methanol mixture was used to 
dissolve compound 36. All reactions were performed under nitrogen at room 
temperature until completion and the mixture was purified by precipitation in 
hexane. The different transition metal catalysts obtained were:  
Table 12: Metalation of the deprotected compounds 36, 37, 44 and 46 using [Ir2Cl2Cp*]2 and following 
the modified protocol from Letondor and co-workers.58 
Substrate Conditions Product Yield 
 
 
MeOH/water, 1h, 
rt 
 
55 % 
 
MeOH, rt 
 
20 % 
 
MeOH, 1h, rt 
 
43 % 
 
MeOH, 1h, rt 
 
43 % 
In all 1H-NMR spectra, the metalation was confirmed by a shift of the two CH2 
hydrogens of the N-sulfonyl-ethylenediamine, from approximately 3.15-3.05 ppm to 
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2.60-2.50 ppm. Upon binding of the metal, the Cp* signal at around 1.76 ppm was 
also identified (see Appendix 1). 
Affinity for the ADHs scaffold was then tested to compare hydrophilic (50), 
hydrophobic (49) and short chain (47) catalysts potential. 
 
Following the computational design, a divergent synthetic strategy was designed to 
produce the selected hit compounds. The strategy was optimised to represent an 
efficient pathway with limited steps. Attempts to obtain the desired anchoring part 
were unsuccessful at the final step of N-Boc deprotection. Several attempts with 
changes in the reaction conditions, the anchoring part substitutions, or the use of an 
alternative protecting group were all non-successful. A degradation of the β-
diketoester always occurred before the necessary deprotecting group cleavage. 
A final strategy was based on reducing the β-diketoester, prior to deprotection. This 
strategy succeeded, with the synthesis of two new anchoring products: a furan 44 
and a triol 46. The product 46 was close enough to the predicted structure 14 (only a 
carboxylic acid replaced by hydroxyl) to be considered as an anchor for the Ir metal. 
Thus, both anchors and an intermediate (product 36) were metalated with Ir to afford 
the final characterised transition metal complexes: [IrClCp*]-benzoic acid 47; 
[IrClCp*]-furan 49; [IrClCp*]-triol 50.   
These new catalysts differed from the expected products, but still hold the functional 
groups and overall structures likely to bind inside the enzyme. 
Three metal catalysts complexes were thus synthesised, as well as their three 
anchoring ligands. Another non Boc-deprotected ligand, product 38, was also 
synthesised to test the binding affinity of ligand similar to computationally selected 
lead structure 14. 
To create an AM, all the different metal complexes were first to be tested for their 
supramolecular binding with HLADH-WT, TbADH-WT and TbADH-5M. As new 
synthesised catalysts, their catalytic activity in the imine reduction was also 
subsequently investigated. 
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All chemical reagents were purchase as analytical grade from Sigma Aldrich and 
Fisher Scientific. The commercially available chemicals were used without 
purification unless otherwise stated. All aqueous solutions were prepared using 
deionised water.  
Analytical thin layer chromatography (TLC) was carried out on aluminium backed 
plates coated with Merck Kieselgel 60 GF254 and visualised under UV light at 254 
and/or 360 nm. Chemical staining was also routinely used, with aqueous basic 
potassium permanganate solution. Flash chromatography was carried out using 
Davisil silica 60 Å, with eluent specified. Infrared spectra were recorded using Burker 
FTIR spectrometer ALPHA II over the range 4000-600 cm-1. NMR spectra were run at 
298 K using a Bruker AV(III)400, AV400. DPX400 (400 MHz 1H frequency, 100 MHz 13C 
frequency). Chemicals shifts are quoted in parts per million (ppm), referenced to the 
residual deuterated solvent quoted as internal standard. Coupling constant J are in 
Hz. Multiplicity of the signals is abbreviated as follow: s, singlet; d, doublet; t, triplet; 
q, quartet; dd, doublet of doublet; dt, doublet of triplet; m, multiplet; br, broad. In 
the 13C spectra, signals corresponding to C, CH, CH2 and CH3 were assigned from DEPT 
experiments. Mass spectra were recorded using a Bruker MicroTOF 61 mass 
spectrometer using electrospray ionisation (ESI). 
 
tert-butyl (2-aminoethyl)carbamate (26)  
 
To a cooled solution of commercial ethylenediamine (9.2 eq, 171.5 mmol, 11 mL) in 
chloroform (200 mL) was added dropwise under stirring a commercial di-tert-butyl 
dicarbonate (1 eq, 18.6 mmol, 4.2 mL). The solution was then stirred overnight at 
room temperature. 
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The solution was washed successively with brine, 1 M NaOH three times, brine and 
deionized water. The organic layers were dried over anhydrous Na2SO4 and the 
solvent evaporated under vacuum to obtain the known product 26 as a yellow 
precipitate (2.48 g, 83 %).285 The characterisation data were consistent with those 
published in the literature.286  
1H NMR (400 MHz, CDCl3): δ = 5.27 (br.s, 1H, H4 NH), 3.12 (dt, 2H, H3 CH2), 2.02 (t, 2H, 
H2 CH2), 2.03 (s, 2H, NH2), 1.40 (s, 9H, H9-H10-H11 CH3),. 13C NMR (100 MHz, CDCl3): δ 
= 28.3 (3C); 41.7; 43.1; 79.0; 156.3.  
3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)benzoic acid (28)  
 
This compound was synthesised by adapting a previously described protocol.220 To a 
cooled solution of the product 26 (1.2 eq, 9.3 mmol, 1.5 g) in dichloromethane (36 
mL) was added dropwise under stirring trimethylamine (1.5 eq, 14 mmol, 2 mL) and 
a solution of the commercially available chlorosulfonyl benzoic acid 3-
(chlorosulfonyl)benzoic acid (1 eq, 7.71 mmol, 1.7 g) in dichloromethane (48 mL). The 
solution was stirred overnight at room temperature and monitored by TLC (CH2Cl2 
95/5 CH3OH + traces of acetic acid). The solution was evaporated under vacuum to 
obtain the known product 28 as a white powder (2.54 g, 92 %).  
1H NMR (400 MHz, Acetone): δ = 8.50 (s, 1H, H4 aryl), 8.30 (d, 1H, J=8.0 Hz, H2 aryl), 
8.28 (d, 1H, J=8.0 Hz, H6 aryl), 8.11 (t, 1H, J=8.0 Hz, H1 aryl), 6.80 (m, 1H, H11 NH); 6.07 
(m, 1H, H14 NH); 3.19 (m, 2H, H12 CH2); 3.05 (m, 2H, H13 CH2); 1.39 (s, 9H, H19-H20-H21 
CH3). 13C NMR (100 MHz, CDCl3): δ = 28.33 (3C); 40.28; 43.83; 61.34; 126.92; 128.89; 
129.05; 132.35; 135.07; 140.06; 168.00 (2C). 
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ESI-MS positive mode calculated for C14H20O6N2S1 344.1042, found 367.0934 
([M+Na+]). 
tert-butyl(2-((3(methoxy(methyl)carbamoyl)phenyl)sulfonamido)ethyl)carbamate 
(29)  
 
This compound was synthesised by adapting a previously described protocol.225 To a 
cooled solution of the acid 28 (1 eq, 0.145 mmol, 50 mg) in anhydrous 
dichloromethane (3 mL) was added dropwise under stirring thionyl chloride (7 eq, 
1.016 mmol, 73 µL). The solution was then stirred at room temperature for 3h. The 
reaction was cooled at 0°C and N,Ndiisopropylethylamine (4 eq, 0.58 mmol, 0.101 
mL) and N,O dimethylhydroxylamine (2 eq, 0.290 mmol, 28 mg) were added 
dropwise. The reaction was then stirred at room temperature overnight. The reaction 
was treated with saturated aqueous NaHCO3 (pH=7) then washed twice with water 
and dried over Na2SO4, filtered, and evaporated under vacuum. 
The crude extract was purified by flash chromatography column on silica gel (ethyl 
acetate 60/40 hexane) to afford product 29 (20 mg, 35 %).  
1H NMR (400 MHz, CDCl3): δ = 8.18 (s, 1H, H4 aryl), 7.95-7.93 (d, 1H, J=8.0 Hz, H2 aryl), 
7.90-7.88 (d, 1H, J=8.0 Hz, H6 aryl), 7.58-7.54 (t, 1H, J=8.0 Hz, H1 aryl), 5.67 (m, 1H, 
H10 NH); 4.99 (m, 1H, H13 NH); 3.54 (s, 3H, H26 CH3); 3.38 (s, 3H, H24 CH3); 3.23-3.19 
(dd, 2H, J1=4.0 Hz, J2=12 Hz, H11 CH2); 3.08-3.03 (dd, 2H, J1=4.0 Hz, J2=12 Hz, H12 CH2); 
1.41 (s, 9H, H18-H19-H20 CH3). 13C NMR (100 MHz, CDCl3): δ = 28.33 (3C); 31.93; 40.28; 
43.80; 61.34; 79.94; 126.92; 128.89; 129.05; 132.35; 135.07; 140.06; 168.00 (2C).  
ESI-MS positive mode calculated for C16H25O6N3S1 387.1464, found 388.1545 
([M+H+]), 410.1348 ([M+Na+]) and 797.2839 ([2M+Na+]). 
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tert-butyl (2-((3-acetylphenyl)sulfonamido)ethyl)carbamate (30)  
 
This compound was synthesised by adapting a previously described protocol.226 To a 
cooled solution of tert-butyl (2-((3-(methoxy(methyl)carbamoyl)phenyl) 
sulfonamido)ethyl)carbamate 29 (1 eq, 0.098 mmol, 38 mg) in anhydrous THF (2 mL), 
under nitrogen, was added dropwise under stirring a solution of methylmagnesium 
bromide (3 eq, 0.294 mmol, 0.15 mL). The solution was then stirred at room 
temperature for 3h. The reaction was monitored by TLC (ethyl acetate 60/40 hexane). 
The solution was treated with saturated aqueous NaHCO3 (pH=7) and extracted twice 
with ethyl acetate. The organic layers were washed with brine and water then dried 
over Na2SO4, filtered, and evaporated under vacuum. The crude extract was purified 
by flash chromatography column on silica gel (ethyl acetate 60/40 hexane) to afford 
product 30 as a yellow oil (20 mg, estimated 54 %).  
1H NMR (400 MHz, CDCl3): δ = 8.41 (s, 1H, H4 aryl), 8.15-8.13 (d, 1H, J=8.0 Hz, H2 aryl), 
8.06-8.04 (d, 1H, J=8.0 Hz, H6 aryl), 7.63 (t, 1H, J=8.0 Hz, H1 aryl), 6.04 (m, 1H, H13 NH); 
5.13 (m, 1H, H16 NH); 3.22 (dd, 2H, J1=4.0 Hz, J2=12 Hz, H14 CH2); 3.07 (dd, 2H, J1=4.0 
Hz, J2=12 Hz, H15 CH2); 2.65 (s, 3H, H9 CH3); 1.39 (s, 9H, H21-H22-H23 CH3). 13C NMR (100 
MHz, CDCl3): δ = 28.33 (3C); 26.70; 40.28; 43.83; 61.34; 126.92; 128.89; 129.05; 
132.35; 135.07; 140.06; 168.00 (2C).  
ESI-MS positive mode calculated for C15H22O5N2S1 342.1249, found 365.1144 
([M+Na+]), 685.2577 ([2M+H+]) and 707.2407 ([2M+Na+]). 
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Ethyl4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)phenyl)-2,4-
dioxobutanoate (31)  
 
This compound was synthesised by adapting a previously described protocol.233 To a 
cooled solution of t-BuOLi 1 M (2.5 eq, 1.65 mmol, 1.65 mL) in anhydrous THF (5 mL) 
was added dropwise under nitrogen diethyl oxalate (2 eq, 1.36 mmol, 0.2 mL). The 
solution was stirred at 0 °C for 10 minutes before the ketone 30 (1 eq, 0.66 mmol, 
226 mg) in anhydrous THF (4 mL) was added dropwise. The mixture was stirred for 
1.5h at room temperature. The reaction was monitored by TLC (ethyl acetate 50/50 
hexane) and treated with saturated aqueous NaHCO3 (pH=6). The aqueous phase was 
extracted twice with dichloromethane. The organic layers were washed with brine 
and water, dried over Na2SO4 and filtered. The solvent was removed in vacuum and 
the resulting residue was purified by flash chromatography column on silica gel (DCM 
60/40 MeOH). The title compound 31 was obtained as a yellow oil (96 mg, estimated 
26 %).  
1H NMR (400 MHz, CDCl3): δ 8.62 (s, 1H, H4 aryl); 8.04 (d, 1H, J=8.0 Hz, H2 aryl); 7.93 
(d, 1H, J=8.0 Hz, H6 aryl); 7.52 (t, 1H, J=8.0 Hz, H1 aryl); 6.73 (s, 1H, H10 CH); 5.68 (m, 
1H, H20 NH); 5.24 (m, 1H, H23 NH); 4.34 (dd, 2H, J1=8.0 Hz, J2=16 Hz, H16 CH2); 2.22 (m, 
2H, H21 CH2); 2.07 (m, 2H, H22 CH2); 1.43 (s, 9H, H28-H29-H30 CH3); 1.35 (s, 3H, H17 CH3). 
13C (100 MHz, CDCl3): δ= 14.11, 28.30 (3C); 40.30; 44.14; 59.02; 62.91; 97.92; 126.24; 
129.96; 131.53; 131.57; 135.97; 141.32; 161.79; 171.01; 188.42. 
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ESI-MS positive mode calculated for C19H26O8N2S1 442.1410, found 465.1298 
([M+Na+]), 885.2881 ([2M+H+]) and 907.2683 ([2M+Na+]). 
(4-carboxyphenylsulfonyl)-ethylenediamine acid (36)  
 
To a cooled solution of the acid 28 (1 eq, 2.87 mmol, 987 mg) in dichloromethane (47 
mL) was added dropwise under stirring trifluoroacetic acid (12.7 eq, 36.45 mmol, 2.8 
mL). The solution was then stirred overnight at room temperature and monitored by 
TLC (CH2Cl2 95/5 CH3OH + traces of acetic acid). The solution was evaporated under 
vacuum and co-distilled three times with dichloromethane to obtain the known 
product 36 as a white powder (358 mg, estimated 30 %).250  
1H NMR (400 MHz, DMSO-d6): δ = 8.35 (s, 1H, H4 aryl); 8.23-8.21 (d, 1H, J=8.0 Hz, 
H2 aryl), 8.10 (m, 1H, H11 NH); 8.06-8.04 (d, 1H, J=8.0 Hz, H6 aryl); 7.87 (m, 3H, 
H14 NH3); 7.80-7.76 (t, 1H, J=8.0 Hz, H1 aryl); 2.98-2.94 (m, 2H, H12 CH2); 2.89-2.86 (m, 
2H, H13 CH2). 13C NMR (100 MHz, DMSO-d6): δ = 38.87; 40.33; 127.74; 130.58; 131.17; 
132.45; 133.77; 140.55; 210.54. 
ESI-MS positive mode calculated for C9H13O4N2S1+ 245.0591, found 245.0589 ([M+]) 
and 267.0395 ([M+Na+]). 
3-acetyl-N-(2-aminoethyl)benzenesulfonamide (37)  
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The same protocol as for the synthesis of the product 36 was applied to the ketone 
30.250 The known compound 37 was collected as a yellow powder (24 mg, estimated 
65 %).  
1H NMR (400 MHz, DMSO-d6): δ = 8.31 (s, 1H, H4 aryl); 8.27 (dt, 1H, J=8.0 Hz, H2 aryl); 
8.13 (t, 1H, J=8.0 Hz, H13 NH); 8.06 (dt, 1H, J=8.0 Hz, H6 aryl); 7.91 (m, 3H, H16 NH3); 
7.81 (t, 1H, J=8.0 Hz, H1 aryl); 2.97 (m, 2H, H14 CH2); 2.88 (m, 2H, H15 CH2); 2.66 (s, 3H, 
H9 CH3). 13C NMR (100 MHz, DMSO-d6): δ = 27.26; 38.94; 40.30; 126.07; 130.59; 
131.17; 131.60; 132.58; 139.20; 209.63. 
ESI-MS positive mode calculated for C10H15N2O3S1+ 242.0798, found 243.0796 ([M+]) 
and 265.0611 ([M++ Na+]).  
4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)phenyl)-2,4-
dioxobutanoic acid (38)
 
This compound was synthesised by adapting a previously described protocol.255 To a 
cooled solution of the N-Boc-β-diketoester 31 (1 eq, 0.78 mmol, 343 mg) in a mix H2O 
3:6 MeOH (20 mL), was added dropwise under stirring NaOH 4 M (263 µL). The 
solution was then stirred for 30 min at room temperature and monitored by TLC 
(DCM 90/10 MeOH). The reaction was treated with 6 N H2SO4 (pH=6) and MeOH was 
evaporated under vacuum before the water layer was extracted twice with ethyl 
acetate. The organic layers were washed with brine and water, dried over Na2SO4 and 
filtered. The solvent was removed in vacuum and the resulting residue was purified 
by flash chromatography column (acetonitrile 90/10 MeOH) and dissolved in 2 mL of 
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dichloromethane before recrystallisation in a excess of hexane. The title compound 
38 was collected as an orange powder (39 mg, 12 %). 
1H NMR (400 MHz, CD3OD): δ = 8.49 (s, 1H, H4 aryl); 8.30 (d, 1H, J=8.0 Hz, H2 aryl); 
8.12 (d, 1H, J=8.0 Hz, H6 aryl); 7.78 (t, 1H, J=8.0 Hz, H1 aryl); 7.20 (s, 1H, H10); 3.12 (m, 
2H, H21 CH2); 2.97 (m, 2H, H22 CH2); 1.42 (s, 9H, H28-H29-H30 CH3). 
ESI-MS negative mode calculated for C17H22O8N2S1 414.1097, found 413.1012 ([M-
H+]). 
tert-butyl (2-((3-propionylphenyl)sulfonamido)ethyl)carbamate (39)  
 
This compound was synthesised by adapting a previously described protocol.226 To a 
cooled solution of the N-Boc amide 29 (1 eq, 1.55 mmol, 138 mg) in anhydrous THF 
(53 mL), was added dropwise, under nitrogen, a solution of ethylmagnesium bromide 
(3 eq, 4.65 mmol, 1.55 mL). The mixture was then stirred at room temperature for 
2h30 and monitored by TLC (ethyl acetate 60/40 hexane). The solution was treated 
with saturated aqueous NaHCO3 (pH=7) and extracted twice with ethyl acetate. The 
organic layers were washed with brine and water then dried over Na2SO4, filtered, 
and evaporated under vacuum to afford product 39 a yellow oil (276 mg, 50 %).  
1H NMR (400 MHz, CDCl3): δ = 8.42 (s, 1H, H4 aryl), 8.15 (d, 1H, J=8.0 Hz, H2 aryl), 8.04 
(d, 1H, J=8.0 Hz, H6 aryl), 7.62 (t, 1H, J=8.0 Hz, H1 aryl), 5.94 (m, 1H, H13 NH); 5.09 (m, 
1H, H16 NH); 3.23 (dd, 2H, J1=8.0 Hz, J2=4.0 Hz, H14 CH2); 3.08 (dd, 2H, J1=8.0 Hz, J2=4.0 
Hz, H15 CH2); 2.65 (q, 2H, J=8.0 Hz, H9 CH2); 1.39 (s, 9H, H21-H22-H23 CH3); 1.30 (t, 3H, 
J=8.0 Hz, H10 CH3). 13C NMR (100 MHz, CDCl3): δ = 7.84; 28.30 (3C); 31.87; 40.01; 
44.35; 55.04; 126.43; 129.65; 130.88; 131.75; 137.67; 140.86; 172.44; 199.34.  
150 
 
ESI-MS positive mode calculated for C16H24O5N2S1 356.1406, found 379.1306 
([M+Na+]), 735.2714 ([2M+Na+]). 
Ethyl4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)phenyl)-3-methyl-
2,4-dioxobutanoate (40)  
 
The same protocol as for the synthesis of the product 31 was applied to the ketone 
39. 233 The title compound 40 was collected as a yellow oil (205 mg, estimated 25 %). 
1H NMR (400 MHz, CDCl3): δ = 8.49 (s, 1H, H4 aryl); 8.20 (d, 1H, J=8.0 Hz, H2 aryl); 8.13 
(d, 1H, J=8.0 Hz, H6 aryl); 7.71 (t, 1H, J=8.0 Hz, H1 aryl); 5.57 (m, 1H, H20 NH); 5.08 (q, 
J=8.0 Hz, 1H, H10); 4.92 (m, 1H, H23 NH); 4.31 (q, 2H, J=8.0 Hz, H16 CH2); 3.26 (dd, 2H, 
J1=4.0 Hz, J2=8.0 Hz, H21 CH2); 3.15 (dd, 2H, J1=4.0 Hz, J2=8.0 Hz, H22 CH2); 1.49 (d, 3H, 
J=8.0 Hz, H31 CH3); 1.45 (s, 9H, H28-H29-H30 CH3); 1.34 (t, 3H, J=8.0 Hz, H17 CH3). 
ESI-MS positive mode calculated for C20H28O8N2S1 456.1566, found 479.1472 
([M+Na+]) and 935.3010 ([2M+Na+]). 
Benzyl (2-((3-acetylphenyl)sulfonamido)ethyl)carbamate (41)  
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This compound was synthesised by adapting a previously described protocol.258 To a 
solution of the deprotected ketone 37 (1 eq, 0.744 mmol, 253 mg) in a bi-phase 
diethyl ether (3 mL) and water (3.72 mL), was added Na2CO3 (3 eq, 2.23 mmol, 237 
mg). The solution was cooled on ice before the dropwise addition of 
benzylchloroformate (1 eq, 0.744 mmol, 0.106 mL). The solution was stirred at room 
temperature for 2.5h and monitored by TLC (ethyl acetate 80/20 hexane). The two 
phases were then separated, and the organic layer was wash with brine and water, 
dried over MgSO4, and filtered. The solvent was removed in vacuum and the resulting 
residue was purified by flash chromatography column on silica gel (ethyl acetate 
80/20 hexane). The title compound 41 was collected as a yellow oil (195 mg, 
estimated 60 %).  
1H NMR (400 MHz, CDCl3): δ =8.40 (s, 1H, H4 aryl); 8.10 (d, J=8.0 Hz, 1H, H2 aryl); 8.03 
(d, J=8.0 Hz, 1H, H6 aryl); 7.48 (t, J=8.0 Hz, 1H, H1 aryl); 7.30 (m, 5H, H22-26 ); 6.04 (m, 
1H, H13 NH); 5.54 (m, 1H, H16 NH); 5.03 (s, 2H, H20); 3.28 (m, 2H, H14 CH2); 3.08 (m, 2H, 
H15 CH2); 2.60 (s, 3H, H9). 13C NMR (100 MHz, CDCl3): δ = 26.70; 40.74; 43.31; 66.61; 
125.83; 126.70; 127.97 (2C); 128.16; 128.53; 129.71; 131.10; 132.12; 136.24; 137.79; 
140.8; 156.99; 196.80. 
ESI-MS positive mode calculated for C18H20O5N2S1 376.1093, found 399.0981 
([M+Na+]) and 775.2032 ([2M+Na+]). 
Methyl4-(3-(N-(2-(((benzyloxy)carbonyl)amino)ethyl)sulfamoyl)phenyl)-2,4-
dioxobutanoate (42)  
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The same protocol as for the synthesis of the product 31 was applied to the Cbz-
ketone 41.233  The title compound 42 was collected as a yellow oil (775 mg, estimated 
69 %). 
1H NMR (400 MHz, CD3Cl3): δ = 8.41 (s, 1H, H4 aryl), 8.15 (d, 1H, H2 aryl), 7.93 (d, 1H, 
H6 aryl), 7.58 (t, 1H, H1 aryl), 7.33 (m, 5H, H29-33 ); 6.80 (s, 1H, H9 ); 5.01 (s, 2H, H27); 
4.32 (dd, 2H, J1=8.0 Hz, J2=16 Hz, H15 CH2); 3.15 (m, 2H, H21 CH2); 2.96 (m, 2H, H22 CH2); 
1.23 (s, 3H, H16 CH3). 13C NMR (100 MHz, CD3Cl3): δ = 16.98; 40.37; 42.32; 45.90; 56.94; 
60.17; 66.11; 125.50; 127.42 (2C); 128.06 (3C); 129.04 (3C); 130.72 (2C); 140.75; 
157.44; 171.64; 218.50. 
tert-butyl(2-((3-(3,4-dihydroxybutanoyl)phenyl)sulfonamido)ethyl)carbamate (43)  
 
This compound was synthesised by adapting a previously described protocol.270 To a 
cooled stirred mixture of the N-Boc-β-diketoester 31 (1 eq, 1.36 mmol, 601 mg) in 
anhydrous THF (44 mL) under nitrogen, was slowly added lithium aluminium hydride 
(4 eq, 5.44 mmol, 206 mg). The reaction mixture was stirred for 3h on ice and 
monitored by TLC (ethyl acetate 80/20 hexane). The reaction was treated with ethyl 
acetate and water at 0°C. The aqueous phase was extracted twice with ethyl acetate. 
The organic layers were washed with brine and water, dried over MgSO4 and filtered. 
The solvent was removed in vacuum and the resulting residue was purified by flash 
chromatography column on silica gel (ethyl acetate 50/50 hexane). The title 
compound 43 was collected as a yellow oil (220 mg, estimated 36 %).  
 1H NMR (400 MHz, CDCl3): δ = 8.47 (s, 1H, H4 aryl); 8.19 (d, 1H, J=8.0 Hz, H2 aryl); 8.09 
(d, 1H, J=8.0 Hz, H6 aryl); 7.66 (t, 1H, J=8.0 Hz, H1 aryl); 5.75 (m, 1H, H17 NH); 4.98 (m, 
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1H, H20 NH); 4.39 (m, 1H, H7 CH); 3.67 (m, 1H, H10 CH2); 3.51 (m, 1H, H10 CH2);  3.34 
(m, 2H, H13 CH2); 3.30 (m, 2H, H18 CH2); 3.11 (m, 2H, H19 CH2); 1.45 (s, 9H, H25-H26-H27 
CH3). 13C NMR (100 MHz, CDCl3): δ = 28.33 (3C); 40.24; 41.89; 43.41; 65.86; 68.45; 
79.88; 124.76; 126.77; 129.68; 131.41; 137.64; 140.84; 156.58; 207.21. 
ESI-MS positive mode calculated for C17H26O7N2S1 402.1461, found 425.1353 ([M++ 
Na+]) and 827.2820 ([2M++ Na+]). 
N-(2-aminoethyl)-3-(furan-2-yl)benzenesulfonamide (44)  
 
To a cooled solution of the ketodiol 43 (1 eq, 0.54 mmol, 220 mg) in dichloromethane 
(0.72 mL), was added dropwise under stirring trifluoroacetic acid (11 eq, 5.99 mmol, 
0.46 mL). The solution was then stirred overnight at room temperature and 
monitored by TLC (ethyl acetate 60/40 hexane). The solution was evaporated under 
vacuum and co-distilled three times with dichloromethane to obtain product 44 as a 
yellow oil (134 mg, estimated 70 %).250  
1H NMR (400 MHz, CD3OD): δ = 8.19 (s, 1H, H4 aryl); 7.98 (d, 1H, J=8.0 Hz, H2 aryl); 
7.77 (d, 1H, J=8.0 Hz, H6 aryl); 7.65 (t, 1H, J=8.0 Hz, H1 aryl); 7.64 (m, 1H, H11 CH); 6.96 
(m, 1H, H10 CH); 6.59 (m, 1H, H9 CH); 3.13 (m, 2H, H16 CH2); 3.09 (m, 2H, H17 CH2). 13C 
NMR (100 MHz, CD3OD): δ =39.28; 40.00; 106.74; 111.76; 121.40; 125.07; 127.39; 
129.64; 132.10; 140.29; 143.21; 151.94. 
ESI-MS positive mode calculated for C12H15O3N2S1+ 266.0798, found 267.0813 
([M+H+]). 
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Benzyl(2-((3-(3,4-dihydroxybutanoyl)phenyl)sulfonamido)ethyl)carbamate (45)  
 
The same protocol as for the synthesis of the product 43 was applied to the Cbz- β-
diketoester 42.270 The title compound 45 was collected as a yellow oil (172 mg, 
estimated 15 %).  
1H NMR (400 MHz, CDCl3): δ = 8.41 (s, 1H, H4 aryl); 8.06 (d, 1H, J=8.0 Hz, H2 aryl); 7.99 
(d, 1H, J=8.0 Hz, H6 aryl); 7.51 (t, 1H, J=8.0 Hz, H1 aryl); 7.28 (m, 5H, H26-30 ); 6.31 (m, 
1H, H17 NH); 5.66 (m, 1H, H20 NH); 4.98 (s, 2H, H24, CH2); 4.30 (m, 1H, H10 CH); 3.66 
(m, 1H, H8 CH2); 3.57 (m, 1H, H8 CH2);  3.22 (m, 2H, H18 CH2); 3.10 (m, 2H, H12 CH2); 
3.04 (m, 2H, H19 CH2). 13C NMR (100 MHz, CDCl3): δ =40.70; 41.83; 43.10; 65.84; 66.87; 
68.43; 124.77; 126.69; 127.96 (2C); 128.18; 128.53; 248.53; 129.69; 131.37; 136.20; 
137.58; 140.72; 157.01; 198.56. 
ESI-MS positive mode calculated for C20H24O7N2S1 436.1304, found 459.1196 ([M++ 
Na+]) and 895.2459 ([2M++ Na+]). 
N-(2-aminoethyl)-3-(3,4-dihydroxybutanoyl)benzenesulfonamide (46)  
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This compound was synthesised by adapting a previously described protocol.259 To a 
Pd/C (1.3 eq, 46 mg, 0.43 mmol) powder purged under N2, was added the Cbz-
ketodiol 45 (1 eq, 0.39 mmol, 172 mg) in methanol (6 mL). The solution was then 
flushed with H2 gas and stirred under H2 atmosphere (balloon) at room temperature 
for 24h.  
The suspension was filtrated through a celite pad and washed with MeOH (2 x 5 mL). 
The filtrate was removed in vacuum to afford the title compound 46 as a yellow oil 
(90 mg, estimated 74 %).  
1H NMR (400 MHz, CD3OD): δ = 7.96 (s, 1H, H4 aryl); 7.81 (t, 1H, J=8.0 Hz, H2 aryl); 
7.71 (t, 1H, J=8.0 Hz, H6 aryl); 7.51 (m, 1H, H1 aryl); 3.96 (m, 1H, H10 );  3.62 (m, 1H, H7 
CH); 3.53 (d, 2H, J=4.0 Hz, H12 CH2); 3.13 (m, 2H, H18 CH2); 3.05 (m, 2H, H19 CH2); 1.83 
(m, 1H, H9 CH2); 1.74 (m, 1H, H9 CH2). 13C NMR (100 MHz, CD3OD): δ = 39.50; 40.52; 
41.97; 65.79; 68.69; 69.97; 124.36; 125.64; 129.12; 130.50; 139.46; 139.51. 
ESI-MS positive mode calculated for C12H20O5N2S1 304.1093, found 305.1180 
([M+H+]). 
[IrClCp*]-(4-carboxyphenylsulfonyl)-ethylenediamine acid (47)  
 
This compound was synthesised by adapting a previously described protocol.58 To a 
suspension of pentamethylcyclopentadienyl iridium(III) chloride dimer (1 eq, 0.063 
mmol, 50 mg) in MeOH (2.3 mL) was added the deprotected acid 36 (3 eq, 0.19 mmol, 
46 mg) in a MeOH (1 mL) and water (1 drop) solution. Triethylamine (4 eq) was then 
added dropwise until the solution turns a clear yellow. The solution was then stirred 
for 1h and the solvent was removed under vacuum. The resulting residue was purified 
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by flash chromatography column on silica gel (DCM 98/2 MeOH to 100% MeOH). The 
title compound 47 was collected as a yellow powder (21 mg, 55 %).  
1H NMR (400 MHz, DMSO-d6): δ = 8.53 (s, 1H, H4 aryl); 8.19 (d, 1H, J=8.0 Hz, H2 aryl); 
7.90 (d, 1H, J=8.0 Hz, H6 aryl); 7.40 (t, 1H, J=8.0 Hz, H1 aryl); 2.74 (m, 2H, H12 CH2); 
2.63 (m, 2H, H13 CH2); 1.82 (s, 15H, Cp*). 13C NMR (100 MHz, DMSO-d6): δ = 7.99 (5C); 
47.39; 48.03; 85.37 (5C); 127.74; 128.66; 130.02; 130.76; 131.05; 136.00; 178.45. 
ESI-MS positive mode calculated for C19H25IrClO4N2S1 605.0853, found 605.1200 
([M]), 569.1490 ([M+H-37Cl]) and 570.1483 ([M-35Cl]).  
[IrClCp*]-3-acetyl-N-(2-aminoethyl)benzenesulfonamide (48)  
 
This compound was synthesised by adapting a previously described protocol.58 To a 
suspension of pentamethylcyclopentadienyl iridium(III) chloride dimer (1 eq, 0.25 
mmol, 148 mg) in MeOH (3 mL) under N2 atmosphere was added a solution of the 
deprotected ketone 37 (2 eq, 121 mg, 0.5 mmol) in MeOH (3 mL). Triethylamine (4 
eq) was then added dropwise until completion of the reaction (yellow solution). The 
solution was evaporated under vacuum and dissolved again in DCM (1 mL). Hexane 
was added for precipitation and the resulting suspension was filtered to afford 
product 48 as a yellow powder (30 mg, 20 %).  
1H NMR (400 MHz, CDCl3): δ = 8.55 (s, 1H, H3 aryl); 8.11 (dt, 1H, J=8.0 Hz, H5 aryl); 
7.98 (dt, 1H, J=8.0 Hz, H1 aryl); 7.45 (t, 1H, J=8.0 Hz, H6 aryl); 2.72 (m, 2H, H16 CH2); 
2.67 (s, 3H, H8 CH3); 2.64 (m, 2H, H19 CH2); 1.77 (s, 15H, Cp*).  
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[IrClCp*]-N-(2-aminoethyl)-3-(furan-2-yl)benzenesulfonamide (49)  
 
The same protocol as for the synthesis of the product 48 was applied to the furan 44. 
58 The title compound 49 was collected as a red powder (29 mg, 43 %).  
1H NMR (400 MHz, CDCl3): δ = 8.29 (s, 1H, H4 aryl); 7.82 (d, 1H, J=8.0 Hz, H2 aryl); 7.69 
(d, 1H, J=8.0 Hz, H6 aryl); 7.51 (m, 1H, H16 CH);  7.46 (t, 1H, J=8.0 Hz, H1 aryl); 6.80 (m, 
1H, H17 CH); 6.47 (m, 1H, H18 CH); 2.74 (m, 2H, H12 CH2); 2.64 (m, 2H, H13 CH2); 1.78 
(s, 15H, Cp*). 13C NMR (100 MHz, CDCl3): δ = 9.42 (5C); 48.52; 50.61; 85.49 (5C); 
105.95; 111.79; 123.45; 125.33; 126.74; 128.48; 130.73; 142.13; 143.75; 153.47.  
ESI-MS positive mode calculated for C22H27ClIrO3N2S1 627.1060, found 591.1412 
([M+-37Cl]), 593.1451 ([M+-35Cl]), 629.1197 ([M+2H+]) and 651.1018 ([M+ H++Na]).  
  
 
The same protocol as for the synthesis of the product 48 was applied to the triol 46.58 
The title compound 50 was collected as an orange powder (43 mg, 43 %).  
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1H NMR (400 MHz, CD3OD): δ = 8.02 (s, 1H, H4 aryl); 7.85 (d, 1H, J=8.0 Hz, H2 aryl); 
7.49 (d, 1H, J=8.0 Hz, H6 aryl); 7.40 (t, 1H, J=8.0 Hz, H1 aryl); 3.92 (m, 1H, H10 );  3.60 
(m, 1H, H7 CH); 3.52 (m, 2H, H11 CH2); 2.60 (m, 2H, H18 CH2); 2.50 (m, 2H, H19 CH2); 
1.92 (m, 2H, H9 CH2); 1.76 (s, 15H, Cp*). 13C NMR (100 MHz, CD3OD): δ = 8.04 (5C); 
41.80; 42.44; 48.03; 65.99; 66.34; 71.70; 85.41 (5C); 125.14; 125.60; 126.33; 126.59; 
143.07; 145.06.  
ESI-MS positive mode calculated for C22H33ClIrO5N2S1 665.1428, found 629.1779 
([M+-37Cl]), 631.1793 ([M+-35Cl]) and 667.1558 ([M+H+]). 
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The focus of this thesis is to design, synthesise, and test nicotinamide cofactor 
structural analogues that bind strongly inside three selected ADHs. Following the 
synthesis of three transition metal catalysts based on in silico study, this chapter will 
investigate the supramolecular binding of the anchor structures and the entire metal 
complexes inside three alcohol dehydrogenases (ADHs). Finally, the biocatalytic 
reduction of cyclic imine and the stereoselectivity of the resulting artificial 
metalloenzymes (AMs) will be investigated.  
The bioconjugation was investigated by means of isothermal titration calorimetry 
(ITC) and inhibition tests against the catalysis with natural ADHs cofactors. This gave 
insight into the affinity between the ADHs and the catalysts. The catalytic activity of 
both AMs and the metal catalysts alone was subsequently analysed with HPLC 
analysis in aqueous media. 
In this study, ADHs have been selected because of their similarities with imine 
reductases, which naturally catalyse the targeted reaction. ADHs use the 
nicotinamide cofactor NAD(P)H to catalyse a hydride transfer reaction with the 
carbon double bonded to oxygen. With a similar C=X reduction reaction and the 
dependence on the same cofactors, it was hypothesised that the well-known ADHs 
were of suitable scaffold shape to engineer AMs toward the reduction of double 
bonded carbon-heteroatom. Besides, ADHs presents better characteristics than 
imine reductases to fit in a synthesis. For example, ADHs show higher tolerance to 
solvents and heat, and a wider substrate scope is accepted.287 
Three ADHs genes, available in our laboratory, were chosen to build the AMs: Horse 
Liver ADH possessing an N-terminal hexahistidine tag (His-HLADH),288 
Thermoanaerobacter brockii ADH wild type (TbADH-WT)289 and a mutant of TbADH 
(TbADH-5M).109 The latter enzyme variant contains five mutations of residues to 
alanine or serine (H59A-D150A-C203S-C283A-C295A), and is devoid of the catalytic 
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zinc ion, by the loss of two coordinating residues (H59 and D150). As already 
discussed in chapter 3, the space freed by Zn2+ favours the accommodation of the 
synthetic iridium catalysts, resulting in a binding closer to the substrate (Figure 72). 
  
Figure 72: Schematic representation of AMs with TbADH-WT scaffold (left) and after site-directed 
mutagenesis with TbADH-5M lacking the catalytic Zn2+ (right). The loss of the metal ion freed space for 
the transition metal catalyst.  
The two wild type enzymes and the zinc-devoid variant will be used as models for the 
non-covalent binding of transition metal catalyst to engineer new AMs. 
 
 
All reagents were purchased from Sigma-Aldrich, E. coli BL21 (DE3) competent cells 
were obtained from Merck and the enzymes were purchased from New England 
Biolabs, unless otherwise stated in the text (Appendix 2). Sterilisation of all media 
and flasks was performed with a Prestige Classic 2100 benchtop autoclave (Medstore 
Medical). The cultures were grown in 2 L Erlenmeyer flasks, in a New Brunswick 
Scientific Innova 40 Incubator Shaker. All cells were harvested using an Avanti J-26 XP 
centrifuge (Beckman Coulter) and a 5810R centrifuge (Eppendorf). One Shot Cell 
Disruptor (Constant System Ltd.) was used to lyse the cells. An AKTA Fast Liquid 
Protein Chromatography System (GE Healthcare) was used to purify the proteins. 
Kinetic assays were performed with an Apollo Scientific Ltd (UK). UV mini 1240 UV-
Vis spectrophotometer (Schimadzu), equipped with CPS-100 temperature controller. 
ITC was assessed using a Microcal iTC200 titration calorimeter (MicroCal Inc., 
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Northampton, MA). For catalytic tests, an HPLC Agilent 1220 Infinity was used with a 
Chiracel OD 4.6 mm x 250 mm. PS 10 µm column.  
 
 
 
Media components were sterilised by autoclaving (121 °C, 20 min, 15 psi) and mixed 
when cooled. Media solutions were prepared with Lysogeny broth (LB) media in 
deionised water and stored at room temperature. Where solid medium was required, 
LB agar (1.5 % w/v, Fisher scientific) was added to the medium prior to autoclaving. 
Where applicable, antibiotics were added to growth media. Antibiotics were 
prepared as 1000 times concentrate of the working concentration. Carbenicillin (50 
mg/mL) solutions were filter sterilised and stored at -20 °C. All cultivations were 
performed at 37 °C, 200 rpm and in baffled Erlenmeyer flasks, with nominal volumes 
five times the culture volume unless otherwise stated. 
 
Commercially available chemically competent E. coli BL21 (DE3) cells (Merck) were 
transformed with the plasmid pRSETb-HisHLADH, according to the manufacturer’s 
instructions. Briefly, the plasmid (3 µL) was added to the cells (100 µL) and incubated 
on ice for 30 min. A heat shock of 42 °C for 10 seconds was applied and the cells were 
cooled on ice for 5 min. SOC medium (950 µL) was then added, and the cells were 
shaking for 60 min at 37 °C. The resulting culture was plated and incubated overnight 
at 37 °C. 
Transformed cells were plated on LB agar supplemented with carbenicillin and 
incubated for 16 h at 37 °C. A single colony was subsequently used to inoculate 100 
mL of LB medium supplemented with carbenicillin, and incubated for 7h at 37 °C, 180 
rpm before cryostocks of cells were prepared and stored at -80 °C in 20 % glycerol. 
An appropriate volume of this starter culture was then used to inoculate fresh LB 
medium (800 mL) supplemented with carbenicillin, in an Erlenmeyer flask (total 
volume 2 L) to an OD600 of 0.1-0.2. The resulting culture was then incubated at 37 °C, 
200 rpm and until the OD600 reached 0.6-0.8. Protein expression was induced by the 
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addition of isopropyl β-D-1-thiogalactopyranoside (IPTG; 1 M stock sterilised by 
filtration; 0.4 mM final concentration). Induced cultures were incubated for 16 h at 
30 °C and 200 rpm, after which the cells were harvested by centrifugation (5 000 g, 
15 min, 4 °C) and the pellets were stored at -80 °C prior to purification. 
Cells pellets were then re-suspended in 15 mL buffer A (Table 13) at pH 7.39, 
supplemented with 0.35 mg/mL lysozyme from chicken egg. The suspension was 
stirred on ice until homogenous (30 min), then sonicated for 5 minutes (35 % 
amplitude) in 10 s bursts, with 30 s intervals for cooling. Cell debris were removed by 
centrifugation at 38 000 g at 4°C for 30 min. The cell free extract was filtered through 
0.22 µm filter, then purified by affinity chromatography on a 5 mL His-Trap FF crude 
column pre-packed with Ni-SepharoseTM Fast Flow resin (GE Healthcare) and pre-
charged with NiSO4 (0.1 M), with a flow rate of 2 mL.min-1. The column was pre-
equilibrated with 10 CV (column volumes) of the buffer A. The protein was eluted in 
2.5 mL fractions by the addition of buffer B (Table 13). Elution fractions displaying a 
strong A280 nm absorbance were analysed by SDS-PAGE and pooled together. EDTA 
was removed from the pooled fractions by dialysis by exchange into buffer C (Table 
13). The protein was stored at -20 °C. 
Table 13: Buffers used for His-HLADH purification. Buffer A corresponded to the binding buffer, buffer 
B was the elution buffer and buffer C the stock buffer. 
Buffer A 20 mM Tris, 500 mM NaCl, 20 mM imidazole 
Buffer B 20 mM TrisHCl, 500 mM NaCl, 15 mM EDTA 
Buffer C 100 mM Tris 
 
Commercially available chemically competent E. coli BL21 (DE3) cells were 
transformed with the plasmid pET-21a(+):TbADH, according to the manufacturer’s 
instructions. The previously described protocol was applied (induction with 1 mM 
IPTG and 1 mM ZnCl2). The pellets were also stored at -80 °C prior to purification. 
Cells were suspended in buffer A (Table 14), supplemented with 1 mg/mL lysozyme, 
complete™ protease inhibitor cocktail (1/4th of tablet/10 mL) and Benzonase® 
endonuclease (1 µL / mL). The suspension was stirred for 1 hour on ice, then 
sonicated for 5 minutes (35 % amplitude) in 10 s bursts, with 30 s intervals for cooling. 
Cell debris were removed by centrifugation (10 °C, 15 min, 25 000 g). The cell free 
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extract was purified by heat treatment at 60 °C for 15 minutes followed by incubation 
on ice for 10 minutes. This was followed by centrifugation (4 °C, 15 min, 16 900 g) to 
remove aggregated protein.  
The cell free extract was filtered through a 0.22 µm filter, then purified by affinity 
chromatography on a 5 mL StrepTrapTM HP column (GE Healthcare) with a flow rate 
of 3 mL.min-1. The column was pre-equilibrated with 10 CV of the buffer A. The 
protein was eluted in 2.5 mL fractions by the addition of buffer B (Table 14). Elution 
fractions displaying a strong A280 nm absorbance were analysed by SDS-PAGE and 
pooled together. D-Desthiobiotin was removed from the pooled fractions by using a 
10000 MWCO Viva-Spin 6 column (Sartorius), by exchange into buffer C (Table 14). 
The protein was stored at -20 °C. 
Table 14: Buffers used for TbADH-WT and TbADH-5M purification. Buffer A corresponded to the 
binding buffer, buffer B was the elution buffer and buffer C the stock buffer. 
Buffer A 100 mM Tris, 150 mM NaCl 
Buffer B 100 mM TrisHCl, 150 mM NaCl, 2.5 mM desthiobiotin 
Buffer C 100 mM Tris 
 
Purity was assessed by SDS-PAGE. Protein samples (20 μL) were mixed with 20 µL of 
Laemmli sample buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% 
bromphenol blue and 0.125 M Tris HCl, pH approx. 6.8) and incubated at 95 °C for 5 
minutes. PageRuler™ Plus Unstained Protein Ladder 10 to 250 kDa (5 µL) and samples 
(10 µL) were loaded onto an 8% polyacrylamide pre-cast gel (Bio-Rad) and ran at 200 
V, 400 mA for 35 min, with Tris-Glycine-SDS running buffer (14.4 g/L glycine, 3 g/L Tris 
base, 1 g/L SDS). Gels were stained with InstantBlue (Expedeon). 
Protein concentration was determined by the Bradford assay using a set of bovine 
serum albumin (BSA) standards, prepared via serial dilution in a range of 0.125 to 1 
mg/mL, in addition to several dilutions of TbADH sample. Assays were performed in 
96-well plates in triplicate, by mixing 300 μL sample Bradford reagent (Bio-Rad 
Laboratories) with 10 μL of either TbADH sample, BSA standard, or sample buffer 
(control). Samples and standards were incubated in the dark at room temperature 
for 30 minutes prior to measurement of the absorbance at 595 nm (FLUOstar 
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OPTIMA, BMG Labtech). The absorbances of BSA standards were used to generate a 
standard curve from which TbADH sample concentrations were estimated. 
 
The NAD(P)+ oxidation and NAD(P)H reduction by purified His-HLADH and TbADH-WT 
respectively, were monitored by following a previously reported method, via change 
in absorbance at 340 nm using a UV-spectrophotometer in kinetics mode, in quartz 
cuvettes with a pathlength of 1 cm. For all activity assays, controls were performed 
where the enzyme or the cofactor were replaced by the assay buffer, and minimal to 
no increase in absorbance was observed. 
The rates of the enzymatic reactions were calculated using the slope of the curve of 
absorbance vs time in the first 60 s and corrected for background activity (in the 
absence of enzyme). 
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Figure 73: Example of initial rate of reaction for an enzymatic assay in the oxidative direction. NAD(P)H 
absorbance was monitored at 340 nm, with butan-2-ol and ethanol as the substrates: -●- TbADH-WT 
150 mM butan-2-ol -●- His-HLADH 200 mM ethanol -●- Control.  
The slope for the initial rate of reaction was converted to NAD(P)H concentration 
using the Beer-Lambert law:  
A = ε.l.c (3) 
where A = absorbance observed at 340 nm; ε = extinction coefficient (NAD(P)H ε340 
= 6220 M-1 cm-1 = 0.00622 µM-1 cm-1); l = path length (cm) and c = concentration of 
NAD(P)H (µM).  
Activity was defined as μmol NAD(P)H min-1. Specific activity was defined as μmol 
NAD(P)H min-1 mg(enzyme)-1. 
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Experiments were performed in triplicate and the standard errors of mean activity 
values calculated. Conditions were as follows in 1 mL quartz cuvette:  
Table 15: Final concentrations for the oxidative and reductive reactions of His-HLADH and TbADH-WT. 
 
Oxidation reaction 
His-HLADH               TbADH-WT 
Reduction reaction 
His-HLADH               TbADH-WT 
Enzymes 15 µg 1 µg 15 µg 1 µg 
Cofactors NAD+ 0.5 mM NADP+ 0.5 mM NADH 0.1 mM NADPH 0.1 mM 
Substrates 
Ethanol  
4 mM 
Butan-2-ol  
150 mM 
Acetaldehyde 
 10 mM 
Butan-2-one 
10 mM 
Buffer 
100 mM TrisHCl  
pH 8 up to 1 mL 
100 mM TrisHCl  
pH 8 up to 1 mL 
100 mM TrisHCl  
pH 8 up to 1 mL 
100 mM TrisHCl  
pH 8 up to 1 mL 
Condition 25 °C 40 °C 25 °C 40 °C 
 
The tests were performed in the oxidative direction. The enzymes, NAD+ and ethanol 
stocks were prepared in 100 mM TrisHCl buffer pH 8 and added to a 1 mL cuvette: 
Table 16: Final concentrations for oxidative Michaelis-Menten assay on His-HLADH. 
 His-HLADH 
Enzyme 15 µg 
NAD+ 0.013 mM to 7mM 
Ethanol 4 mM 
Buffer 100 mM TrisHCl pH 8 up to 1 mL 
The solution was incubated for 5 minutes at 25 °C and the reaction was initiated by 
the addition of the enzyme, followed by a quick reverse of the cuvette for mixing. 
The increase of absorbance at 340 nm was monitored and the previously described 
activity calculations (section 5.2.2.2, page 164) were applied, to obtain the specific 
activity for each cofactor concentrations. GraphPad Prism 8 was used to determine 
the Michaelis-Menten parameters KM and Vmax by non-linear regression, with a 
narrow confidence interval fit of the parameters (the Appendix 3). All experiments 
were run in triplicates and corrected for background activity (in the absence of 
enzyme). 
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The procedures described for Michaelis-Menten kinetics were applied for inhibition 
kinetics of the oxidation reaction. The cofactor concentration was kept fixed, and 
inhibitors were added with concentrations described in Table 17. The synthesised 
iridium complexes and their unprotected diamine form were used as inhibitors: 
Benzoic acid 36; [IrClCp*]-benzoic acid 47; Furan 44; [IrClCp*]-furan 49; Triol 46; 
[IrClCp*]-triol 50. 
Table 17: Final concentrations for oxidative inhibition assays 
 His-HLADH TbADH-WT 
Enzymes 15 µg 1.0 µg 
Cofactors NAD+ 0.5 mM NADP+ 0.5 mM 
Substrate Ethanol 4 mM Butan-2-ol 150 mM 
Buffer 
100 mM TrisHCl pH 8 up to 1 mL, 
at 25 °C 
100 mM TrisHCl pH 8 up to 1 mL, 
at 40 °C 
Inhibitors 0.001 mM to 150 mM 0.001 mM to 40 mM 
 
The following reaction protocol was adapted from a procedure established by Ward 
and co-workers.291 The imine substrate used was 6,7-dimethoxy-1-methyl-3,4-
dihydroisoqunoline and the corresponding amine product was 6,7-dimethoxy-1-
methyl-1,2,3,4-tetrahydroisoquinoline. The previously synthesised iridium 
complexes were used as catalysts: [IrClCp*]-benzoic acid 47; [IrClCp*]-furan 49; 
[IrClCp*]-triol 50. 
The commercially available imine and amine were prepared in 100 mM Phosphate-
buffered saline (PBS) pH 7 at 10 mM. The iridium complexes and the enzymes were 
prepared in PBS buffer pH 7 at 2 mM concentration and diluted to 250 µM 
concentration. Sodium formate was prepared at a concentration of 1 M in 100 mM 
PBS pH 7 buffer.  
The following reagents were added to a vial: Sodium formate (150 μL, final conc. 300 
mM), imine substrate (200 μL, final conc. 4 mM), iridium complex and enzymes (100 
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μL, final conc. 50 µM) and 100 mM PBS buffer pH 7 up to 500 µL. The reaction mixture 
was vortexed and incubated at 25 °C for His-HLADH and 40 °C for TbADH-WT and 
TbADH-5M. After 24 h, the mixture was cooled down and quenched by 10 M NaOH 
(55 µL). The product was extracted with 1 mL ethyl acetate. The organic phase was 
separated and dried over MgSO4. The dried organic phase was transferred in a clean 
vial and analysed by HPLC using a Chiracel OD column (1 µL / injection, mobile phase 
hexane / isopropanol / diethylamine 95/5/0.1, 25 °C, flow rate of 0.85 mL/min).  
Experiments were run in triplicates and controls were performed with no iridium 
complexes and no enzymes.  
A calibration curve was developed to assess the formation of amine product and the 
consumption of imine substrate. The commercially available substrate and product 
were added to a sodium formate and PBS buffer at several concentrations: 0.1 mM, 
1 mM, 2 mM, 3 mM, 4 mM. The mixture was adjusted with NaOH, extracted with 
ethyl acetate, and dried over MgSO4. The dried organic phase was analysed by HPLC 
following the previous protocol (Appendix 5, Figure 102). 
The kinetic results for the three iridium catalysts were expressed in turnover 
frequency (TOF, min-1), defined as μmol of imine consumed per μmol of catalyst per 
hour.  
 
The sample cell of the calorimeter (300 µL) was filled with a phosphate buffer solution 
of the four enzymes: TbADH-WT (13 µM to 129 µM), TbADH-5M (99-123 µM) and 
His-HLADH (100 µM).  
The spinning syringe (750 rpm) was filled with the NAD(P)+ / NAD(P)H cofactors, the 
benzoic acid 37 and the β-diketoester 31 in phosphate buffer solution (2100-2400 
µM). The syringe injected the solution into the cell at 25 °C. Injections of 2.4 µL were 
made 17 times for 4.8 seconds and every 180 seconds over a period of 51 min. The 
data points were then collected every 2 seconds. 
Data analysis was carried out using the NITPIC292 and SEDPHAT293 software, where 
the area of the peaks is integrated versus the molar ratio of ligands to protein 
(example of raw data in Figure 76).  
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The plasmid for His-HLADH was obtained from Prof. Francesca Paradisi’s group and 
the plasmid for TbADH-WT was synthesised by Biomatik (Ontario, Canada). Both 
genes were already available in the laboratory, into the expression vectors pRSETb 
for His-HLADH and pET-21a for TbADH-WT. The mutant TbADH-5M gene (5M-C37), 
already reported in previous work from our laboratory,289 was available in the pET-
21a(+) vector. The genes sequences are presented in Appendix 2. 
Following previously described protocols (section 5.2.2.1, page 161), E.coli BL21 (DE3) 
was transformed with the three plasmids, and the three enzymes were expressed in 
LB medium with IPTG induction at 30 °C, prior to affinity chromatography 
purification.  
Both TbADH variants contained a N-terminus Strep tag II (W-S-H-P-Q-F-E-K) and the 
HLADH contained a C-terminus hexahistidine tag (His-HLADH). The TbADHs proteins 
were purified successfully. However, for a successful and reproducible purification of 
His-HLADH, the existing protocol was optimised. Based on previous work in the 
laboratory, the first attempt using imidazole 500 mM to remove His-HLADH from the 
Ni2+- agarose matrix of the column resulted in the His-HLADH showing no activity for 
the oxidation of ethanol. These data may suggest an irreversible inhibition of His-
HLADH by imidazole, as described by Dahl and McKinley-McKee.294 
Based on the purification method developed by Paradisi and co-workers, EDTA was 
utilised as an alternative eluent buffer.288 Following this protocol, the pooled His-
HLADH fractions were dialysed overnight, as a precaution to remove EDTA known for 
its inhibitory effect on zinc-dependent enzymes. This second protocol proved to be 
successful, resulting in an enzyme activity consistent with literature (Table 18). 
The purity of the enzymes was assessed by SDS-PAGE gel (Figure 74). The purified 
enzymes migrated at a single band of an apparent weight of ~44 kDa and ~40 kDa for 
TbADHs and His-HLADH respectively, corresponding to the expected ADHs subunit 
weight (Appendix 2). 
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Figure 74: Protein SDS-PAGE of three ADHs variants after purification of A) TbADH-WT, B) TbADH-5M 
and C) His-HLADH. F= flowthrough and L= Ladder. 
The concentrations of the purified proteins were tested by the Bradford method and 
a total of 10 mg for His-HLADH, 17 mg TbADH-WT and 15 mg TbADH-5M for 400 mL 
of culture medium was found. The enzymes were then stored at -80 °C until further 
use.  
 
The activity of both His-HLADH and TbADH-WT was measured to confirm the integrity 
and functionality of the wild type enzymes. The specific activity was determined in 
the oxidative and the reductive direction by monitoring NAD(P)H spectroscopically at 
340 nm. Ethanol and butan-2-ol were used with His-HLADH and TbADH-WT as 
substrate in the oxidation reactions, and acetaldehyde and butan-2-one were used 
for the reduction reactions. The activities were calculated following the published 
protocol described in section 5.2.2.2, page 164: 
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Table 18: Specific activity of His-HLADH and TbADH-WT for the oxidation and reduction of their natural 
substrates, compared to the literature reports.288,295 One unit of activity is defined by the amount of 
enzyme that catalyses the formation of 1 µmol of NAD(P)H per minute (U / mg). The protocol is 
described in section 5.2.2.2, page 164. 
 Specific activity in this work Literature references288,295 
His-HLADHa 
Oxidation: 0.73 U / mg 
Reduction: 6.7 U / mg 
Oxidation: 0.77 U / mg 
Reduction: no data 
TbADH-WTb 
Oxidation: 62 U / mg 
Reduction: 9.3 U/mg 
Oxidation: 78 U / mg 
Reduction: 7.6 U/mg 
The experimental activities of both enzymes were considered in range with 
previously published data, confirming the enzymes integrity.  
After the difficulties encountered for His-HLADH purification, steady state kinetic 
parameters were also determined for confirmation of a functional protein. The 
kinetic results in the oxidation of ethanol were KM = 0.12 mM (95 % CI 0.07819 <KM< 
0.1773) and Vmax = 0.73 U / mg, (95 % CI 0.6625 < Vmax < 0.7924) compared to the 
reported values of KM = 0.26 mM  and  Vmax = 0.77 U / mg (Appendix 3).288  
The resulting kinetic data attested of the His-HLADH and TbADH-WT integrity. 
Therefore, the results were set as a reference for further inhibition tests. TbADH-5M 
was not tested because of the absence of the catalytic Zn2+. 
 
In order to achieve the objective to non-covalently insert a catalyst in ADHs, its 
binding affinity inside the cofactor pocket is an important parameter to assess. After 
the design and synthesis of three metal catalysts, the next step was to investigate the 
binding affinity of their anchors inside NAD(P)H pocket. 
A ligand-protein binding affinity can be assessed by direct means using various 
methods. For example, label tests typically use fluorescent labels on the ligand to 
analyse the binding. However, this requires expensive synthesis which can be 
challenging for the binding and integrity of the catalyst. Spectroscopic methods (e.g. 
X-ray, NMR) are also interesting tools to examine details on the binding site, the 
ligand orientation, conformation and interactions. These methods are however time 
consuming.  
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In this work, two different methods were tested to investigate the binding affinity of 
the three metal catalysts inside the ADHs. Firstly, the label free ITC experiment was 
used to directly measure the binding affinity of a ligand for a protein. Secondly an 
indirect binding affinity assessment was conducted by inhibition tests against 
NAD(P)+, the natural cofactor of ADHs.  
 
ITC was used to assess the binding affinities of the catalyst anchoring part inside the 
enzymes scaffold. This method is frequently used to analyse the thermodynamic 
parameters of a binding interaction based on the measurement of heat absorbed or 
released upon binding. At constant pressure, the heat equals the enthalpy of binding. 
With the ITC technique it is possible to directly measure a dissociation constant (Kd), 
and thus the binding affinity of a ligand for a protein. One disadvantage is the 
uncertainty to determine if the displayed ligand affinity accounts only for the 
targeted binding and not for other unspecific binding.  
The resulting data are represented by a sigmoidal binding curve, where the slope 
corresponds to the association constant (1/Kd) and the height to the enthalpy of 
binding. The binding curve and the dissociation constant depend on the 
concentration of both enzyme and ligands (Figure 75). A theoretical “c value” has 
been defined by the ratio of ligands concentration to the dissociation constant 
(equation (4), with n = stoichiometry):296 
C = n[titrand] / Kd (4)  
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Figure 75: Representation of the c-value influence on the sigmoidal curve. When the slope is too 
shallow (c = 0.5) or too stipe (c = 5000), the Kd can't be defined with accuracy.297 
From literature, the determination of Kd become reliable when the c-window is 
higher than 40 and under 1000, with a sigmoidal curve. 
The first set of experiments was a blank control with no ligands in the dropping from 
the syringe solution. These injections showed the artefacts of dilution from the 
syringe content in the cell solution. The blank was then deduced from the 
experiments. In the second set of experiments, both forms of natural cofactors were 
investigated to set a strong binding reference with the three ADHs.  
The final set of experiments measured the affinity of the previously synthesised 
deprotected carboxylic acid anchor 36 and the Boc protected β-diketoester anchor 
38. Compound 38 was not deprotected from the Boc group, but the anchoring part 
β-diketoester was interesting to test for affinity. 
 
No data were found in literature for TbADH-WT ITC experiment testing the affinity of 
its natural cofactor NADP(H). The NADPH binding was previously assessed by ITC with 
an ADH yeast with an enzyme concentration of 50 µM.93 Only NAD+ binding was 
reported for His-HLADH, with an enzyme concentration of 150 µM, by Ross and co-
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workers.298,299 In a standard ITC experiment, the standard concentrations of enzymes 
are 10-30 µM with a 10-fold concentration of ligand. From these data, a starting 
concentration of 50 µM enzymes was attempted, with no relevant signal for both His-
HLADH and TbADH-WT.  
At the level of 100 µM, the natural NAD(P)H cofactors start to show an affinity for all 
the enzymes (Figure 76). However, without a better binding curve shape, it was 
impossible to determine with precision a significant Kd.  
 
Figure 76: ITC experiment with the enzyme natural cofactor at [E]=100 µM and [NAD(P)H] = 2100 µM. 
A) In TbADH-5M, the left panel displays an example of raw data of the heat pulses resulting from each 
titration. On the right, the curve represents the integration of the heat, normalised per mole of 
NADPH; B) TbADH-WT and C) His-HLADH. The molar ratio refers to titrant (ligands) / titrand (enzymes). 
These results might imply a low binding affinity of the ADHs for their natural cofactor. 
Higher concentration of ligand and enzymes were necessary to improve the signal. 
Similar low affinities were obtained with the oxidised NAD(P)+ cofactors, which data 
showed a nearly flat curve (Figure 77).  
B C 
A 
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Figure 77: ITC experiment using 2100 µM NADP+ and 100 µM enzyme concentration. A) TbADH-5M 
and B) TbADH-WT. The molar ratio refers to titrant (ligands) / titrand (enzymes). 
The beginning of the curve was decreasing. With low significance, it was difficult to 
interpret the results as the first peak could refer to an artefact. A second possibility 
would be a change in conformation of the enzyme upon binding of NADP+, impacting 
the binding of more ligand and thus reducing the heat. The conformational changes 
induced by NAD+ binding in HLADH was also hypothesised by Ross and co-worker298 
during calorimetry measurement. A change in conformation could enhance the 
affinity toward the cofactor, implying a higher affinity for NADP+ than NADPH or other 
ligands. 
 
The synthesised anchors were tested in parallel to the natural cofactor.  
Similar to the natural cofactors test, the first attempts at low enzyme concentration 
gave inconclusive results for both products 36 and 38 (flat line). An increase in 
concentrations at [E]= 100 µM and [L]= 2100 µM also provided a flat binding curve 
(Figure 78), whereas experiments with NADPH started to show a slight curve. These 
observations were in agreement with previous docking results suggesting the 
designed anchors bound with weaker affinity to the enzymes than NAD(P)H.  
A B
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Figure 78: Example of ITC experiments at [E]= 100 µM and [L]=2100 µM with A) E= His-HLADH, L= acid 
36 and B) E= TbADH-WT, L= β-diketoacid 38. The molar ratio refers to titrant (ligands) / titrand 
(enzymes). 
The enzyme concentration was again increased to 130 µM with a ligand 
concentration of 2400 µM. For the acid 36, a flat line was again observed with both 
TbADH-WT and His-HLADH.  
The experiments with anchor 38 started to show a shallow slope (Figure 79). This 
proved a start of binding affinity, even if the curve was less steep than the experiment 
with the natural cofactors.  
 
Figure 79: ITC experiment with [E]=130 µM and [L]=2400 µM with A) E= TbADH-WT, L= β-diketoacid 
38 B) E= His-HLADH, L= β-diketoacid 38. The molar ratio refers to titrant (ligands) / titrand (enzymes). 
The concentrations of enzymes applied in the experiments were again not high 
enough for a relevant binding curve slope. Thus, the Kd and thermodynamics reported 
contained significant uncertainty.  
From the data, cautious conclusions can be attempted. First, with absence of signal, 
the benzoic acid 36 had weak or no affinity for the enzymes. With a shallow slope, 
the anchor 38 seemed to bind with better affinity to the enzymes than the shorter 
benzoic acid anchor 36. Nonetheless, both bound to the enzymes with a weaker 
affinity compared to the natural NAD(P)H cofactor. These conclusions were also in 
A B
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accord with the in silico study findings, where NAD(P)H showed the highest affinity 
score and the ligands with several hydrophilic groups (hydroxyls and carboxylic acids) 
were ranked just after. 
The ITC binding curve quality can mainly be enhanced by increasing the amount of 
protein (to 150-200 µM) and ligands. Encouraging reported data with 150 µM or 10 
mg/mL concentration of other ADHs types strengthen this hypothesis.299,300 
However, with increase in concentration, the proteins might aggregate in solution 
and thus reduce the binding capacity. An investigation of the enzyme behaviour 
would thus give input on the experiment quality. The high amount of enzymes and 
ligands needed for this experiment conducted to no further ITC assays. 
 
With inconclusive ITC results, the catalysts access and affinity to the cofactor binding 
pocket was investigated by indirect means using inhibition assays.  
Assuming the synthesised ligands act as competitive inhibitors, their binding to a 
protein active site will prevent the natural reaction to occur. They would replace 
NAD(P)+ by binding in its pocket, but without its reactivity due to the loss of the 
nicotinamide function.  
The inhibitory potential of a ligand gives an input in its binding capacity with small 
amounts of enzymes and ligands. However, this method of affinity measurement is 
indirect and depends on the affinity of the enzyme for its natural cofactor.  
Inhibition of both His-HLADH and TbADH-WT activity was tested in the oxidative 
reaction of ethanol and butan-2-ol respectively. Without Zn2+, TbADH-5M was 
unfunctional and not tested in these experiments.  
The diamine anchors (compounds 36, 44, 46, Figure 80) were designed through 
docking to anchor the metal with high affinity, catalytic orientation and location 
(Chapter 3, page 57). Therefore, their affinity was tested alongside the transition 
metal complexes (compounds 47, 49, 50, Figure 80). The large size of the iridium 
functionality is likely to have an impact on the binding inside the tight cofactor 
binding pocket.  
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Figure 80: Synthesised anchors and their corresponding iridium complexes used in this affinity study. 
Both types of compounds will be tested for their supramolecular binding strength and specificity 
within the wild type TbADH-WT and His-HLADH. 
Several concentrations of each ligand were evaluated against a constant 
concentration of cofactor (0.5 mM) in the presence of the substrate. The formation 
of NADH was followed at 340 nm and the data were plotted on a logarithmic scale 
(graphs in Appendix 4). A sigmoidal fit was computed with the Prism software and 
the IC50 of each inhibitor was calculated for the two enzymes with a good parameter 
fit (SD replicates between 0.01 and 0.1, Figure 81). The IC50 corresponds to the 
concentration of inhibitor required to inhibit half of the enzyme activity, in 
competition with NAD(P)+. 
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Figure 81: IC50 values of synthesised anchors and iridium complexes with His-HLADH (blue) and TbADH-
WT (orange) in the oxidative reaction. NAD(P)+ (0.5 mM), ethanol (4 mM) and butan-2-ol (150 mM) 
were used with His-HLADH (15 µg) and TbADH-WT (1 µg) in 100 mM TrisHCl pH 8 buffer. The molecules 
ranged from 10-4 to 102 mM (> 10mM for compound 46: not enough stocks to test further). 
Deprotected diamine anchors (36, 44 and 46) expressed an IC50 between 5 mM and 
more than 10 mM for both His-HLADH and TbADH-WT. These results indicate a low 
inhibition to the enzymes and so a low affinity in comparison with the natural NAD(P)+ 
cofactor. The corresponding iridium complexes (47, 49 and 50) showed higher 
inhibitions between 0.03 mM and 3.5 mM. The furan anchor with or without iridium 
metal (44 and 49) is the best inhibitor for both TbADH-WT and His-HLADH. The Triol 
anchor (46 and 50) follows, finishing by the acid (36 and 47). 
The first scenario that could explain these observed inhibitions was the binding of the 
metal complex anchoring part to ADHs. This could have occurred either in the 
cofactor pocket or via unspecific inhibiting binding to other sites.  
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For example, in the case of catalyst 49, the lowest IC50 could be explained by the furan 
hydrophobicity favouring 49 binding in the substrate pocket, mainly hydrophobic.217 
As anticipated by the docking study, any hydrophobic part of a ligand tends to be 
introduced inside the substrate pocket, inducing an inhibition by lack of space for the 
substrate to bind (section 3.3.1, page 63). Thus, 49 higher inhibitions would come 
from competition with the substrate, which is less specific than competing with the 
natural cofactor. By comparison, the more hydrophilic compounds 50 and 47 could 
bind properly inside the cofactor pocket with a stronger competition against the 
natural cofactor, explaining a lower inhibition.  
This binding of the anchor hypothesis can be challenged by the differences in 
inhibition between the deprotected and the metalated compounds. With a higher 
affinity observed when the iridium was present, it can be speculated a second 
scenario of an impact of the metal on the binding. d6 piano-stool metals iridium and 
rhodium are known to bind to enzymes.301 If the binding occurs in an inhibiting 
position (i.e. entrance of a pocket) the NAD(P)+ or the substrate might be excluded 
from the pocket and not able to react.  
The second scenario would be an aggregation promoted by the iridium that would 
inhibit the enzyme activity. However, no precipitation in any of the iridium complexes 
solutions discarded this last hypothesis. 
In conclusion, the iridium catalysts 49 and 50 inhibited the two wild type enzymes. 
To explain this inhibition, two hypotheses could be established:  
• the anchoring part of the catalyst bound in the cofactor or substrate pocket, 
preventing their binding and the natural reaction.  
• the catalysts bound by the iridium in a position inhibiting the reaction.  
Certainty on how the binding happen and the affinity for the ADHs cannot be defined 
because of the indirect analysis. More rigorous experiments, like crystallography, 
could further be attempted for details on the location and orientation of the bound 
ligands.  
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The inhibition observed in the previous section by the metal catalysts could reflect 
an affinity for the wild type ADHs. The reactivity of the AMs will here be tested by 
catalytic assays for cyclic imine reduction (Scheme 23). 
 
Scheme 23: Transfer hydrogenation of 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline to produce 
the chiral amines 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroquinoline, catalysed by the artificial 
metalloenzymes or the iridium catalysts alone, adapted from a previously describe protocol by Ward 
and co-workers.291 
Before starting the catalytic experiments, a standard curve was established to analyse 
the HPLC results quantitatively (Appendix 5). The substrate imine 6,7-dimethoxy-1-
methyl-3,4-dihydroisoquinoline and the two chiral amines products 6,7-dimethoxy-
1-methyl-1,2,3,4-tetrahydroisoquinoline were used and extracted following the 
protocol described in the catalytic assays method (section 5.2.2.5, page 166).  
The imine retention time was at 11.18 minutes and the two amines retention times 
were at 19.59 minutes and 23.93 minutes. 
 
HPLC kinetic assays for the synthesised metal complexes were performed in aqueous 
solution to evaluate their catalytic potential for cyclic imine reduction.  
The three iridium catalysts (47, 49, 50) were tested for the catalytic transformation 
of the 6,7-dimethoxy-1-methyl-3,4-dihydroisoqunoline into the racemic mixture of 
the amine 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline for 24h in 
aqueous media (curves in Appendix 5). 
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Table 19: Turnover frequency (TOF) of the three iridium catalysts is presented for the reduction of 
4mM cyclic imine substrate with 50 µM of catalysts at 38°C after 1h of reaction. The experiments were 
run in triplicates for 24h and the results presented are the mean ± standard error. 
Catalysts yield % TOF (min-1) TON 
47 54 ± 0.03 1.4 ± 0.11 59 ± 8.39 
49 57 ± 0.04 1.8 ± 0.07 66 ± 1.45 
50 94 ± 0.01 4.5 ± 0.09 90 ± 1.04 
The reactivity of the three catalysts was validated for the aromatic imine reduction 
with no chiral induction. According to the results, the TOF depends on the anchor 
structure linked to the metal. The iridium catalyst 50 with a triol group was highly 
reactive compared to the iridium complex 47 with a benzoic acid anchoring part. 
These activity data were satisfying compared to previous work in literature. Ward and 
co-workers convert the same isoquinoline substrate in racemic mixtures with 10 TON 
using a Cp* iridium complex9 and with 35 TON using a biotinylated iridium complex.64  
Outside the scope of this project, these synthesised iridium catalysts were of interest 
for the chemical reduction of imine to chiral amine building blocks, in aqueous media.  
 
Investigation into the catalytic reactivity of the iridium transition metal complexes in 
combination with the three enzymes were performed. The protocol applied in the 
previous section was only modified in temperature with His-HLADH, which is more 
efficient at 25 °C.288 The following graphs are presenting the three catalysts 47, 49 
and 50 in combination with TbADH-WT, His-HLADH and TbADH-5M at different 
concentrations.  
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Figure 82: The product and substrate concentrations obtained from the reduction of 4 mM cyclic imine 
at 38 °C in PBS buffer, catalysed by 50 µM iridium complex 50 and 50 µM enzymes, for 24h (25°C for 
His-HLADH reaction). The graph presents the iridium complex alone and in combination with the three 
selected enzymes for AMs engineering: His-HLADH, TbADH-WT and TbADH-5M. 
This first graph displays the catalytic activity of iridium complex 50 alone and in a one-
to-one concentration combination with the three ADHs (Figure 82). The catalyst 
alone presented a catalytic activity with no stereoselectivity like previously 
mentioned. No reaction was achieved with His-HLADH and only a very small quantity 
of amine was detected with TbADH-WT. Finally, formation of the amine was observed 
with TbADH-5M. No significant stereoselectivity was observed for all setups.  
The activity displayed by TbADH-5M gave a first indication of success for the rational 
design of this AM. To further perturb the equilibrium towards the bound state inside 
the enzyme binding pocket, the concentration of enzyme was doubled. In parallel, a 
rise in the iridium complex concentration was also applied to saturate potential 
binding sites and verify the AM selectivity and possible inhibition (Figure 83). 
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Figure 83: The product and substrate concentrations obtained from the reduction of 4 mM cyclic imine 
at 38 °C in PBS buffer, for 24h. The graph presents the iridium complex 50 with TbADH-5M and TbADH-
WT, at various concentrations combinations. 
For an increased enzyme concentration, the catalysis was slowed down. It can be 
suggested that no free metal catalyst remained in the mixture and the observed 
activity should come from bounded catalyst.  
On the other hand, the production of amine was higher when the metal catalyst was 
four times the enzyme concentration. The wild-type enzyme taken as a reference 
showed activity this time, potentially indicating a reaction of the free metal only. In 
comparison TbADH-5M got higher conversion, indicating an activity from the free and 
bounded catalyst in excess. This suggested again that the reaction proceeded with 
metal catalyst bound to TbADH-5M, even though with lower turnover, whereas in the 
wild type, the reaction was mainly inhibited by the enzyme.  
From these results, two main observations could be made: in combination with wild 
type enzymes, the catalytic activity of the transition metal catalyst was inhibited. On 
the other hand, the mutant TbADH-5M proved to form a functional AM with 
reproducibility but no stereoselectivity.  
The absence of activity with the wild type enzymes correlated with the binding 
inhibition observed in the preceding inhibition tests. This lack of activity can be 
explained by different scenarios already considered previously (section 5.3.2.2, page 
176). The first option is a binding of the catalyst 50 to the enzyme through its metal 
iridium, with a mutual inhibition. The second scenario is the expected binding of 50 
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anchoring part inside the cofactor pocket, but without space for the substrate to 
approach the catalyst.  
In the first hypothesis, the iridium metal could have reacted with amino acids in the 
enzyme (mainly cysteine and histidine), blocking the catalytic activity. The chloride 
linked to the iridium is known to be hydrolysed in aqueous media.301 This could 
represent an activation step, followed by the reactivity of the iridium to amino acids. 
Hollmann and co-workers developed a theoretical mechanism for the mutual 
inhibition of rhodium catalyst and an ADH.301 This mechanism can be extended to 
similar iridium complexes, which have also been implicated in monoamine oxidases 
inhibition.70 The theory implies the hydrolysis of chloride, followed by metal 
coordination with cysteine or histidine residues which induce the inhibition of the 
metal catalytic activity (Figure 84). In addition, if these amino acids were involved in 
catalysis or positioned in a cofactor / substrate pocket, this would also provoke the 
protein inhibition. 
 
Figure 84: Proposed mechanism of the inhibition of d6 piano-stool iridium complexes by binding to 
amino acids, adapted from Hollmann and co-workers theory.301 
In this project, this hypothesis was supported by the observed activity of catalyst 50 
in the five-cysteine mutant TbADH-5M, when no activity was found in the wild types. 
If no cysteine were present, the iridium catalyst was free to react with the imine 
substrate without binding to an amino acid.  
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In the same way, His-HLADH AM being totally inactive, the binding of iridium to the 
polyhistidine tag could add to this theory. The His-tag is well known to bind to cation 
transition metal ion.302 Many researches showed examples of metalloenzymes and 
zinc, copper, nickel metals being coordinated by the His-tag.303,304,305,306 In this 
project, the natural Zn2+ was not affected by the His-tag (proved by kinetic assays) . 
However, the introduction of iridium with weakly bound ligands could have followed 
the previously described mechanism and bind to histidine (Figure 84). 
Cleavage of the tag to obtain a closer to nature HLADH or the use of commercially 
available wild type HLADH would discard any potential impact of the His-tag. Another 
solution would be the use of acidic conditions (pH= 5) to avoid the metal binding. 
Those conditions might however affect the enzyme, which activity is optimal at pH = 
8.8.288 
The metal binding theory is however also debatable. Other authors have succeeded 
in using these transition metal complexes with TbADH and HLADH without any 
mutual inhibition.301,307 Besides, Hollmann and co-workers used a four-time ratio of 
metal complex to obtain inhibition, where in this experiment, the stoichiometry was 
equivalent and no inhibition was observed at a four to one ratio. 
Thus, the second plausible theory could be a binding of the anchoring part of 50, 
without possible transfer hydrogenation reaction being performed in the wild types. 
For example, mutual inhibition could come from a binding of the catalyst in the 
substrate pocket, in an unspecific allosteric site or in the cofactor pocket, but with 
obstacles to meet the substrate. This final proposition was endorsed by the activity 
showed with the mutant TbADH-5M as scaffold. The only structural difference with 
the TbADH-WT is the lack of catalytic Zn2+ and the space made in the catalytic area 
by mutation of H59 and D150 into alanine residues. As already suspected in docking 
and in the choice of mutated enzymes, more space inside the catalytic area allowed 
meeting of the substrate and metal catalyst, resulting in amine production (i.e. Figure 
72, page 160). 
However, precautions need to be taken as the reaction with TbADH-5M showed no 
stereoselectivity, suggesting the possibility of a reaction catalysed by free catalysts 
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outside the enzyme. In addition, the integrity of TbADH-5M activity was not tested 
prior to catalysis experiments due to the lack of catalytic Zn2+. 
To properly investigate the mutual inhibition, catalytic activity could further be 
assessed with amino acid (particularly cysteine) in the mixture. If the activity 
decreases, binding with cysteine should have occurred, which verify the first 
hypothesis of inhibition by iridium binding. Besides, adding NADH as a competitor in 
the case of TbADH-5M catalysis experiment could affect the reactivity if the binding 
occurs inside the pocket.  
The two other metal catalysts (47 and 49) were also tested for their reactivity within 
the three ADHs, following the same protocol (Figure 85 and Figure 86).  
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Figure 85: The product and substrate concentrations obtained from the reduction of 4 mM cyclic imine 
at 38 °C in PBS buffer, catalysed by iridium complex 49 alone and in combination with the three 
enzymes, for 24h (25°C for His-HLADH reaction). 
Catalyst 49 complex alone was active with no stereoselectivity. In combination with 
all the three enzymes, the iridium complex 49 gave low to no activity. When the 
concentrations of metal catalyst 49 were raised, again low activities were shown, 
especially compared to the same experiment with catalyst 50, which obtained a 
complete conversion. Thus, it can be suggested that the observed small activity of 49 
catalysis came from free metal catalyst in solution. These inhibition results in 
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combination with IC50 data highlighted a binding of 49 with all the ADHs and a mutual 
inhibition. 
With no activity showed by TbADH-5M lacking cysteines residues, the theory of a 
mutual inhibition by iridium binding was again less plausible. Thus, the second 
scenario of a binding in a non-catalytic way was again privileged. Contrary to catalyst 
50, which may bind properly in the cofactor pocket, the lack of activity of 49 with 
TbADH-5M suggest another inhibiting binding. Prior conclusions from inhibition 
assays tended to hypothesise the binding of 49 inside the substrate pocket, in 
correlation with docking studies. Compound 49 being hydrophobic, it would take the 
substrate place and thus cannot realise the imine reduction while inhibiting the ADHs 
natural activity. 
Finally, catalytic tests on compound 47 also presented no activity in combination with 
all the enzymes (Figure 86).  
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Figure 86: The product and substrate concentrations obtained from the reduction of 4 mM imine at 
38 °C in PBS buffer, catalysed by 50 µM iridium complex 47 alone and with 50 µM of the three enzymes 
His-HLADH, TbADH-WT and TbADH-5M, for 24h (25°C for His-HLADH reaction). 
The total lack of catalytic activity, compared to the complex 50, again highlight a 
difference in the binding mode to ADHs. The inhibition of the catalyst 47, even 
without Zn2+, tends toward similar binding hypothesis than catalyst 49: an unspecific 
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binding of the anchor part. As this catalyst represented a truncated intermediate 
structure, with no designed features for the binding in NAD(P)H pocket, the correct 
binding might not be supported, which led to unspecific inhibitory binding instead 
(e.g. in the substrate pocket). These data were in correlation with docking studies 
where 47 was part of the designed small library of catalysts but was not selected in 
the lead structures because of a very low ranking in affinity score. 
 
The three selected AMs (TbADH-WT, TbADH-5M and His-HLADH) were successfully 
expressed and purified. The two wild type enzymes integrity and functionality were 
validated through kinetic parameters consistent with literature. 
Two assays were run to assess the binding affinity of the synthesised catalysts for the 
three ADHs. A direct measurement with ITC assay was not able to validate binding 
affinity. The second indirect experiment in form of inhibition assays of the catalysts 
against the catalytic activity of the natural cofactor NAD(P)+ showed binding affinities 
in the low mM regime for the metal catalysts (47, 49 and 50) with the two wild type 
enzymes. Poorer binding affinity was displayed by the shorter ligands 36 and 47, 
which was consistent with the in silico study and previous work from M. Basle.109   
Finally, the catalytic activity of the three metal catalysts (47, 49 and 50) and the 
resulting AMs was assessed by HPLC monitoring of the products of a catalysed imine 
reduction in aqueous media. The three iridium catalysts alone were active for the 
imine reduction with no stereoselectivity. 
From the catalytic data of the conjugated metal with ADHs, a more complicated 
picture arose. 
No activity was found for all catalysts in combination with His-HLADH and TbADH-
WT. A clear but lower activity was obtained by the catalyst 50 in TbADH-5M, with no 
stereoselectivity. Further experiments with higher concentrations of the catalyst 50 
and comparison with the other metal catalysts and inhibition studies confirmed that 
the activity was unlikely to come from free catalyst in solution. Thus, the catalyst 50 
was deemed to have bound to the enzyme in an active way, revealing the design of 
an AM. 
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The lack of stereoselectivity for the TbADH-5M – 50 AM could be explained by an 
active binding of the catalyst 50 to TbADH-5M, but not in the deemed cofactor 
binding pocket. For example, a surface exposed binding could explain the lack of 
stereoselectivity of the designed AM. However, it remained unclear where this 
binding site would be located. It is also not directly supported by the inhibition studies 
that clearly show direct inhibition, suggesting binding in the cofactor or substrate 
binding pocket. 
The two other catalysts 47 and 49 lacked activity with all enzymes, suggesting a 
different inhibitory pathway, and again supporting the assumption of an active AM 
with catalyst 50.  
Three scenarios were developed to explain the inhibiting binding modes: 
- The iridium metal bound to amino acids (e.g. cysteine) and provoked mutual 
inhibition of the catalyst and enzyme. This theory was invalidated by 
literature301,307 and by the lack of activity from 47 and 49 with TbADH-5M, yet 
missing cysteines.  
- The metal catalyst anchoring part made unspecific binding contacts in an 
inhibiting position, notably inside the hydrophobic substrate binding pocket. 
The truncated catalyst 47 and the hydrophobic catalyst 49 were perfect 
candidates for this hypothesis. This was supported by the combination of lack 
of activity for 47 and 49 based AM constructs with existing inhibition of the 
natural activity in both cases. 
- The metal catalyst 50 binds properly inside the cofactor pocket, but the 
contacts with the substrate in wild type enzymes are prohibited by a lack of 
space due to Zn2+. This last hypothesis was supported by the effective catalytic 
assays of 50, only in TbADH-5M where Zn2+ was missing. 
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This thesis presents the rational design of artificial metalloenzymes (AMs) for the 
transfer hydrogenation of imines. A supramolecular anchoring strategy was chosen 
for the introduction of a transition metal catalyst inside an enzyme scaffold based on 
alcohol dehydrogenases (ADHs). The reactivity was introduced by a d6 piano-stool 
iridium metal complex.  
The initial focus of this project was the creation of small anchors with high affinity for 
the NAD(P)H binding pocket of ADHs. The final objective was then to metalate these 
anchors to form imine reduction catalysts and non-covalently bind the resulting 
complexes inside ADHs scaffold. The engineered AM should be new, robust, and 
efficient toward the catalytic reduction of imine into chiral amines.  
 
Anchors of the transition metal catalysts were first designed by computational 
modelling studies focused on the development of docking protocols. The Horse Liver 
ADH (HLADH) and the Thermoanaerobacter brockii ADH (TbADH) were chosen as 
scaffolds due to their large substrate scope and the similarity of their natural reaction 
(aldehyde reduction) to the targeted imine reduction. TbADH is also both 
thermostable and resistant to solvents,97 which is advantageous in a synthesis 
pathway where high temperatures and organic solvents are commonplace. In 
addition, by process of evolution, the candidate enzymes have a natural high affinity 
to bind their native NAD(P)H cofactors, therefore the docking focused on finding high 
affinity NAD(P)H analogues for the supramolecular catalyst anchoring.  
A docking protocol was developed and validated for the reliable approximation of 
affinity inside the ADHs cofactor binding pocket. The natural cofactor, online libraries 
and fragments of NAD(P)H were docked as a starting point of the in silico study. 
Enzymes scaffold with and without their catalytic Zn2+ were considered. The space 
offered by lacking the zinc ion could indeed be a potential advantage to insert the 
metal catalyst further toward the substrate.  
In addition, the presence of substrate in the co-crystallised structure was essential to 
the docking. The substrate pocket being essentially hydrophobic, any hydrophobic 
structures were inserted inside the pocket, obstructing the substrate insertion. 
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A model for anchors was designed based on conclusions from the first docking 
screening. The typical structure was composed of an aromatic ring substituted with 
a hydrophilic anchoring part on one side, and a sulfonamide support for the metal on 
the other side. Hydrophilic functional groups are necessary for maximising the 
interactions inside NAD(P)H binding pocket. This was supported by experimental 
results from the literature, suggesting low affinity and activity for truncated 
hydrophobic mimics of NADH inside HLADH.106,109 Hydrophobic features were also 
discarded because of their potential insertion in the hydrophobic substrate pocket 
(inducing possible inhibition of substrate binding). 
The resulting library of anchors was screened inside ADHs with a new docking 
protocol considering the affinity score, the location and orientation of the anchors. A 
catalytic position of the metal catalyst was indeed essential to the activity. This 
created docking protocol includes first the use of the Glide XP method for anchor 
affinity screening, then the Induce Fit Docking (IFD) method was applied to 
investigate the binding affinity and orientation of metalated anchors. The IFD method 
was necessary to introduce flexibility into the enzyme and insert the metal. However, 
effect induces by the binding of a metal on the electronic state and geometry of the 
first coordination sphere, the ligand and the scaffold are considerations introducing 
very high complexity for the molecular modelling of AMs.308 Thus, the results have to 
be considered carefully as approximations with crucial information on anchor 
structure model and hydrogen bonding. Nevertheless, a set of lead anchor structures 
was selected based on their affinity score, the location and orientation of the metal. 
In future, refinement with more rigorous experiments may be necessary, for example 
to improve the detailed knowledge of the catalytic reaction and the catalysts binding 
process. Molecular dynamic simulations or QM/MM are increasingly used methods 
for the in depth analysis of a binding site and catalytic reaction, however at the costs 
of higher time and computational resource comsumption.165,308 In addition, should 
an appropriate anchor be discovered experimentally, new computational 
experiments can also be considered for further optimisations. For example, genetic 
mutations of residues in the cofactor pocket or modification of anchor shape would 
likely increase binding capacities and stereoselectivity. 
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Based on the docking, metal complexes coordinated with the anchoring structures 
were synthesised. This objective included the design of a short divergent synthetic 
pathway able to provide a small library of anchors. 
The key intermediate β-diketoester showed the disadvantage of its sensitivity to the 
applied and necessary deprotection conditions. The subsequent solution chosen was 
the reduction of this anchoring part to a ketodiol that is more resistant and still close 
to the initial anchor design. A complete modification of the key intermediate β-
diketoester could also have been a solution. However, this would have varied entirely 
the anchoring part, possibly moving away from the docking models. 
The subsequent metalation provided three catalysts: Ir-triol 50, Ir-acid 47 and Ir-furan 
49 (Error! Reference source not found.). 
 
Figure 87: Synthesised metal catalyst complexes: Ir-triol 50, Ir-acid 47 and Ir-furan 49. 
Based on previous docking conclusions, catalyst 50 met the requirement of several 
hydrophilic features and looked similar to the selected lead structures, missing only 
a carboxylic acid. Catalyst 49 and 47 were also interesting for a comparison in the 
binding affinity of selected hit structures and hydrophobic or truncated ligands. 
Further possible chemical optimisations of the first coordination sphere are decisive, 
especially coupled with genetic optimisations, as observed in the work of many 
groups.49,58,63 In addition, optimisations in the previous in silico study could also result 
in a new synthesis path toward different catalysts libraries. 
The final part of this project focused on the construction of efficient AMs that aimed 
to reduce cyclic imine into chiral amines. Three ADHs available in the laboratory were 
expressed and evaluated as scaffolds: two wild types His-HLADH and TbADH-WT, and 
a mutant version of the wild type TbADH called TbADH-5M. The mutation resulted in 
the loss the Zn2+ ion, thus giving more space for the introduction of the iridium in the 
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catalytic site. Two main parameters were then analysed in this chapter: the binding 
affinity of the synthesised catalysts inside ADHs and the catalytic activity of the 
resulting AMs. 
First, a direct and label-free means was run to test affinity by Isothermal Titration 
Calorimetry (ITC). This robust technique would provide the binding, kinetics and 
thermodynamic information needed to evaluate the anchoring part of the catalyst 
with high accuracy.296,309 Although the assay was sensitive to detect binding affinity, 
inconclusive data were retrieved due to weak signals displayed by the binding 
enthalpy between the enzymes and NAD(P)H. This drawback is often described in ITC 
technique and implied the need of very high quantities of enzymes and ligands to 
accurately determine a binding constant.310 Further robust direct means techniques 
could be considered in the future to provide information on affinity, like the sensitive 
mass spectrometry or the label fluorescence methods. They are, however, time-
consuming analyses with need of cautious conditions and may cause disruption in the 
synthesised cofactor (e.g. labelled experiments). 
Indirect means were then applied to investigate the binding affinity. Using inhibition 
assays, smaller concentrations of synthesised catalysts were used to compete with 
the natural cofactor NAD(P)+ inside ADHs. This method resulted in an IC50 around low 
mM level for 49 and 50, in agreement with the docking study. A higher affinity was 
obtained by the natural cofactor compared to the other ligands. However, low IC50 
values for the ligands still represented inhibition of the enzyme catalysis and gave 
insights into their affinity indirectly. In this project, the affinity for the enzyme is a 
main parameter for the design of AMs based on supramolecular anchoring. 
Therefore, a precise measurement of the binding affinity of the catalysts in ADHs 
must still be established. 
The three iridium catalysts combined with the three ADHs were then evaluated for 
the imine reduction of 6,7-dimethoxy-1-methyl-3,4-dihydroisoqunoline into the 
chiral amines 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline, in aqueous 
media. The three metal catalysts (47, 49 and 50) tested alone exhibited catalytic 
activity without stereoselectivity, and the best turnover frequency was displayed by 
the catalyst 50.  
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The data obtained for the catalyst-ADH constructs were more complicated. Catalyst 
50 in combination with TbADH-5M showed reduction of cyclic imine without 
stereoselectivity. The two other catalysts and the wild-type scaffolds showed no 
activity. These results confirmed the inhibition assays’ conclusion of a binding of all 
the catalysts inside the enzymes, with mutual inhibitions.  
The theory that catalyst 50 bound correctly in the NADPH pocket was supported by 
the catalytic activity observed for the construct TbADH-5M - 50. Besides, the lack of 
activity of the wild type enzymes in combination with 50 reinforced this theory. 
Indeed, the difference in the scaffolds was the presence of Zn2+ in the wild type, 
reducing the active site space and preventing accommodation of both catalyst 50 and 
substrate.  
Experiments with His-HLADH lacking Zn2+ would be a plus to support this hypothesis. 
Besides, Michaelis Menten experiment on TbADH would confirm any binding inside 
a pocket, while the addition of NAD(P)H to the catalytic mixture could also conclude 
on a binding in the cofactor pocket if an inhibition of the activity of the TbADH-5M - 
50 system would occur.  
The lack of stereoselectivity was a major drawback and point of debate for the 
constructed AM. Absence of stereoselectivity has been explained in previous work 
with, for example, the exposition of the metal to the solvent and far from the chiral 
environment of the enzyme.79 This would confirm some prior docking results which 
showed an orientation of the metal toward the pocket outside. A binding on the 
enzyme surface or a too large pocket, which would accommodate the ligand and the 
substrate, could also be considered.311 However, a binding of catalyst 50 in these 
achiral positions would have also created active AMs with the wild type, which 
scaffold is similar to TbADH-5M.  
Another explanation of the lack of stereoselectivity could be the need of refinement 
of the active site. At the beginning of their AM creation, Ward and co-workers also 
encountered very low stereoselectivity.67,57 Further chemo-genetic optimisations of 
the ligands and the scaffold provided high selective AM.312 
On the other hand, the presence of free catalyst could also explain activity with no 
stereoselectivity. The known binding of iridium metal to cysteine and histidine amino 
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acids301 could explain the absence of activity for catalyst 50 with wild type enzymes, 
while the mutated TbADH-5M with no cysteine showed activity due to free catalyst 
50 in solution. This hypothesis was even more suspected in His-HLADH by the 
presence of a chelating His-tag tail, known to bind cation transition metals. Ir(III) 
luminescent probes are notably used to selectivity bind histidine residues in 
proteins.313,314 The metal binding theory is however debated by literature, where 
similar metals and enzymes have been used with success.301,307 Besides, the 
hypothesis of activity from free catalyst 50 in solution was very unlikely, as the 
negative results of the other catalysts 47 and 49 with TbADH-5M and their low 
inhibition in competition with NADPH were again supporting the formation of an AM 
with catalyst 50.  
The absence of activity of catalysts 47 and 49 gave clear indirect evidence for the 
formation of an active AM with catalyst 50. Their inhibition could then be explained 
by a different and unspecific binding of the anchoring part to the enzymes, in a non-
reactive way. The main example would be a binding inside the substrate pocket, for 
example by the hydrophobic compound 49. This theory was supported by the docking 
studies which predicted the insertion of ligand hydrophobic parts inside the substrate 
pocket. Future inhibition assays against the substrate would assess a binding inside 
the substrate pocket. 
To investigate the creation of TbADH-5M - 50 AM and validate the docking 
approximations, further long-term approaches could be used. For example, NMR 
studies or crystallisation of this AM would provide rigorous details on the binding 
location of the metal complex and the spatial arrangement with the substrate.315 The 
crystallisation of the other AMs developed might shed a light on the two other 
unspecific binding described.  
Following the biochemical results, the better understanding of the anchor structure 
and the enzyme pocket will lead to future opportunities for substantial chemical and 
genetic optimisations (Error! Reference source not found.). The created 
supramolecular AM represented the beginning of an interesting concept, with only 
few enzymatic scaffolds previously used for the supramolecular engineering of 
AMs.45,47  
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By returning to the docking studies, screening for enzyme mutations and new anchors 
will result in discovering an increased affinity between the scaffold and the metal 
catalysts, ultimately resulting in a more reactive, robust, and selective AM. 
 
Figure 88: Schematic representation of the rational design of an AM and the possible optimisations 
cycle. 
The work presented in this thesis sets the foundations for future engineering of 
supramolecular AMs, capable of competing with current biological and chemical 
catalysts. The results proved the efficiency of a new rational design strategy using 
computational modelling in the conception of an active AM. As a renewable catalyst, 
this newly created AM participates in the development of green chemistry for the 
selective catalysis of green chemical reactions with high performance, mimicking 
natural products synthesis.  
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Appendix 1 – NMRs and ESI-MS analysis from the synthesis of a transition 
metal catalyst 
1H-NMR 3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)benzoic acid, 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
223 
 
 
13C-NMR 3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)benzoic acid, 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
224 
 
1H-NMR tert-butyl(2-((3(methoxy(methyl)carbamoyl)phenyl)sulfonamido)ethyl) 
Carbamate, 29  
  
 
 
 
 
 
 
 
 
 
 
 
225 
 
13C-NMR tert-butyl(2-((3(methoxy(methyl)carbamoyl)phenyl)sulfonamido)ethyl) 
Carbamate, 29  
 
ESI-MS tert-butyl(2-((3(methoxy(methyl)carbamoyl)phenyl)sulfonamido)ethyl) 
Carbamate, 29  
 
[2M + Na+] 
226 
 
1H-NMR tert-butyl (2-((3-acetylphenyl)sulfonamido)ethyl)carbamate, 30
 
13C-NMR tert-butyl (2-((3-acetylphenyl)sulfonamido)ethyl)carbamate, 30
 
227 
 
1H-NMR Ethyl 4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)phenyl)-2,4-
dioxobutanoate, 31a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
228 
 
1H-NMR Ethyl 4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)phenyl)-2,4-
dioxobutanoate, 31b 
 
13C-NMR Ethyl 4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)phenyl)-2,4-
dioxobutanoate, 31b 
 
229 
 
COSY-NMR Ethyl 4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)phenyl)-
2,4-dioxobutanoate, 31a 
 
HSQC-NMR of both 31a and 31b 
 
230 
 
1H-NMR (4-carboxyphenylsulfonyl)-ethylenediamine acid, 36 
 
13C-NMR (4-carboxyphenylsulfonyl)-ethylenediamine acid, 36 
 
231 
 
COSY-NMR (4-carboxyphenylsulfonyl)-ethylenediamine acid, 36 
 
HSQC-NMR (4-carboxyphenylsulfonyl)-ethylenediamine acid 36 
 
232 
 
ESI-MS (4-carboxyphenylsulfonyl)-ethylenediamine acid, 36 
 
1H-NMR 3-acetyl-N-(2-aminoethyl)benzenesulfonamide, 37 
 
[M+] 
233 
 
13C-NMR 3-acetyl-N-(2-aminoethyl)benzenesulfonamide, 37 
 
COSY-NMR (4-carboxyphenylsulfonyl)-ethylenediamine acid, 37 
 
234 
 
1H-NMR 4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)phenyl)-2,4-
dioxobutanoic acid, 38 
 
COSY-NMR 4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)phenyl)-2,4-
dioxobutanoic acid, 38 
 
235 
 
1H-NMR tert-butyl (2-((3-propionylphenyl)sulfonamido)ethyl)carbamate, 39 
  
13C-NMR tert-butyl (2-((3-propionylphenyl)sulfonamido)ethyl)carbamate, 39 
 
236 
 
ESI-MS tert-butyl (2-((3-propionylphenyl)sulfonamido)ethyl)carbamate, 39 
 
1H-NMR Ethyl 4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)phenyl)-3-
methyl-2,4-dioxobutanoate, 40 
 
[M+Na+] 
237 
 
COSY-NMR Ethyl 4-(3-(N-(2-((tert-butoxycarbonyl)amino)ethyl)sulfamoyl)phenyl)-3-
methyl-2,4-dioxobutanoate, 40 
 
1H-NMR Methyl 4-(3-(N-(2-(((benzyloxy)carbonyl)amino)ethyl)sulfamoyl)phenyl)-
2,4-dioxobutanoate, 42 
 
238 
 
13C-NMR Methyl 4-(3-(N-(2-(((benzyloxy)carbonyl)amino)ethyl)sulfamoyl)phenyl)-
2,4-dioxobutanoate, 42 
 
COSY-NMR Methyl 4-(3-(N-(2-(((benzyloxy)carbonyl)amino)ethyl)sulfamoyl)phenyl)-
2,4-dioxobutanoate, 42 
 
239 
 
1H-NMR tert-butyl (2-((3-(3,4-
dihydroxybutanoyl)phenyl)sulfonamido)ethyl)carbamate, 43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
240 
 
13C-NMR tert-butyl (2-((3-(3,4-
dihydroxybutanoyl)phenyl)sulfonamido)ethyl)carbamate, 43 
 
COSY-NMR tert-butyl (2-((3-(3,4-
dihydroxybutanoyl)phenyl)sulfonamido)ethyl)carbamate, 43 
 
241 
 
HSQC-NMR tert-butyl (2-((3-(3,4-
dihydroxybutanoyl)phenyl)sulfonamido)ethyl)carbamate, 43 
 
tert-butyl (2-((3-(3,4-dihydroxybutanoyl)phenyl)sulfonamido)ethyl)carbamate, 43
 
[2M+Na+] 
[M+Na+] 
242 
 
1H-NMR N-(2-aminoethyl)-3-(furan-2-yl)benzenesulfonamide, 44 
 
13C-NMR N-(2-aminoethyl)-3-(furan-2-yl)benzenesulfonamide, 44 
 
243 
 
COSY-NMR N-(2-aminoethyl)-3-(furan-2-yl)benzenesulfonamide, 44 
 
HSQC-NMR N-(2-aminoethyl)-3-(furan-2-yl)benzenesulfonamide, 44 
 
244 
 
ESI-MS N-(2-aminoethyl)-3-(furan-2-yl)benzenesulfonamide, 44 
 
1H-NMR Benzyl (2-((3-(3,4-dihydroxybutanoyl)phenyl)sulfonamido)ethyl) 
carbamate,45
 
[M+H+] 
245 
 
13C-NMR Benzyl (2-((3-(3,4-dihydroxybutanoyl)phenyl)sulfonamido)ethyl) 
carbamate,45
 
COSY-NMR Benzyl (2-((3-(3,4-dihydroxybutanoyl)phenyl)sulfonamido)ethyl) 
carbamate, 45 
 
246 
 
HSQC-NMR Benzyl (2-((3-(3,4-dihydroxybutanoyl)phenyl)sulfonamido)ethyl) 
carbamate, 45 
 
ESI-MS Benzyl (2-((3-(3,4-dihydroxybutanoyl)phenyl)sulfonamido)ethyl)carbamate, 
45 
 
M+Na+ 
2M+Na+ 
247 
 
1H-NMR N-(2-aminoethyl)-3-(3,4-dihydroxybutanoyl)benzenesulfonamide, 46
 
13C-NMR N-(2-aminoethyl)-3-(3,4-dihydroxybutanoyl)benzenesulfonamide, 46
 
248 
 
COSY-NMR N-(2-aminoethyl)-3-(3,4-dihydroxybutanoyl)benzenesulfonamide, 46
 
HSQC-NMR N-(2-aminoethyl)-3-(3,4-dihydroxybutanoyl)benzenesulfonamide, 46
 
249 
 
ESI-MS N-(2-aminoethyl)-3-(3,4-dihydroxybutanoyl)benzenesulfonamide, 46 
 
1H-NMR [IrClCp*]-(4-carboxyphenylsulfonyl)-ethylenediamine acid, 47 
 
M+H+ 
250 
 
13C-NMR [IrClCp*]-(4-carboxyphenylsulfonyl)-ethylenediamine acid, 47 
 
ESI-MS [IrClCp*]-(4-carboxyphenylsulfonyl)-ethylenediamine acid, 47 
 
251 
 
1H-NMR [IrClCp*]-N-(2-aminoethyl)-3- (furan-2-yl)benzenesulfonamide, 49 
 
13C-NMR [IrClCp*]-N-(2-aminoethyl)-3- (furan-2-yl)benzenesulfonamide, 49 
 
252 
 
 
ESI-MS [IrClCp*]-N-(2-aminoethyl)-3- (furan-2-yl)benzenesulfonamide, 49 
 
1H-NMR [IrClCp*]- N-(2-aminoethyl)-3-(3,4-dihydroxybutanoyl)benzenesulfonamide, 
50
 
253 
 
 
13C-NMR [IrClCp*]-N-(2-aminoethyl)-3-(3,4-dihydroxybutanoyl)benzenesulfonamide, 
50 
 
ESI-MS [IrClCp*]- N-(2-aminoethyl)-3-(3,4-dihydroxybutanoyl)benzenesulfonamide, 
50 
 
[M+H+]-Cl 
[M+H+] 
254 
 
Appendix 2 - Horse Liver ADH, Thermoanaerobacter brockii ADH and 
Thermoanaerobacter brockii ADH mutant constructs 
His-HLADH and TbADH-WT 
The HLADH gene inserted into the pRSETb expression vector was obtained as a gift 
from Dr Paradisi’s group. The vector provides ampicillin (carbenicillin) resistance, and 
a C-terminus hexahistidine tag followed by an enterokinase cleavage site. The HLADH 
gene is cloned between the SacI and the EcoRI restriction sites, as displayed below 
with the start and stop codons highlighted in red, and the restriction sites highlighted 
in green. 
ATGCGGGGTTCTCATCATCATCATCATCATGGTATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATC
TGTACGACGATGACGATAAGGATCCGAGCTCGATGAGCACAGCAGGAAAAGTAATAAAATGCAAAGCGGCT
GTGCTGTGGGAGGAAAAGAAACCATTTTCCATCGAGGAGGTGGAGGTTGCACCCCCGAAGGCCCATGAAGTC
CGTATAAAGATGGTGGCCACAGGAATTTGTCGCTCAGATGACCACGTGGTTAGTGGAACCCTTGTCACACCTC
TTCCTGTGATCGCAGGCCATGAGGCAGCGGGCATTGTGGAGAGCATTGGAGAAGGCGTCACTACAGTAAGAC
CAGGTGATAAAGTCATCCCACTCTTTACTCCCCAGTGTGGAAAATGCAGGGTTTGTAAGCACCCTGAAGGCAA
CTTCTGCTTGAAAAATGATCTGAGCATGCCTCGGGGAACCATGCAGGATGGTACCAGCAGGTTCACCTGCAGA
GGGAAGCCCATCCACCACTTCCTTGGCACCAGCACCTTCTCCCAGTACACCGTGGTGGACGAGATCTCAGTGG
CCAAGATCGATGCGGCCTCACCGCTGGAGAAAGTCTGTCTCATTGGCTGTGGATTTTCTACTGGTTATGGGTCT
GCAGTCAAGGTTGCCAAGGTCACCCAGGGCTCCACCTGTGCCGTGTTTGGCCTTGGAGGAGTGGGCCTGTCT
GTTATCATGGGCTGTAAAGCAGCCGGAGCGGCCAGGATCATTGGGGTGGACATCAACAAAGACAAGTTTGCA
AAGGCCAAAGAAGTGGGTGCCACTGAGTGTGTCAACCCTCAGGACTACAAGAAACCCATCCAGGAGGTGCTG
ACAGAAATGAGCAATGGAGGTGTGGATTTTTCCTTTGAAGTCATTGGTCGGCTCGACACTATGGTGACTGCCT
TGTCATGCTGTCAAGAAGCATATGGTGTGAGCGTCATTGTGGGAGTACCTCCTGATTCCCAAAATCTCTCTATG
AATCCTATGTTGCTACTGAGTGGACGTACCTGGAAAGGAGCTATTTTTGGCGGTTTTAAGAGTAAAGATTCTG
TCCCCAAACTTGTGGCCGATTTTATGGCTAAAAAGTTTGCACTGGATCCTTTAATCACCCATGTTTTACCTTTTG
AAAAAATAAATGAAGGATTTGACCTGCTTCGCTCTGGAGAGAGTATCCGTACCATCCTGACGTTTTGAGACCA
TACAAATGTCTGCACTTGTAGCCGTCTTCTGGCTCCTCTATCCTCTGGATCATCAGCCAAACGACATCAATAATT
CTGTTCCTCAAAGATGCTATTAATAGTTACCGCTGGGAGCTTTCTAAAAGAAACAAAAATTGATGTGAAGTCAC
TTTTCAAGCAAACGTTTAAAATCCAAGTGAGAGCTAGAGGAACCATCAGCTGGGTAACTGAGCCCACTAAACT
TTCCTTCTTAATCATTCTCCTCACGTTGAATCCTGTCACCTTTCCCGAATTC 
The His-HLADH primary sequence is shown below. The C-terminus hexahistidine tag 
and enterokinase cleavage site are listed as bold letters. Predicted properties: MW = 
43850; pI = 7.5. 
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPSSMSTAGKVIKCKAAVLWEEKKPFSIEEVEVAPPKAHEV
RIKMVATGICRSDDHVVSGTLVTPLPVIAGHEAAGIVESIGEGVTTVRPGDKVIPLFTPQCGKCRVCKHPEGNFCLK
NDLSMPRGTMQDGTSRFTCRGKPIHHFLGTSTFSQYTVVDEISVAKIDAASPLEKVCLIGCGFSTGYGSAVKVAKVT
QGSTCAVFGLGGVGLSVIMGCKAAGAARIIGVDINKDKFAKAKEVGATECVNPQDYKKPIQEVLTEMSNGGVDFS
FEVIGRLDTMVTALSCCQEAYGVSVIVGVPPDSQNLSMNPMLLLSGRTWKGAIFGGFKSKDSVPKLVADFMAKKF
ALDPLITHVLPFEKINEGFDLLRSGESIRTILTF 
The TbADH-WT gene fused to an N-terminus Strep-tag (II) followed by a thrombin 
cleavage site was synthesized by Biomatik (Ontario, Canada) and inserted into the 
pET-21a(+) expression vector. The vector provides ampicillin (carbenicillin) 
resistance. The TbADH-WT gene is cloned between the NdeI and the XhoI restriction 
sites, as presented below with the start and stop codons highlighted in red, and the 
restriction sites highlighted in green. 
AGAAGCTAACTTCCCCTCTAGAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGTGGAGCCACCCGCA
GTTCGAAAAATCTTCTGGTCTGGTTCCGCGTGGATCCATGAAGGGCTTCGCGATGCTGAGCATTGGTAAGGTT
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GGCTGGATCGAGAAAGAAAAACCGGCTCCGGGTCCGTTCGACGCTATCGTGCGTCCGCTGGCTGTTGCGCCG
TGCACCTCTGACATCCATACCGTTTTCGAGGGTGCGATCGGTGAGCGCCACAACATGATCCTGGGTCACGAAG
CGGTGGGCGAGGTTGTTGAAGTTGGCTCTGAGGTGAAAGACTTTAAGCCGGGTGATCGTGTTGTTGTTCCGG
CAATCACCCCGGACTGGCGTACTTCCGAAGTTCAGCGCGGCTACCACCAGCACTCTGGCGGTATGCTGGCGGG
TTGGAAATTCTCCAACGTTAAGGACGGCGTGTTCGGCGAGTTCTTCCATGTGAACGACGCTGACATGAACCTG
GCGCACCTGCCGAAGGAAATCCCGCTGGAAGCGGCGGTTATGATTCCGGATATGATGACTACTGGTTTCCATG
GTGCAGAGCTGGCAGACATTGAGCTGGGTGCAACCGTTGCGGTTCTGGGTATCGGTCCGGTTGGCCTGATGG
CGGTGGCTGGTGCGAAACTGCGTGGTGCGGGTCGTATCATCGCGGTTGGTTCTCGTCCGGTGTGCGTTGATG
CTGCTAAATACTACGGTGCGACCGACATTGTTAACTACAAAGACGGTCCGATCGAATCTCAGATTATGAACCT
GACCGAGGGCAAAGGCGTGGACGCAGCGATTATCGCAGGTGGTAACGCGGATATCATGGCGACCGCTGTTA
AAATCGTTAAACCGGGTGGTACTATTGCGAACGTGAACTATTTCGGTGAAGGCGAAGTGCTGCCGGTGCCGC
GTCTGGAATGGGGTTGTGGTATGGCACATAAGACCATTAAAGGTGGTCTGTGTCCGGGCGGTCGTCTGCGCA
TGGAACGTCTGATTGACCTGGTTTTCTACAAACGTGTTGACCCGTCTAAACTGGTTACCCACGTGTTCCGTGGT
TTCGACAACATCGAAAAGGCTTTTATGCTGATGAAAGATAAACCGAAAGATCTGATCAAACCGGTGGTTATCC
TGGCGTAACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGAAGCGTACGTC 
The TbADH-WT primary sequence is shown below. The N-terminus Strep-tag (II) and 
thrombin cleavage site are listed as bold letters. Predicted properties: MW = 
39659.18; pI = 6.61. 
MWSHPQFEKSSGLVPRGSMKGFAMLSIGKVGWIEKEKPAPGPFDAIVRPLAVAPCTSDIHTVFEGAIGERHNMIL
GHEAVGEVVEVGSEVKDFKPGDRVVVPAITPDWRTSEVQRGYHQHSGGMLAGWKFSNVKDGVFGEFFHVNDA
DMNLAHLPKEIPLEAAVMIPDMMTTGFHGAELADIELGATVAVLGIGPVGLMAVAGAKLRGAGRIIAVGSRPVCV
DAAKYYGATDIVNYKDGPIESQIMNLTEGKGVDAAIIAGGNADIMATAVKIVKPGGTIANVNYFGEGEVLPVPRLE
WGCGMAHKTIKGGLCPGGRLRMERLIDLVFYKRVDPSKLVTHVFRGFDNIEKAFMLMKDKPKDLIKPVVILA 
 
TbADH-5M 
The mutated TbADH-5M gene was obtained from Dr. Mattias Basle. The DNA 
sequence of the gene is displayed below. The different features are highlighted as 
follow: restriction sites in green, start and stop codons in blue, the N-terminus strep-
tag (II) in brown, the mutations applied to gene in red. 
AGAAGCTAACTTCCCCTCTAGAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGTGGAGCCACCCGCA
GTTCGAAAAATCTTCTGGTCTGGTTCCGCGTGGATCCATGAAGGGCTTCGCGATGCTGAGCATTGGTAAGGTT
GGCTGGATCGAGAAAGAAAAACCGGCTCCGGGTCCGTTCGACGCTATCGTGCGTCCGCTGGCTGTTGCGCCG
TGCACCTCTGACATCCATACCGTTTTCGAGGGTGCGATCGGTGAGCGCCACAACATGATCCTGGGTGCCGAAG
CGGTGGGCGAGGTTGTTGAAGTTGGCTCTGAGGTGAAAGACTTTAAGCCGGGTGATCGTGTTGTTGTTCCGG
CAATCACCCCGGACTGGCGTACTTCCGAAGTTCAGCGCGGCTACCACCAGCACTCTGGCGGTATGCTGGCGGG
TTGGAAATTCTCCAACGTTAAGGACGGCGTGTTCGGCGAGTTCTTCCATGTGAACGACGCTGACATGAACCTG
GCGCACCTGCCGAAGGAAATCCCGCTGGAAGCGGCGGTTATGATTCCGGCTATGATGACTACTGGTTTCCATG
GTGCAGAGCTGGCAGACATTGAGCTGGGTGCAACCGTTGCGGTTCTGGGTATCGGTCCGGTTGGCCTGATGG
CGGTGGCTGGTGCGAAACTGCGTGGTGCGGGTCGTATCATCGCGGTTGGTTCTCGTCCGGTGAGCGTTGATG
CTGCTAAATACTACGGTGCGACCGACATTGTTAACTACAAAGACGGTCCGATCGAATCTCAGATTATGAACCT
GACCGAGGGCAAAGGCGTGGACGCAGCGATTATCGCAGGTGGTAACGCGGATATCATGGCGACCGCTGTTA
AAATCGTTAAACCGGGTGGTACTATTGCGAACGTGAACTATTTCGGTGAAGGCGAAGTGCTGCCGGTGCCGC
GTCTGGAATGGGGTGCTGGTATGGCACATAAGACCATTAAAGGTGGTCTGGCTCCGGGCGGTCGTCTGCGCA
TGGAACGTCTGATTGACCTGGTTTTCTACAAACGTGTTGACCCGTCTAAACTGGTTACCCACGTGTTCCGTGGT
TTCGACAACATCGAAAAGGCTTTTATGCTGATGAAAGATAAACCGAAAGATCTGATCAAACCGGTGGTTATCC
TGGCGTAACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGAAGCGTACGT
C 
 
256 
 
Appendix 3 – Kinetics Michaelis-Menten of His-HLADH oxidative 
reaction. 
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Figure 89: Michaelis-Menten curve of HLADH in the oxidation of ethanol. 
Appendix 4 – Inhibition kinetics graphs for His-HLADH and TbADH-WT. 
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Figure 90: Inhibition test on His-HLADH with anchor benzoic acid 36. 
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Figure 91: Inhibition test on TbADH-WT with anchor benzoic acid 36. 
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Figure 92: Inhibition test on His-HLADH with anchor furan 44. 
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Figure 93: Inhibition test on TbADH-WT with anchor furan 44. 
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Figure 94: Inhibition test on His-HLADH with anchor Triol 46. 
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Figure 95: Inhibition test on TbADH-WT with anchor Triol 46. 
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Figure 96: Inhibition test on His-HLADH with anchor [IrClCp*]-benzoic acid 47. 
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Figure 97: Inhibition test on TbADH-WT with anchor [IrClCp*]-benzoic acid 47. 
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Figure 98: His-HLADH inhibition test with anchor [IrClCp*]-furan 49. 
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Figure 99: Inhibition test on TbADH-WT with anchor [IrClCp*]-furan 49. 
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Figure 100: Inhibition test on His-HLADH with anchor [IrClCp*]-triol 50. 
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Figure 101: Inhibition test on TbADH-WT with anchor [IrClCp*]-triol 50. 
Appendix 5 – Catalysis assays. 
 
Figure 102: Calibration curve of the imine 6,7-dimethoxy-1methyl-3,4-dihydroisoqunoline substrate 
and the two chiral amine 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline products (Amine 1 
and 2).  
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Figure 103: The kinetic profile for the reduction of 4mM 6,7-dimethoxy-1-methyl-3,4-
dihydroisoqunoline at 38 °C catalysed by 50 µM iridium complex [IrClCp*]-benzoic acid 47. 
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Figure 104: The kinetic profile for the reduction of 4mM 6,7-dimethoxy-1-methyl-3,4-
dihydroisoqunoline at 38 °C catalysed by 50 µM iridium complex [IrClCp*]-furan 49. 
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Figure 105: The kinetic profile for the reduction of 4mM 6,7-dimethoxy-1-methyl-3,4-
dihydroisoqunoline at 38 °C catalysed by 50 µM iridium complex [IrClCp*]-triol 50. 
